USRE39672E1 - Method and devices for laser induced fluorescence attenuation spectroscopy - Google Patents
Method and devices for laser induced fluorescence attenuation spectroscopy Download PDFInfo
- Publication number
- USRE39672E1 USRE39672E1 US10/056,335 US5633502A USRE39672E US RE39672 E1 USRE39672 E1 US RE39672E1 US 5633502 A US5633502 A US 5633502A US RE39672 E USRE39672 E US RE39672E
- Authority
- US
- United States
- Prior art keywords
- sample
- fluorescence
- modulated
- distance
- radiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 108
- 238000004611 spectroscopical analysis Methods 0.000 title claims abstract description 15
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 title abstract description 22
- 230000005855 radiation Effects 0.000 claims abstract description 115
- 206010021143 Hypoxia Diseases 0.000 claims abstract description 54
- 238000012544 monitoring process Methods 0.000 claims abstract description 40
- 239000013307 optical fiber Substances 0.000 claims description 43
- 230000003287 optical effect Effects 0.000 claims description 40
- 230000005284 excitation Effects 0.000 claims description 35
- 208000028867 ischemia Diseases 0.000 claims description 32
- 230000007954 hypoxia Effects 0.000 claims description 28
- 108010054147 Hemoglobins Proteins 0.000 claims description 25
- 102000001554 Hemoglobins Human genes 0.000 claims description 25
- 238000010521 absorption reaction Methods 0.000 claims description 19
- 239000000835 fiber Substances 0.000 claims description 19
- 230000001766 physiological effect Effects 0.000 claims description 13
- 238000006213 oxygenation reaction Methods 0.000 claims description 12
- 238000002834 transmittance Methods 0.000 claims description 7
- 230000001575 pathological effect Effects 0.000 claims description 5
- 230000002238 attenuated effect Effects 0.000 claims description 3
- 230000015654 memory Effects 0.000 claims description 3
- 238000012417 linear regression Methods 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 230000000287 tissue oxygenation Effects 0.000 claims description 2
- 239000012620 biological material Substances 0.000 claims 32
- 230000001678 irradiating effect Effects 0.000 claims 16
- 238000001179 sorption measurement Methods 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 abstract description 34
- 230000001419 dependent effect Effects 0.000 abstract description 32
- 230000001146 hypoxic effect Effects 0.000 abstract description 21
- 230000008569 process Effects 0.000 abstract description 8
- 239000000523 sample Substances 0.000 description 150
- 210000001519 tissue Anatomy 0.000 description 127
- 238000001228 spectrum Methods 0.000 description 58
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 26
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 26
- 230000000694 effects Effects 0.000 description 20
- 238000005259 measurement Methods 0.000 description 19
- 230000003595 spectral effect Effects 0.000 description 19
- 230000036982 action potential Effects 0.000 description 15
- 230000008602 contraction Effects 0.000 description 15
- 238000010586 diagram Methods 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 102000016942 Elastin Human genes 0.000 description 8
- 108010014258 Elastin Proteins 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 229920002549 elastin Polymers 0.000 description 8
- 238000012549 training Methods 0.000 description 8
- 238000013528 artificial neural network Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000010287 polarization Effects 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 3
- 239000011149 active material Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008081 blood perfusion Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000005350 fused silica glass Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000005003 heart tissue Anatomy 0.000 description 3
- 230000000222 hyperoxic effect Effects 0.000 description 3
- 229950006238 nadide Drugs 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000005084 renal tissue Anatomy 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000010238 partial least squares regression Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012306 spectroscopic technique Methods 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020674 Hypermetabolism Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- UIZLQMLDSWKZGC-UHFFFAOYSA-N cadmium helium Chemical compound [He].[Cd] UIZLQMLDSWKZGC-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000014541 detection of hypoxia Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012799 electrically-conductive coating Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000012770 industrial material Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000000985 reflectance spectrum Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 238000000411 transmission spectrum Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
- A61B5/0084—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/47—Scattering, i.e. diffuse reflection
- G01N21/49—Scattering, i.e. diffuse reflection within a body or fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6402—Atomic fluorescence; Laser induced fluorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
- A61B5/0084—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
- A61B5/0086—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters using infrared radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
- A61B5/7267—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems involving training the classification device
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
- G01N2021/6484—Optical fibres
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2201/00—Features of devices classified in G01N21/00
- G01N2201/06—Illumination; Optics
- G01N2201/061—Sources
- G01N2201/06193—Secundary in-situ sources, e.g. fluorescent particles
Definitions
- the present invention is directed to methods and devices for determining a spectroscopic characteristic of a sample utilizing laser induced fluorescence attenuation spectroscopy (“LIFAS”). More particularly, the invention is directed to methods and devices for measurement of the wavelength-dependent attenuation of the sample and subsequent restoration of the intrinsic laser induced fluorescence (“LIF”) for physiological monitoring, biological tissue characterization and biochemical analysis.
- LIFAS laser induced fluorescence attenuation spectroscopy
- samples have been characterized by determining the attenuation and laser induced fluorescence (“LIF”).
- LIF laser induced fluorescence
- these spectroscopic properties can be utilized to determine a physical or physiological property of the sample.
- the attenuation of a sample can be used to determine the concentrations of mixture components or turbidity of a fluid.
- the LIF of a sample has been used in fields such as analytical chemistry, environmental monitoring, industrial inspection and medical diagnosis. In the medical field, for example, LIF spectroscopic techniques have been used for tissue characterization, malignant tumor identification, atherosclerotic plaque diagnosis, metabolism evaluation, and the like.
- the attenuation or the absorption of a sample is determined by placing the sample between a light source and a detector and measuring any reduction in the intensity of the light as it passes through the sample.
- the thickness of the sample and the wavelength of the incident light are important factors affecting the reliability of the resulting measurement.
- it is necessary to place the sample between the light source and the detector it is difficult to perform attenuation measurements on certain types of samples, such as living tissue.
- fiber optic techniques have been developed for the measurement of attenuation in which an optical fiber is used to guide the incident light to illuminate a sample inside a small chamber at the tip of a probe.
- a reflector is placed on the opposite side of the chamber to reflect the incident light into a second fiber which is associated with a detector.
- these techniques find limited application with materials, such as fluids, that can readily pass into the chamber in the tip of the probe.
- LIFS laser induced fluorescence
- spectroscopic techniques utilize various optical configurations in which a laser is directed at a sample using an optical fiber and the LIF from the sample is collected using a second optical fiber.
- the same fiber can be used for excitation of the sample and the collection of LIF.
- the LIF collected by the fiber is modulated by the sample, e.g. by the wavelength-dependent absorption and scattering of constituents of the sample. Therefore, existing LIFS methods are limited by the fact that the “intrinsic” or “true” fluorescence of the sample's fluorophores cannot be determined.
- Recent reports have suggested measuring the diffuse reflectance spectrum of the tissue as a means for correcting the intrinsic LIF using Monte-Carlo mathematical formulations. However, such correction methods are critically dependent on the backscattering characteristics of the tissue. Furthermore, backscattering does not account for the effects of absorption and scattering suffered by the intrinsic fluorescence prior to its measurement.
- fluorophores in the sample In biological LIF techniques, lasers are used to cause fluorophores in the sample to emit fluorescence.
- the main fluorophores in normal biological tissue are tryptophan, collagen and elastin.
- Other fluorophores such as NAD (nicotinamide adenine dinucleotide) and FAD (flavin adenine dinucleotide), are also normally present, but at much lower concentrations.
- NAD nicotinamide adenine dinucleotide
- FAD flavin adenine dinucleotide
- the weak fluorophore NAD will be converted into the strong fluorophore reduced nicotinamide adenine dinucleotide (“NADH”).
- NADH nicotinamide adenine dinucleotide
- the LIF collected from the sample will reflect an increased contribution from NADH. This change is typically observed as a rise in the intensity of the LIF spectrum in the region of peak NADH emission, from about 470 to 490 nm.
- the metabolic state of the tissue can be determined by measuring the relative change in LIF intensity at the wavelength of peak NADH emission as compared to the relative change of the LIF intensity of fluorophores that are normally present in the tissue, such as elastin or collagen.
- the LIF of biological tissue is heavily modulated in the 390-450 nm range by the peak absorption of the main tissue chromophore, hemoglobin.
- the measured LIF spectra has a valley in the 400-450 nm region that is associated with the hemoglobin absorption.
- the measured LIF spectrum tissue appears to have a double peak instead of the single peak spectrum associated with the pure fluorophores of the tissue.
- the LIF spectrum of normal tissue begins to resemble the spectrum associated with tissue suffering hypoxia or ischemia, which makes it more difficult to identify tissue abnormalities.
- the measured LIF will vary with the level of blood perfusion throughout the cardiac cycle.
- the LIF of contractile tissue such as the myocardium, is highly dependent on its state of contraction. Contraction increases the concentration of the fluorophore NADH and, hence, its contribution to tissue fluorescence. During contraction, however, blood is pumped out of the tissue, thereby reducing its hemoglobin concentration and, hence, light attenuation. Thus, a contracted myocardium retains less blood (i.e., a lower hemoglobin concentration) and, therefore, exhibits lower light absorption, than when relaxed.
- Organs such as the brain, heart and kidney are the most sensitive to oxygen deficiency and can suffer permanent damage following an ischemic or hypoxic event.
- ischemic or hypoxic event During open-heart surgery, for example, continuous monitoring of kidney perfusion, i.e., ischemia, is required.
- ischemia i.e., ischemia
- continuous monitoring of the organ is typically required.
- Ischemia and hypoxia are both conditions that deprive tissue of oxygen, leading to anaerobic metabolism and the accumulation of the metabolic coenzyme NADH.
- the coenzyme NADH is a fluorescent molecule. Therefore, ischemia and hypoxia can be indirectly detected using LIF techniques by sensing increased concentrations of NADH and interpreting its elevation as a sign of oxygen deficiency.
- a common indicator of oxygen deficiency is the ratio between the LIF intensity at wavelengths associated with the peak fluorescence emission of NADH, collagen and elastin.
- such methods have not been practically applied for the detection of ischemia because of several complications. First, these methods cannot determine whether the elevated NADH concentration is caused by ischemia, hypoxia or hypermetabolism.
- the indicator ratios are calculated by normalizing the intensity of NADH peak fluorescence by that of collagen or elastin. Although the fluoresence of the structural proteins elastin and collagen does not vary with tissue oxygenation, their fluorescence vary varies with the site of measurement.
- the intrinsic LIF of biological tissue has a single peak spectral profile resembling that of the pure structural proteins which are primarily elastin and collagen.
- this single peak profile is modulated by the attenuation of hemoglobin, especially about 410 nm, to yield a distorted, double-peak spectrum.
- the second spurious peak at about 470 nm results from the spectral valley created by heavy hemoglobin absorption at about 410 nm.
- this second peak overlaps and obscures the peak fluorescence emission of NADH at about 470-490 nm, which may impede ischemia detection techniques that are based on NADH concentration.
- the methods and devices of the present invention will enable measurement of several LIF parameters that directly relate to the state of tissue perfusion and/or hemoglobin oxygenation. This offers superior accuracy over the currently available LIF techniques which detect ischemia and hypoxia indirectly by sensing an upsurge in NADH fluorescence.
- the methods and devices of the present invention can directly indicate the presence and the level of hypoxia or ischemia.
- the methods of the present invention utilize novel criteria for discrimination between normal and ischemic or hypoxic tissue.
- the present invention is embodied in a system and related method for laser-induced fluorescence attenuation spectroscopy (“LIFAS”) in which the attenuation and intrinsic LIF of a sample can be determined.
- the LIFAS system employs a source, a first sensor, a second sensor and a processor.
- the source preferably a laser, emits light to irradiate a sample volume in a sample so that the sample volume produces return light, which preferably includes laser induced fluorescence.
- the first sensor monitors the return light at a first distance from the sample volume and generates a plurality of signals representing the intensity of the return light in predetermined wavelength bands.
- the second sensor monitors the return light at a second distance from the sample volume and generates a plurality of signals representing the intensity of the return light, preferably over the same wavelength bands.
- the processor can be used to determine the wavelength-dependent attenuation of the sample using the signals of both sensors.
- the measured attenuation will typically reflect the effects of both absorption and scattering by the sample.
- the first and second detectors monitor return light from the sample volume at a location in proximity to the sample volume.
- the attenuation can be used to restore the intrinsic LIF of the fluorophores of the sample. Once the attenuation and intrinsic fluorescence have been determined, these factors can be used in a variety of applications, including medical diagnosis.
- the attenuation and fluorescence are used for the detection of ischemia and hypoxia of biological tissue. Ischemia and hypoxia are detected by monitoring spectral changes in the intrinsic LIF to detect a rise in the concentration of NADH in the tissue. Since ischemia is caused by a decrease in the blood content of the tissue, ischemic tissue will have lower concentrations of hemoglobin.
- multicriteria associative memories can be used as an attenuation or fluorescence spectral classifier.
- FIG. 1 is a schematic diagram of a spectroscopic system in accordance with the invention
- FIG. 2(a) is a schematic diagram of a Laser Induced Fluorescence Attenuation Spectroscopy system (“LIFAS”) in accordance with the present invention having an excitation waveguide and a first and second collection waveguides;
- LIFAS Laser Induced Fluorescence Attenuation Spectroscopy system
- FIG. 2(b) is a schematic diagram of an alternative configuration of the collection waveguides of FIG. 2(a);
- FIG. 2(c) is a schematic diagram of yet another alternative configuration of the collection waveguides of FIG. 2(a);
- FIG. 3(a) is a schematic diagram of a LIFAS system in accordance with the present invention having a first excitation-collection waveguide and a second collection only waveguide;
- FIG. 3(b) is a schematic diagram of an alternative configuration of the collection waveguides of FIG. 3(a);
- FIG. 4 is schematic diagram of a LIFAS system for biomedical applications in which excitation radiation is used to induce fluorescence of tissue;
- FIGS. 5(a) and (b) are end perspective views of a LIFAS probe having an optical fiber and an optical fiber bundle as the central waveguide;
- FIGS. 6(a) and (b) are partial perspective views of an electrical subsystem used to synchronize a LIFAS system with the electrical activity of tissue using electrodes integrated into the optical probe;
- FIGS. 7(a) and (b) are schematic diagrams showing the relative positions of the action potential and electrodes integrated into the optical probe.
- FIGS. 7(c) and (d) are the corresponding action potential timing diagrams
- FIG. 8 is a perspective view of a probe incorporating a visible light source for probe positioning and a circular LED array for indicating the direction of contraction propagation;
- FIGS. 9(a)-(c) are partial perspective views of three LIFAS probes having waveguides arranged in different geometrical configurations adapted for different applications (top row is an elevation view; middle row is a side view; bottom row is a bottom view);
- FIG. 10 is a schematic diagram of a biomedical LIFAS system in accordance with the invention in which a single optical detector is used to measure the return light from two collection fibers;
- FIG. 11 18 is a block diagram of the method for determining the attenuation and the intrinsic fluorescence of a sample
- FIG. 12 19 is a graph of the attenuation spectrum measured from normal and ischemic renal cortex of rabbit kidney using LIFAS devices and methods in accordance with the invention.
- FIG. 13 20 is a scatter plot of the fluorescence intensity at 480 nm acquired from hypoxic (+), normal (o) and hyperoxic (x) tissue through excitation-collection and collection-only waveguides;
- FIG. 14 21 is a graph of the intensity I co ( ⁇ ) c of the signal measured by a collection-only waveguide from normal, hyperoxic and hypoxic tissue;
- FIG. 15 (a) 22 (a) is a graph of the modulated LIF spectra of normal and ischemic kidney.
- FIG. 15 (b) 22 (b) is a graph of the intrinsic LIF spectra of normal and ischemic kidney
- FIGS. 16 (a) and (b) 23 (a) and (b) are graphs of typical modulated LIF spectra of normal and ischemic kidney, respectively, depicting the difference in the symmetry of the main lobe;
- FIGS. 17(a)-(b) are graphs of the mean LIF intensity of live kidney and heart tissue and
- FIGS. 17(c)-(d) are the corresponding LIFAS-derived attenuation spectra.
- the present invention is embodied in a spectroscopic system 110 and related method for measuring the attenuation and/or optical rotation caused by a sample 114 .
- the spectroscopic system 110 shown in FIG. 1 includes a source 111 that produces radiation 112 , which is directed at a sample volume 113 within the sample 114 .
- the source 111 is preferably a laser and the radiation 112 is preferably monochromatic ultraviolet (UV), visible or infrared (IR) radiation 112 . Nevertheless, the source 111 can be selected to produce other types of radiation, such as broadband or polarized radiation, useful for a particular application.
- UV monochromatic ultraviolet
- IR infrared
- the spectroscopic system 110 further includes a first sensor 116 displaced by a distance Z 1 from the sample volume 113 , and a second sensor 118 displaced by a distance Z 2 from the sample volume 113 , which are used to monitor return radiation 120 from the sample 114 .
- the return radiation 120 will include fluorescence of the fluorophores of the sample 114 .
- the sensors 116 and 118 each include an aperture 116 a and 118 a, respectively, through which the return radiation 120 is observed and collected.
- the sensors 116 and 118 typically can only observe the events occurring within the volume defined by a solid angle emerging from the aperture of the sensor. This volume is known as the numerical aperture or the field of view of the sensor.
- first and second sensors 116 and 118 include numerical apertures 117 and 119 , respectively, that are adapted to receive a portion of the return radiation 120 from the sample 114 .
- the sensors 116 and 118 can be tilted at different angles ⁇ 1 and ⁇ 2 and selected to have different numerical apertures 117 and 119 so that the sensors 116 and 118 can selectively monitor return radiation 120 from all or part of the sample volume 113 .
- the sensors 116 and 118 each generate a signal 124 a and 125 a, respectively, representing the intensity I c1 ( ⁇ ) and I c2 ( ⁇ ) and/or polarization of the return radiation 120 .
- the signals 124 a and 125 a are generated at a plurality of wavelengths within predetermined wavelength bands.
- the signal 124 a from the first sensor 116 and the signal 125 a from the second sensor 118 are communicated by signal paths 124 and 125 , respectively, to a processor 123 .
- the processor 123 processes the signals 124 a and 125 a to determine a spectral characteristic of interest, such as the attenuation and/or optical rotation of the return radiation 120 caused by the sample 114 .
- the sensors 116 and 118 are positioned at non-equivalent distances Z 1 and Z 2 from the sample volume 113 .
- the first and second sensors 116 and 118 will be positioned so that one of the sensors will be in the immediate proximity of the sample volume 113 while the other sensor is positioned at a location adjacent to the first sensor, but displaced slightly further from the sample volume 113 . It has been found that this arrangement advantageously improves the signal-to-noise ratio and, hence, measurement accuracy of the spectroscopic system 110 .
- the attenuation of the return radiation 120 is dependent on the distance traveled by the return radiation 120 through the sample 114 .
- the signal 124 a measured by the first sensor 116 and the signal 125 a measured by the second sensor 118 will suffer different attenuation where the distances Z 1 and Z 2 from the sample volume 113 are not equivalent.
- the processor 123 can be used to process the signals 124 a and 125 a to determine the wavelength-dependent attenuation of the sample 114 .
- the attenuation determined by the spectroscopic system 110 will reflect the effects of light absorption and scattering by the sample 114 .
- the attenuation of the sample 114 can be used to determine the intrinsic fluorescence 129 of the fluorophores in the sample volume 113 .
- the methods by which the attenuation and intrinsic LIF are determined are discussed in detail below.
- the source 111 can be any radiation source, such as a laser or lamp emitting excitation radiation 112 at a wavelength capable of interacting with the sample 114 .
- the sensors 116 and 118 will preferably include a detector, which can be as simple as individual light-sensitive diodes with appropriate band pass filters, or more complicated sensors such as an optical spectrum analyzer.
- the sensor is a suitable spectrograph or spectrometer equipped with a suitable sensor.
- the sensor can include a multispectral CCD camera.
- the source 111 is an XeCl excimer laser emitting monochromatic ultraviolet radiation at 308 nm.
- Each of the sensors 116 and 118 is a spectrograph (Model FF250, ARIES Inc., Concorde, Mass.) associated with a 1024 element intensified photo diode array (PDA) to image the resolved spectrum.
- PDA photo diode array
- Each PDA is connected to an optical multichannel analyzer (OMA III, EG&G Princeton Applied Research Corporation, Princeton, N.J.). The OMA reads the light spectrum imaged by the PDA to produce the signals 124 a and 125 a.
- a 335 nm longpass filter (Schott WG335) is placed in front of the aperture of each of the sensors 116 and 118 to remove any backscattered 308 nm excitation radiation.
- the processor 123 is a personal computer that is networked to each of the sensors 116 and 118 via the signal paths 124 and 125 to receive the signals 124 a and 125 a, respectively.
- optical rotation is observed in optically active materials.
- An optically active material is characterized by a lack of symmetry in its molecular or crystalline structure which causes a rotation of the plane of polarization in incident-plane-polarized radiation.
- the extent to which the plane of polarization is rotated will typically vary from one optically active material to another.
- the extent of rotation may depend on the number of molecules in the path of the radiation, the wavelength of the radiation, and the temperature of the material.
- Anisotropy is caused be a selective response of the sample to radiation travelling in different directions.
- anisotropy can result from microscopic inhomogeneity in the tissue structure.
- Use of equivalent distances Z 1 and Z 2 will minimize the contribution of the path-length-dependent attenuation to the overall attenuation measured by the system 110 . Therefore, the optical rotation or anisotropy of the sample can be determined more easily.
- the LIFA system 110 shown in FIG. 1 can be adapted to measure optical rotation by utilizing first and second sensors 116 and 118 which are adapted to measure the polarization-dependent intensity of the return radiation.
- the first sensor 116 can be adapted to measure a first optical angle ⁇ 1 (not shown) yielding the maximum intensity of the first portion of the return radiation 120 .
- the second sensor 118 can be adapted to measure a second optical angle ⁇ 2 (not shown) yielding the maximum intensity of the second portion of the return radiation 120 .
- the optical rotation of the return light 120 will be given by the difference between the angles ⁇ 1 and ⁇ 2 , provided that the system has been properly calibrated.
- the same sensor is used for determination of the attenuation of the sample will find utility for monitoring the optical rotation.
- These sensors can be adapted to such measurements by placing a rotatable polarizing filter at each of the apertures 116 a and 118 a of the first and second sensors 116 and 118 , respectively.
- FIG. 2(a) An alternative embodiment of the present invention is shown in FIG. 2(a).
- the spectroscopic system 110 of FIG. 1 has been adapted as a Laser Induced Fluorescence Attenuation Spectroscopy (“LIFAS”) system 210 .
- LIFAS Laser Induced Fluorescence Attenuation Spectroscopy
- a source 211 emits laser radiation 212 at an intensity and a wavelength capable of inducing fluorescence of the sample 214 .
- the laser radiation 212 is transmitted through an excitation waveguide 215 to a sample volume 213 within the sample 214 where the laser radiation 212 excites local fluorophores in the sample volume 213 to emit intrinsic fluorescence 229 .
- the intrinsic fluorescence 229 of the fluorophores in the sample volume 213 is modulated, for example, by the absorption and scattering of the local chromophores (not shown) and scatterers (not shown) present in the sample 214 , respectively.
- Two collection waveguides 221 and 222 having apertures 221 a and 222 a and numerical apertures 217 and 219 are disposed about the excitation waveguide 215 .
- the collection waveguides 221 and 222 may be positioned such that their apertures 221 a and 222 b are laterally displaced from the excitation waveguide 215 by the distances x1′ and x2′ and/or axially displaced from the aperture 215 a of the excitation waveguide 215 by the distances y1′ and y2′.
- the lateral distances x1′ and x2′ are small or zero.
- the axial distances y1′ and y2′ are preferably selected to be small and unequal, while one of the axial distances is preferably zero. Also, it is desirable to position the apertures 215 a, 221 a and 222 a of the waveguides 215 , 221 and 222 in close proximity to or in contact with the sample 214 during use of the LIFAS system 210 , as shown in FIG. 2(a).
- FIG. 2(c) An alternative configuration of the collection waveguides is shown in FIG. 2(c).
- the axial distances y1′ and y2′ are both zero.
- the lateral distances x1′ and x2′ are selected to be small and unequal.
- the apertures 240 a and 242 a of the waveguides 240 and 242 are oblique such that the fields of view 244 and 246 are directed toward the sample volume 213 and to advantageously encompass the bulk of the sample volume 213 . As shown in FIG.
- the distances z1′ and z2′ are directed along the respective axes of the numerical apertures 244 and 246 and extend from the surface of the apertures 240 a and 242 a to the point of intersection of the axes of the numerical apertures 244 and 246 , respectively.
- the collection waveguide 221 collects a first portion 228 of the return light 220 and transmits the first portion 228 of the return light 220 to a first sensor 216 .
- the first sensor 216 generates a first signal 224 a, representing the intensity I c1 ( ⁇ ) of the first portion 228 of the return light 220 at a plurality of wavelengths within predetermined wavelength bands.
- the collection waveguide 222 collects a second portion 230 of the return light 220 and transmits the second portion 230 of the return light 220 to the second sensor 218 .
- the second sensor 218 generates a second signal 225 a representing the intensity I c2 ( ⁇ ) of the second portion 230 of the return light 220 at a plurality of wavelengths preferably within the same wavelength bands monitored by the first sensor 216 .
- the processor 223 then processes the first and second signals 224 a and 225 a to determine the wavelength-dependent attenuation of the sample 214 . As discussed in detail, below, once the attenuation is known, either of the signals 224 a or 225 a can be processed to minimize the effects of attenuation and determine the intrinsic LIF 229 of the fluorophores in the sample volume 213 . Alternatively, if the sensors 216 and 218 are selected to monitor the polarization of the first portion 228 and the second portion 230 of the return light 220 , the processor 223 can be used to determine the optical rotation of the return light 220 caused by the sample 214 .
- the intensity and wavelength of the laser radiation 212 should be sufficient to create a sample volume 213 that is large enough to have some overlap with the numerical apertures 217 and 219 of the collection waveguides 221 and 222 , respectively.
- the numerical apertures 217 and 219 can be selected to encompass all or parts of the sample volume 213 .
- longpass filters are placed before the inputs of the sensors 216 and 218 to selectively block backscattered excitation radiation.
- the source 211 is an Xe—Cl excimer laser emitting 308 nm ultraviolet excitation radiation 212 .
- the waveguides 215 , 221 and 222 are advantageously comprised of optical fibers or optical fiber bundles, which can be integrated into a probe for ease of use and durability.
- the optical bundle and fibers are made of fused silica which is transparent to ultraviolet radiation. Specifically, a 1.4 mm diameter optical bundle is used as the excitation waveguide 215 while the collection waveguides 221 and 222 are 0.4 mm optical fibers disposed about the excitation bundle.
- the lateral range x1′ and x2′ are equal to zero while the axial distance y1′ is about 0.6 mm and the axial distance y2′ is about zero.
- the probe may be configured within, for example, the shaft of a hypodermic needle, so that the in-vivo physiological or pathological properties of biological tissue can be determined.
- each of the sensors 216 and 218 is a spectrograph (Model FF250, ARIES Inc., Concorde, Mass.) associated with a 1024 element intensified photo diode array (PDA).
- PDA 1024 element intensified photo diode array
- Each PDA is connected to an optical multichannel analyzer (OMA III, EG&G Princeton Applied Research Corporation, Princeton, N.J.) which measures the intensity of the light spectrum imaged by the PDA and produces the signals 224 a and 225 a.
- OMA III optical multichannel analyzer
- the processor 223 is a personal computer that is networked to each of the sensors 216 and 218 via the signal paths 224 and 225 to receive the signals 224 a and 225 a, respectively.
- FIG. 11 18 illustrates the main steps involved in determining the wavelength-dependent attenuation coefficient ⁇ ( ⁇ ) and the intrinsic fluorescence I T ( ⁇ ) of a sample in accordance with the current invention.
- the first and second portions 228 and 230 of the return light 220 experience different attenuation effects due to the unequal path lengths traversed by the return light 220 from the sample volume 213 to the apertures 221 a and 222 a of the collection waveguides 221 and 222 .
- the first portion 228 of the return light 220 collected by the aperture 221 a travels an additional path-length of ⁇ y1′-y2′ ⁇ through the tissue as compared to the second portion 230 of the return light 220 which is collected by the aperture 222 a.
- the first portion 228 of the return light 220 suffers more path-length-dependent attenuation as compared to the second portion 230 of the return light 220 .
- the signals 224 a and 225 a representing the intensity I c1 ( ⁇ ) and I c2 ( ⁇ ) at different wavelengths will exhibit differing levels of modulation caused by the attenuation of the sample 214 .
- the signals 224 a and 225 a will also exhibit wavelength-dependent modulations caused by the instrumental effects.
- the wavelength-dependent modulations due to the instrumental effects can be determined and, in turn, compensated for by conducting a calibration of the LIFAS system 210 .
- System calibration can be performed using light from a standard lamp (Quartz Halogen Lamp, Model No. 63358, Oriel Instruments, Stratford, Conn.) having a predetermined continuous spectrum to measure the wavelength-dependent instrumental effects of the LIFAS system 210 .
- the processor 223 can be adapted to correct the measured intensities I c1 ( ⁇ ) and I c2 ( ⁇ ) for modulations caused by the wavelength-dependent instrumental effects.
- the corrected intensities I c1 ( ⁇ ) c and I c2 ( ⁇ ) c representing the intensity of the first and second portions 228 and 230 of the return light 220 at different wavelengths can then be used to determine the attenuation coefficient ⁇ ( ⁇ ) of the sample 214 as described below.
- the regions ⁇ circle around (1) ⁇ and ⁇ circle around (2) ⁇ , of FIG. 2(a) may be at an effective range, symbolized as “R,” from which the collection waveguides 221 and 222 collect the majority of the first and second portions of return light 228 and 230 , respectively.
- the effective range “R” will vary with the attenuation of the sample.
- the regions ⁇ circle around (1) ⁇ and ⁇ circle around (2) ⁇ are geometrically symmetric with respect to the aperture 215 a of the excitation waveguide 215 and, hence, have identical intensity of the intrinsic fluorescence 229 represented by I T ( ⁇ ).
- the intrinsic fluorescence, I T ( ⁇ ) can be restored from either of the signals I c1 ( ⁇ ) c or I c2 ( ⁇ ) c (preferably I c2 ( ⁇ ) c where y2′ ⁇ y1′) by assuming an average effective range “R” from which most of the intrinsic fluorescence is collected.
- the constant “R” is approximately about 0.2 mm at 308 nm excitation radiation.
- the measured attenuation accounts for absorption and/or scattering is mainly determined by the wavelength band of interest and the nature of the sample.
- the optical properties of biological tissue and the effects of tissue on LIF are greatly different for the wavelengths below and above approximately 600 nm. Below about 600 nm, the optical attenuation of biological tissue is primarily due to absorption and, hence, the attenuation coefficient ⁇ ( ⁇ ) will represent absorptivity ⁇ ( ⁇ ) a ( ⁇ ). Absorptivity is a property of a substance, while absorbance is a property of a particular sample of a substance. Therefore, absorbance will vary with the concentration of the substance (e.g., hemoglobin) and geometry of the tip of the probe.
- the concentration of the substance e.g., hemoglobin
- the source 311 emits laser radiation 312 at a wavelength and intensity capable of inducing fluorescence of the sample 314 .
- the laser radiation 312 is reflected by a dichroic mirror 326 into an excitation-collection waveguide 321 , which transmits the laser radiation 312 to the sample volume 313 where the laser radiation 312 excites local fluorophores to emit intrinsic fluorescence 329 .
- the intensity of the laser 312 should be sufficient to create a sample volume 313 that overlaps with the numerical aperture 319 of the collection-only waveguide 322 .
- the dimensions of the sample volume 313 will also depend on the numerical aperture of the excitation-collection waveguide 321 , on the wavelength and intensity of the excitation radiation 312 and on the optical properties of the sample 314 .
- the intrinsic fluorescence 329 is modulated, for example, by the absorption and scattering of the local chromophores (not shown) and scatterers (not shown) of the sample 314 .
- the excitation-collection waveguide 321 collects a first portion 328 of the return light 320 directly from the sample volume 313 .
- the first portion 328 of the return light 320 is transmitted through the dichroic mirror 326 to the first sensor 316 .
- the first sensor 316 generates a first signal 324 a representing the intensity I xc ( ⁇ ) of the first portion 328 of the return light 320 at a plurality of wavelengths within a predetermined wavelength band.
- the collection-only waveguide 322 may be positioned such that the aperture 322 a is laterally displaced from the excitation-collection waveguide 321 by the distance x3 and axially displaced from the aperture 321 a of the excitation-collection waveguide 321 by the range y3.
- the lateral distance x3 is zero while the axial distance y3 is non-zero.
- the apertures 321 a and 322 a of the waveguides 321 and 322 are preferably positioned in close proximity to or in contact with the sample 314 during use of the LIFAS system 310 , as shown in FIG. 3(a).
- the numerical aperture 319 of the collection-only waveguide 322 is selected to include at least a portion of the sample volume 313 .
- the collection-only waveguide 322 collects a second portion 330 of the return light 320 which is transmitted to a second sensor 318 .
- the second sensor 318 generates a second signal 325 a representing the intensity I co ( ⁇ ) of the second portion 330 of the return light 320 at a plurality of wavelengths preferably within the same wavelength bands as the signal 324 a generated by the first sensor 316 .
- a longpass filter is placed in front of the aperture of each of the sensors 316 and 318 to selectively block backscattered excitation radiation.
- the first and second portions 328 and 330 of the return light 320 experience different attenuation effects due to the unequal pathlengths traversed by the return light 320 from the sample volume 313 to the apertures 321 a and 322 a of the waveguides 321 and 322 , respectively.
- the second portion 330 of the return light 220 collected by the aperture 322 a travels an additional path-length through the tissue as compared to the first portion 328 of the return light 320 which is collected by the aperture 321 a directly from the sample volume 313 .
- the first portion 328 of the return light 320 suffers less path-length-dependent attenuation as compared to the second portion 330 of the return light 320 .
- the signals 324 a and 325 a representing intensity I xc ( ⁇ ) and I co ( ⁇ ) at different wavelengths will exhibit different levels of modulation caused by the sample 314 .
- the signals 324 a and 325 a will also exhibit wavelength-dependent modulations caused by the instrumental effects.
- the wavelength-dependent modulations due to instrumental effects can be determined and, in turn, compensated for by conducting a calibration of the LIFAS system 310 .
- System calibration is performed using light from a standard lamp (Qaurtz Halogen Lamp, Model No. 63358, Oriel Instruments, Stratford, Conn.) having a predetermined continuous spectrum to measure the wavelength-dependent instrumental effects of the LIFAS system 310 .
- the processor 323 can be adapted to correct the measured intensities I xc ( ⁇ ) and I co ( ⁇ ) for modulations caused by the wavelength-dependent instrumental effects.
- the corrected intensities I xc ( ⁇ ) c and I co ( ⁇ ) c representing the intensity of the first and second portions 328 and 330 of the return light 320 at different wavelengths can then be used by the processor 323 to determine the wavelength-dependent attenuation ⁇ ( ⁇ ) of the sample 314 .
- the processor 323 can then be used by the processor 323 to determine the wavelength-dependent attenuation ⁇ ( ⁇ ) of the sample 314 .
- either of the signals 324 a or 325 a, preferably 324 a can be corrected for the effects of attenuation to restore the intrinsic LIF 329 of the fluorophores in the sample volume 313 .
- the source 311 is an Xe—Cl excimer laser emitting ultraviolet excitation radiation at a wavelength of 308 nm.
- the waveguides 321 and 322 are advantageously comprised of optical fibers or optical fiber bundles, which can be integrated into a probe for ease of use and durability.
- a 1.4 mm diameter optical bundle and a 0.4 mm optical fiber are used as the excitation-collection and the collection-only waveguides, respectively.
- the collection-only waveguide is a plurality of 0.4 mm optical fibers disposed about the periphery of the excitation-collection waveguide.
- the optical bundle and fibers are made of fused silica which is transparent to the 308 nm ultraviolet radiation.
- the probe may be configured within, for example, the shaft of a hypodermic needle, so that the in-vivo physiological or pathological properties of biological tissue can be determined.
- Each of the sensors 316 and 318 is a spectrograph (Model FF250, ARIES Inc., Concorde, Mass.) associated with a 1024 element intensified photo diode array (PDA) to image the resolved spectrum.
- PDA element intensified photo diode array
- Each PDA is connected to an optical multichannel analyzer (OMA III, EG&G Princeton Applied Research Corporation, Princeton, N.J.) which measures the intensity of the light spectrum imaged by the PDA and produce the signals 324 a and 325 a.
- the processor 323 is a personal computer that is networked to each of the sensors 316 and 318 via the signal paths 324 and 325 to receive the signals 324 a and 325 a, respectively.
- the method of determining the attenuation coefficient ⁇ ( ⁇ ) and the intrinsic fluorescence I T ( ⁇ ) of a sample using the embodiment of FIG. 3(a) in accordance with the current invention is as follows.
- “D” represents the effective range, from which the collection waveguide 321 collects a majority of the portion 328 of the return light 320 .
- the portion 328 of the return light 320 is collected directly from the sample volume 313 by the excitation-collection waveguide 321 .
- the wavelength-dependent intensity I xc ( ⁇ ) c of the portion 328 of the return light 320 collected by the excitation-collection waveguide 321 will be substantially similar to the wavelength-dependent intensity of the return light 320 , represented as I o ( ⁇ ).
- the return light 320 with the intensity I o ( ⁇ ) will suffer additional wavelength-dependent attenuation as it travels the extra path-length to reach the aperture 322 a and is collected as the second portion 330 of the return light 320 with the intensity I co ( ⁇ ) c .
- the lateral and axial distances x3 and y3 will be predetermined by the configuration of the waveguides 321 and 322 .
- the intrinsic fluorescence, I T ( ⁇ ) can be restored from either of the signals I xc ( ⁇ ) c or I co ( ⁇ ) c , preferably I xc ( ⁇ ) c , by assuming an average effective range “D” from which most of the intrinsic fluorescence is collected.
- the constant “D” is approximately about 0.2 mm at 308 nm excitation radiation.
- a LIFAS system 410 in accordance with the present invention has been adapted for biomedical applications.
- the LIFAS system 410 has been adapted to determine the optical attenuation of biological tissue.
- the laser 411 emits radiation 412 at a wavelength capable of exciting the tissue 414 to emit fluorescence.
- the radiation 412 is directed through an iris 440 at a dichroic mirror 442 which reflects the radiation 412 onto a lens 444 which focuses the radiation 412 onto the proximal tip 445 of an optical fiber 446 .
- the adjustable iris 440 is advantageously used to reduce the energy of the radiation 412 .
- the adjustable iris 440 can be replaced by any suitable attenuator.
- the probe 448 includes a central optical fiber 446 that is used as the excitation-collection fiber and peripheral optical fibers 450 a-h are used as the collection-only fibers. The distal end of the optical fibers 446 and 450 a-h are incorporated into the optical probe 448 .
- the aperture 448 a the optical fiber probe 448 is placed in proximity to the tissue 414 so that the aperture 446 a of the excitation-collection fiber 446 and apertures 451 a-h of the collection-only fibers 450 a-h are in contact with the tissue 414 . As shown in a partial perspective view in FIG.
- the optical fiber probe 448 includes a central optical fiber 446 and a plurality of optical fibers 450 a-h disposed about the periphery of the central optical fiber 446 .
- the apertures 451 a-h of the distal ends of the collection-only fibers 450 a-h are axially displaced by a small distance y3 with respect to the aperture 446 a of the excitation-collection fiber 446 .
- the return light 420 collected by apertures 451 a-h of the collection-only fibers 450 a-h pool into the aperture 418 a of the sensor 418 .
- optical fibers 446 and 450 a-h can advantageously be replaced by optical fiber bundles in order to obtain greater flexibility and durability.
- the central optical fiber 446 can be replaced with an optical fiber bundle 454 .
- the excitation radiation 412 is transmitted through the optical fiber 446 to the tissue 414 to induce intrinsic fluorescence of the fluorophores of the tissue 414 .
- the intrinsic fluorescence is modulated, for example, by the chromophores and/or scatterers of the tissue 414 .
- a first portion 428 of the return light 420 is collected by the optical fiber 446 from the tissue volume that is directly irradiated by the excitation radiation 412 and transmitted through the optical fiber 446 to a first lens 444 where the return light is directed through the dichroic mirror 442 and then focused by a second lens 449 onto the aperture 416 a of a first sensor 416 .
- the collection-only optical fibers 450 a-h collect a second portion 430 of the return light 420 and transmit the second portion 430 of the return light 420 to the second sensor 418 .
- longpass filters are placed in front of the apertures 416 a and 418 a of the sensors 416 and 418 to selectively block backscattered excitation radiation.
- a first signal 424 a and a second signal 425 a representing the intensity of the first and second portions 428 and 430 , respectively, of the return light 420 are generated by the first and second sensors 416 and 418 and transmitted via signal paths 424 and 425 to the processor 423 .
- the processor 423 uses the first and second signals 424 a and 425 a generated by the detectors 416 and 418 to determine the wavelength-dependent attenuation of the sample 414 using equations (8), (9) and (10) as described in the previous embodiment.
- an illumination source 490 emitting visible light 492 is mounted on the probe 448 to act as a spotlight for the operator. Because room illumination can contaminate the spectral measurements of the system 410 by adding background light, use of the illumination source 490 will allow the operator to see and accurately position the probe 448 under low-light conditions.
- the illumination source 490 is configured to illuminate the sample at all times, except when the LIFAS system is monitoring return light from the sample 414 .
- the biological electrical signal arising in nerves or contractile tissue, such as muscle, is known as the “action potential” and is caused by sudden changes in the ion conductivity of the cell membrane.
- the occurrence of an action potential in contractile tissue initiates a contraction.
- the action potential propagates and spreads in a wave-like manner to induce a local myocardial contraction wherever it travels.
- An action potential propagating in the tissue local to the aperture 448 a of the probe 448 can be detected by the electrode 464 which is incorporated into the probe 448 as shown, for example, in FIG. 6(a). Voltage alternations caused by the occurrence of the action potential are picked up by the electrode 464 in reference to the common electrode 466 and are transmitted to the amplifier 460 .
- the common electrode 466 provides the electrical ground for the amplifier 460 by maintaining contact with the tissue of interest 414 or the whole body.
- the amplified action potential 468 is transmitted to the processor 423 to trigger the acquisition process of the LIFAS system 410 at a pre-selected phase of the tissue contraction or of the cardiac cycle, whichever is applicable.
- a plurality of electrodes or fibers with a conductive coating can be distributed circumferentially about the tip of the optical fiber probe 448 .
- the probe 448 can be equipped with three electrodes 470 , 472 and 474 arranged in a triangular configuration.
- the action potentials measured by each of the electrodes 470 , 472 and 474 are amplified through separate channels of the amplifier 460 and transmitted to the processor 423 .
- the processor 423 processes the received signals to determine the direction of propagation of the contraction vector 462 .
- the processor detects the phase lead/lag between the action potentials collected by the electrodes 470 , 472 and 474 to determine the orientation of the contraction vector 462 with respect to the location of the electrodes 470 , 472 and 474 .
- the contraction vector 462 shown in FIG. 7(a) is propagating from the tissue site 476 a to the site 478 a and, hence, as shown in FIG. 7(c), the action potential 474 a arrives before the action potential 472 a which in turn arrives before the action potential 470 a.
- the phase difference or time delay between a pair of action potentials indicates how the contraction vector 462 is centered between the location of the corresponding pair of electrodes.
- the contraction vector 462 propagates from the tissue site 476 b to the site 478 b.
- the corresponding time of arrival of action potentials 470 b, 472 b and 474 b will vary.
- the processor 423 processes the signals and indicates the direction of the propagation of the contraction to the system operator.
- the direction of propagation can be indicated, for example, by a circular array 496 of light emitting diodes (LED) 498 mounted circumferentially on the probe 448 , as shown in FIG. 8.
- the processor 423 transmits a signal to the LED array 496 so that, for example, only the LED element pointing in the direction of contraction propagation would glow.
- the amplifier 460 can be replaced by any device that can measure the electrical activity of biological tissue such as a differential amplifier, an electrocardiogram (ECG), an electromyogram (EMG), an electroencephalogram (EEG), depending on the LIFAS application.
- ECG electrocardiogram
- EMG electromyogram
- EEG electroencephalogram
- optical fibers with a metallic or electrically conductive coating can be used in place of one or all of the electrode 464 , 470 , 472 or 474 to measure the action potential of the tissue.
- conventional ECG is generally not suitable for triggering the acquisition of LIFS or LIFAS systems, since it does not accurately indicate the instantaneous state of myocardial contraction at the sample volume.
- customary ECG using limb or chest leads can be used to trigger data acquisition of the LIFAS system 410 where the sample 414 is non-contractile tissue.
- the light source 411 is preferably a lamp or a laser that emits ultraviolet, visible or infrared radiation.
- the source 411 is an XeCl excimer laser emitting pulses of ultraviolet excitation radiation at 308 nm.
- the optical components used in the acquisition system be made of synthetic quartz (fused silica) to ensure maximal ultraviolet transmission and minimal instrumental fluorescence.
- a nitrogen laser, a helium-cadmium laser, a frequency-multiplied laser, a solid-state laser, an arc lamp or a light-emitting diode can be used as the light source 411 .
- the energy of the excitation light 412 is typically between 0.001-10 m Joules. However, it will be appreciated that the selected energy level should be low enough to avoid tissue ablation and/or photobleaching while still being adequate to produce detectable LIF.
- the sensors 416 and 418 are each comprised of a spectrograph (Model FF250, ARIES Inc., Concorde, Mass.) associated with a 1024 element intensified photo diode array (PDA) detector.
- An optional low fluorescence, long-pass filter (not shown) with a cutoff wavelength above 308 nm, preferably 335 nm (Schott WG335), is placed before the entrance slit of each spectrograph to selectively block any backscattered excitation radiation from reaching the sensors 416 and 418 .
- the entrance slit of the spectrograph preferably has a width of 100 micrometers.
- the spectrograph uses a 150 lines per millimeter diffraction grating to disperse the incoming return light 420 into its spectral components.
- the spectrum formed by the spectrograph is imaged by a detector, preferably an intensified linear photodiode array (Model 1420, EG&G Princeton Applied Research Corporation, Princeton, N.J.) facing the output port of the spectrograph.
- the photodiode array generates a plurality of electrical signals representing the intensity of the return light 420 at wavelengths within predetermined wavelength bands.
- the sensors can be constructed of any suitable materials, such as individual light-sensitive diodes with appropriate band-pass filters for the analysis of spectral bands of the return light or an optical spectrum analyzer (“OSA”) for analysis of a broader spectrum. Selection of the return light monitoring device will depend on a variety of factors, including cost, accuracy, resolution, and whether the user is interested in monitoring a single wavelength, a wavelength band or an entire spectrum.
- the optical fiber probe includes a central excitation-collection optical fiber or optical fiber bundle with a plurality of collection-only optical fibers disposed around its periphery
- the probe can take many forms.
- the central optical fiber can be used as the collection-only waveguide while all or some of the peripheral fibers can be used for excitation-collection or collection-only. The latter arrangement is preferred when testing highly-attenuating samples to achieve a better signal-to-noise ratio.
- FIG. 9 shows three alternative geometrical configurations of the collection-only optical fibers 950 450 ′a-h about the excitation-collection waveguide 946 446 ′.
- the collection-only waveguides 950 450 ′a-h are arranged about the excitation-collection waveguide 946 446 ′so that their apertures have a helical configuration.
- each successive collection-only waveguide is shifted axially away from the aperture 947 447 ′of the excitation-collection waveguide 946 446 ′, the return light collected by each of the collection-only waveguides 950 450 ′a-h will be attenuated in varying degrees.
- Use of a probe arrangement having a plurality of collection distances will be useful in measuring the polarization and/or the attenuation of, especially, a sample having a higher sensitivity to attenuation due to absorption.
- a probe incorporating a plurality of collection distances have has application to a larger variety of samples.
- the collection-only waveguides having apertures close to the excitation site can be used to collect the return light.
- the return light collected by the waveguides having apertures that are further from the excitation site will be useful in determining the attenuation.
- the collection-only waveguides 950 450 ′a-c are displaced laterally with respect to the excitation-collection waveguide 946 446 ′.
- Such a probe configuration will be useful in measuring the polarization and/or the attenuation of the sample where the sample has a higher sensitivity to attenuation due to scattering.
- the return light collected by the waveguide 950 450 ′c will be useful in measuring attenuation of a lightly attenuating sample.
- the return light measured by the closest waveguide 950 450 ′a will be useful in measuring the attenuation of a heavily-attenuating sample.
- the collection-only waveguides 950 450 ′a-c are both axially and laterally displaced with respect to the excitation-collection waveguide 946 446 ′.
- This configuration combines the advantages of both of the aforementioned configurations shown in FIGS. 9(a) and 9(b).
- a single sensor 1016 and an associated optical multiplexer 1080 are utilized.
- the multiplexer 1080 is used to switch the input of the sensor 1016 between the excitation-collection optical path ( 1046 , 1044 , 1042 , 1049 , 1046 ′) and the collection-only optical path ( 1050 ) such that the return light from each pathway is measured sequentially.
- the processor 1023 sends trigger signals to the source 1011 , the sensor 1016 and the optical multiplexer 1080 to synchronize their actions. If the source 1011 is a pulsed laser, two or more radiation pulses are typically required to acquire a single attenuation measurement using the multiplexed system 1010 .
- a single laser pulse can be used if the laser pulse lasts long enough to sustain the emission of return light 1020 during the minimum period of time required by the optical multiplexer 1080 and associated sensor 1016 to acquire the spectral measurements from both the excitation-collection and the collection only optical paths.
- the preferred embodiment of the LIFAS system 1010 is similar to that of 410 , except that the system 1010 utilizes an electromagnetic dual port shutter as the optical multiplexer 1080 associated with a single sensor 1016 in a configuration where the portion 1028 and the portion 1030 of the return light 1020 are measured sequentially.
- the LIFAS methods and devices of the present invention can be used advantageously for the in-vivo diagnosis of hypoxia and ischemia of biological tissue.
- Hypoxia is a deficiency in the amount of oxygen reaching the tissue, e.g., due to pneumonia
- ischemia is a localized reduction in arterial blood perfusion, e.g., due to a narrowing of arteries by spasm or disease.
- Ischemia can also result from hemorrhage of an arterial wound or during surgical procedure that temporarily interrupts the blood flow to a body region.
- the present invention describes new criteria and methods for the discrimination between normal, ischemic and hypoxic biological tissue, including, in particular renal and myocardial tissue, as follows.
- LIFAS laser induced fluorescence attenuation
- the LIFAS-derived LIFA spectra of normal and ischemic rabbit kidney are shown in FIG. 12 19 .
- the LIFA spectra shown in FIG. 12 19 are acquired using a LIFAS system employing 308 nm excitation radiation produced by an XeCl excimer laser.
- This LIFAS system uses a 335 nm longpass filter (Schott WG335) to cutoff backscattered excitation radiation form the collected return light.
- the LIFA values below 350 nm are not reliable.
- the LIFA values in the wavelength band about 480 nm have the highest signal-to-noise ratio and hence measurement accuracy.
- the LIFA of ischemic tissue is lower than the LIFA of normal tissue over the entire spectrum and is particularly low in the region from 350 to 450 nm.
- the LIFA, absorbance or percent transmittance at a predetermined wavelength or wavelength bands can be used for the detection of ischemia or hypoxia.
- predictive models, spectral recognition techniques and associated classifiers can be applied to identify whether a given LIFA, absorbance or percent transmittance spectrum has been acquired from normal, ischemic or hypoxic tissue.
- the classifiers can be initially trained with LIFA, at a predetermined wavelength or wavelength bands acquired from tissue with a known state of perfusion or oxygenation.
- the [I xc (480) c , I co (480) c ] from normal and oxygen deficient tissue tend to cluster in two linearly separable regions of the two dimensional I xc ( ⁇ ) c ⁇ I co ( ⁇ ) c space.
- a simple linear or nonlinear classifier function can be trained on a set of [I xc ( ⁇ ) c , I co ( ⁇ ) c ] pairs measured using a LIFAS system from normal, ischemic and hypoxic tissue.
- Other classifiers such as artificial neural networks (ANN) are also being used.
- the trained classifier function can then be used to classify an unknown [I xc ( ⁇ ) c , I co ( ⁇ ) c ] pair as normal, ischemic or hypoxic.
- a “nearest neighbor” (NN) classifier has been found to perform satisfactorily.
- the NN classifier checks the proximity of an unknown [I xc (480) c , I co (480) c ] pair to clusters of predetermined [I xc (480) c , I co (480) c ] pairs measured from known normal, ischemic and hypoxic tissue.
- Other classifiers such as artificial neural networks (ANN) can also be utilized.
- ANN artificial neural networks
- [I xc ( ⁇ ) c , I co ( ⁇ ) c ] at other single or multiple pre-selected wavelengths can also be used.
- ⁇ max-T the wavelength of the peak transmittance of the tissue
- ⁇ max-co the wavelength of the peak I co ( ⁇ ) c in the 450-500 nm band.
- ⁇ max-co the wavelength of the peak I co ( ⁇ ) c in the 450-500 nm band
- ⁇ max-co the wavelength of the peak I co ( ⁇ ) c in the 450-500 nm band
- ⁇ max-co the wavelength of the peak I co ( ⁇ ) c in the 450-500 nm band
- ⁇ max-co Both ⁇ max-T and ⁇ max-co shift towards shorter wavelengths as the hemoglobin in the tissue becomes deoxygenated.
- FIG. 14 21 shows I co ( ⁇ ) c spectra that are acquired using the LIFAS system shown in FIG. 10 employing 308 nm excitation radiation produced by and XeCl excimer laser.
- ⁇ max-co varies between about 480 and 500 nm as blood or hemoglobin oxygenation varies between deoxygenated to oxygenated, respectively.
- a separation border can be identified at about 489.5 nm to separate ⁇ max-co of normal tissue (peaks above 489.5 nm) from hypoxic/ischemic tissue (peaks below 489.5 nm).
- a simple classifier can be trained to identify tissue as hypoxic if its ⁇ max-co is below 489.5, and vice versa. The degree of hypoxia is determined from the magnitude of the shift in ⁇ max-co from the normal value, the smaller the shift the subtle the hypoxia.
- the presence of renal or myocardial ischemia can be detected from the shape of the main lobe of the common LIF (e.g. I xc ( ⁇ ) c ) spectrum in the wavelength band 350-450 nm.
- the common LIF can be acquired via an excitation-collection waveguide of a LIFAS or a conventional LIFS system.
- FIGS. 16 23 (a) and (b) show typical LIF spectra acquired from normal and ischemic rabbit kidneys at an excitation wavelength of 308 nm.
- the shape of the main lobe of the LIF acquired from normal tissue is skewed to the right (a positive skewness value).
- the shape of the main lobe of the LIF acquired from ischemic tissue is almost symmetric (a very small skewness value).
- Skewness can be measured by a single parameter which indicates the degree of asymmetry of a lobe or curve around its mean value. For a symmetrical lobe the skewness is zero, however for an asymmetrical lobe the skewness can be either positive or negative depending on the shape.
- x is the intensity of the fluorescence at the wavelength ⁇
- x is the mean intensity of the lobe
- ⁇ is the wavelength
- N is the number of wavelength measurements in the lobe.
- tissue ischemia can be detected by monitoring the skewness of the main lobe of a common (i.e. modulated) LIF acquired using an excitation-collection fiber from the tissue.
- a zero or negative skewness value indicates that the LIF spectra is acquired from ischemic tissue, while a positive skewness will indicate normally perfused tissue.
- the bottom of the central spectral valley is considered as the baseline for the definition of the main lobe as indicated in FIG. 16 23 .
- the intrinsic LIF of normal biological tissue will have a spectrum with a single peak resembling that of the main tissue fluorophores, collagen and elastin.
- the intrinsic LIF develops a secondary peak or a hump at about 470-490 nm which is associated with the peak fluorescence emission of NADH.
- the appearance of this hump in an intrinsic LIF spectrum is a direct indication of oxygen deficiency resulting from hypoxia or ischemia.
- this NADH-related hump is not readily detectable in common LIF spectra because of an overlapping spurious hump created by an intensity dip associated with peak hemoglobin absorption at about 410 nm.
- the intrinsic LIF spectrum of normal kidney does not exhibit the second hump created by the spectral valley associated with hemoglobin absorption.
- the intrinsic fluorescence of hypoxic myocardium exhibits a secondary hump indicating high NADH concentration.
- ischemia or hypoxia can be detected from a LIFAS-derived intrinsic LIF spectrum by assessing its NADH-related secondary hump either visually or through simple qualitative analysis.
- the magnitude of the NADH hump will indicate the level of oxygen deficiency caused by hypoxia or ischemia while its absence indicate normal oxygenation.
- ischemia or hypoxia detection techniques use predetermined ratios of spectral intensities at wavelengths associated with NADH, elastin and collagen to discriminate normal from abnormal tissue.
- the magnitude of the intensity does not fully characterize spectral changes associated with ischemia or hypoxia. Instead, it is desirable to undertake spectral classification based on the shape of wavelength bands or the whole spectrum.
- the introduction of the LIFAS methods and devices of the present invention enables the application of a new modeling approach for the measurement of ischemia and hypoxia.
- the approach relies on methods of multivariate linear regression (MLR), principle component regression (PCR) and the method of partial least squares (PLS).
- MLR multivariate linear regression
- PCR principle component regression
- PLS partial least squares
- the MLR, PCR and the PLS models are trained with LIFA or absorbance spectra as their input and the concentration of both oxygenated and deoxygenated hemoglobin as their outputs.
- the blood content (i.e. quantity of blood) in the tissue is determined by combining the concentrations of both oxygenated and deoxygenated hemoglobin.
- the MLR, PCR and the PLS models are trained with LIFA spectra from normal, hypoxic or ischemic rabbit heart and kidney.
- a model can be used to predict the concentrations of oxygenated and deoxygenated hemoglobin if given a LIFA spectrum measured from tissue with unknown oxygenation.
- the presence and level of hypoxia can be determined by comparing the latter-predicted concentrations values to those known values previously measured from normal tissue. Hypoxic tissue has less oxygenated and more deoxygenated hemoglobin concentrations than normal tissue.
- the presence and level of ischemia can be determined by combining the predicted concentrations to determine the total blood content and then comparing the total blood content to known values of blood content measured in normal tissue. Ischemic tissue will have a lower blood content than normally perfused tissue.
- the PLS model was found to have the optimal accuracy in detecting the presence and level of ischemia and hypoxia.
- a new mathematical classifier has been developed and applied to categorize spectral data for ischemia or hypoxia detection.
- the recent multicriteria associative memories (MAM) technique is modified to perform as a data classifier. Similar to existing classifiers, the MAM requires initial training on a set of input-output data pairs.
- the matrices “S” and “R” holds the input and output training vectors as their columns, respectively.
- T and ⁇ 1 indicate matrix transpose and inversion, respectively, and “I” is the identity matrix.
- the parameter ⁇ is initially set to 0.98; however, it can assume any value between 0 and 1 depending on the noise of the system.
- an appropriate transfer function is used to assign the output “r” into one of several predetermined classification categories.
- the MAM classifier is initially trained with LIFA (or absorbance) spectra acquired from normal or ischemic tissue as the training inputs.
- the corresponding normal or ischemic state can be encoded as, for example, “ ⁇ 1” or “1,” respectively and used as the training outputs. Therefore, the training LIFA spectra are placed as columns of the input matrix “S” while their corresponding state-coded values are arranged in the same order as elements of the output row vector “R.” The number of columns in “S” and elements in “R” are equal to the number of available training sets.
- the MAM classifier can be applied for the detection of hypoxia and the discrimination between normal, ischemic and hypoxic tissue.
- this input can be an entire spectrum, a re-sampled version of a spectrum or a set of statistical parameters or features characterizing a spectrum.
- actual ischemia or hypoxia levels can be used as the classifier outputs instead of the binary coded output values employed in the above demonstration. In this case a linear transfer function may be used to categorize the output “r” of the MAM classifier.
- the MAM technique outperformed the commonly-used artificial neural network (ANN) classifier in accurately classifying LIF/LIFA spectra resulting from normal and ischemic tissue.
- ANN artificial neural network
- the superiority of the MAM classifier is most probably due to its insensitivity to spectral noise that might be present in LIF/LIFA spectra measured from biological systems.
- the foregoing MAM classifier is currently applied to discriminate spectral data for the purpose of ischemia or hypoxia detection, it is understood that those skilled in the art may apply it in various ways for different classification purposes.
- LIFAS devices and methods can be applied to tissue characterization, i.e., to differentiate between normal and diseased tissue, for tissue diagnostics and malignancy detection.
- Current LIFS techniques use the intensity spectrum of modulated LIF to identify malignant (cancerous and pre-cancerous) tissue and classify its type.
- LIFAS techniques offer a unique tissue characterizing capability not offered by conventional LIFS, based upon measurement of the attenuation spectrum.
- FIGS. 17(a)-(d) A simple demonstration of LIFAS diagnostic capability is shown in FIGS. 17(a)-(d). Although normal kidney and heart tissue are different in nature, their common LIF spectra, shown in FIGS. 17(a) and (b) are almost identical and, hence, are not so useful for classification purposes. However, heart and kidney LIFA spectra, shown in FIGS. 17(c) and d are different in terms of both shape and peak attenuation values. Thus, LIFAS techniques offer better tissue identification power than conventional LIFS techniques.
- LIFAS methods and devices will include laser removal of decorative tattoos, detection of the in-vivo glucose level, assessment of the degree of burn trauma, detection of atherosclerotic plaque, angioplasty, measurement of acidity or alkalinity, pH measurement, the analysis of biochemical fluids, and the like.
- measurement of the in vivo skin absorption using LIFAS methods and devices in accordance with the present invention can aid in the selection of optimal laser wavelengths for removing tattoos of different colors.
- LIFAS techniques can be used to determine absorbance from a hypodermic sample volume, the skin color and the depth of the tattoo dye can be more accurately characterized than in surface reflectance techniques.
- burn injury assessment can be accomplished by using LIFAS techniques to measure the depth of burn by probing for the presence of blood perfusion at varying locations within the tissue.
- LIFAS techniques can also be used to determine the absorbance or turbidity of a liquid in-situ without the necessity of extracting a sample for use in a spectrometer.
- LIFAS system and method is shown in the exemplary method as applied to biological tissue, it is also readily applicable to chemical and industrial material.
- LIFAS devices and methods can be used to measure the absorbance and/or turbidity of materials and mixtures in medical, food, beverage, detergent, plastic, glass, oil, paint, textile, and semiconductor applications.
- concentration of the pure components of the mixture can be determined from the absorbence spectrum using chemometric techniques such as multivariate regression (MLR), partial least squares (PLS) or artificial neural networks described above.
- MLR multivariate regression
- PLS partial least squares
Abstract
The Laser Induced Fluorescence Attenuation Spectroscopy (LIFAS) method and apparatus preferably include a source adapted to emit radiation that is directed at a sample volume in a sample to produce return light from the sample, such return light including modulated return light resulting from modulation by the sample, a first sensor, displaced by a first distance from the sample volume for monitoring the return light and generating a first signal indicative of the intensity of return light, a second sensor, displaced by a second distance from the sample volume, for monitoring the return light and generating a second signal indicative of the intensity of return light, and a processor associated with the first sensor and the second sensor and adapted to process the first and second signals so as to determine the modulation of the sample. The methods and devices of the inventions are particularly well-suited for determining the wavelength-dependent attenuation of a sample and using the attenuation to restore the intrinsic laser induced fluorescence of the sample. In turn, the attenuation and intrinsic laser induced fluorescence can be used to determined a characteristic of interest, such as the ischemic or hypoxic condition of biological tissue.
Description
The present invention is directed to methods and devices for determining a spectroscopic characteristic of a sample utilizing laser induced fluorescence attenuation spectroscopy (“LIFAS”). More particularly, the invention is directed to methods and devices for measurement of the wavelength-dependent attenuation of the sample and subsequent restoration of the intrinsic laser induced fluorescence (“LIF”) for physiological monitoring, biological tissue characterization and biochemical analysis.
Conventionally, samples have been characterized by determining the attenuation and laser induced fluorescence (“LIF”). Once the attenuation and LIF of a sample have been determined, these spectroscopic properties can be utilized to determine a physical or physiological property of the sample. For example, the attenuation of a sample can be used to determine the concentrations of mixture components or turbidity of a fluid. Similarly, the LIF of a sample has been used in fields such as analytical chemistry, environmental monitoring, industrial inspection and medical diagnosis. In the medical field, for example, LIF spectroscopic techniques have been used for tissue characterization, malignant tumor identification, atherosclerotic plaque diagnosis, metabolism evaluation, and the like.
Conventionally, the attenuation or the absorption of a sample is determined by placing the sample between a light source and a detector and measuring any reduction in the intensity of the light as it passes through the sample. In order to obtain a measurement having an acceptable signal-to-noise ratio using these conventional techniques, it is important to transmit the incident light with sufficient intensity. Thus, the thickness of the sample and the wavelength of the incident light are important factors affecting the reliability of the resulting measurement. Moreover, because it is necessary to place the sample between the light source and the detector, it is difficult to perform attenuation measurements on certain types of samples, such as living tissue.
More recently, fiber optic techniques have been developed for the measurement of attenuation in which an optical fiber is used to guide the incident light to illuminate a sample inside a small chamber at the tip of a probe. A reflector is placed on the opposite side of the chamber to reflect the incident light into a second fiber which is associated with a detector. Unfortunately, these techniques find limited application with materials, such as fluids, that can readily pass into the chamber in the tip of the probe.
Conventionally, laser induced fluorescence (“LIFS”) spectroscopic techniques utilize various optical configurations in which a laser is directed at a sample using an optical fiber and the LIF from the sample is collected using a second optical fiber. Alternatively, the same fiber can be used for excitation of the sample and the collection of LIF. In either case, the LIF collected by the fiber is modulated by the sample, e.g. by the wavelength-dependent absorption and scattering of constituents of the sample. Therefore, existing LIFS methods are limited by the fact that the “intrinsic” or “true” fluorescence of the sample's fluorophores cannot be determined. Recent reports have suggested measuring the diffuse reflectance spectrum of the tissue as a means for correcting the intrinsic LIF using Monte-Carlo mathematical formulations. However, such correction methods are critically dependent on the backscattering characteristics of the tissue. Furthermore, backscattering does not account for the effects of absorption and scattering suffered by the intrinsic fluorescence prior to its measurement.
In biological LIF techniques, lasers are used to cause fluorophores in the sample to emit fluorescence. The main fluorophores in normal biological tissue are tryptophan, collagen and elastin. Other fluorophores, such as NAD (nicotinamide adenine dinucleotide) and FAD (flavin adenine dinucleotide), are also normally present, but at much lower concentrations. Under certain conditions, the contribution of the various fluorophores to the LIF can change. For example, during an ischemic or hypoxic event, the tissue is deprived of oxygen and anerobic respiration takes place. Consequently, the weak fluorophore NAD will be converted into the strong fluorophore reduced nicotinamide adenine dinucleotide (“NADH”). As a result, the LIF collected from the sample will reflect an increased contribution from NADH. This change is typically observed as a rise in the intensity of the LIF spectrum in the region of peak NADH emission, from about 470 to 490 nm. Thus, the metabolic state of the tissue can be determined by measuring the relative change in LIF intensity at the wavelength of peak NADH emission as compared to the relative change of the LIF intensity of fluorophores that are normally present in the tissue, such as elastin or collagen.
Unfortunately, the LIF of biological tissue is heavily modulated in the 390-450 nm range by the peak absorption of the main tissue chromophore, hemoglobin. Thus, although the intrinsic LIF spectra of normal tissue should approximately resemble that of the pure fluorophore components of the tissue, the measured LIF spectra has a valley in the 400-450 nm region that is associated with the hemoglobin absorption. As a result, the measured LIF spectrum tissue appears to have a double peak instead of the single peak spectrum associated with the pure fluorophores of the tissue. Hence, the LIF spectrum of normal tissue begins to resemble the spectrum associated with tissue suffering hypoxia or ischemia, which makes it more difficult to identify tissue abnormalities.
Furthermore, since the optical properties of biological tissue are influenced by its hemoglobin concentration, the measured LIF will vary with the level of blood perfusion throughout the cardiac cycle. The LIF of contractile tissue, such as the myocardium, is highly dependent on its state of contraction. Contraction increases the concentration of the fluorophore NADH and, hence, its contribution to tissue fluorescence. During contraction, however, blood is pumped out of the tissue, thereby reducing its hemoglobin concentration and, hence, light attenuation. Thus, a contracted myocardium retains less blood (i.e., a lower hemoglobin concentration) and, therefore, exhibits lower light absorption, than when relaxed.
Organs such as the brain, heart and kidney are the most sensitive to oxygen deficiency and can suffer permanent damage following an ischemic or hypoxic event. During open-heart surgery, for example, continuous monitoring of kidney perfusion, i.e., ischemia, is required. Similarly, since the success of a transplantation surgery is highly dependent on the level of organ perfusion at harvest and during preservation of the tissue, continuous monitoring of the organ is typically required.
Ischemia and hypoxia are both conditions that deprive tissue of oxygen, leading to anaerobic metabolism and the accumulation of the metabolic coenzyme NADH. The coenzyme NADH is a fluorescent molecule. Therefore, ischemia and hypoxia can be indirectly detected using LIF techniques by sensing increased concentrations of NADH and interpreting its elevation as a sign of oxygen deficiency. A common indicator of oxygen deficiency is the ratio between the LIF intensity at wavelengths associated with the peak fluorescence emission of NADH, collagen and elastin. However, such methods have not been practically applied for the detection of ischemia because of several complications. First, these methods cannot determine whether the elevated NADH concentration is caused by ischemia, hypoxia or hypermetabolism. Second, scarred or fibrosed tissue would be detected as normal because of their low NADH concentration. Finally, the indicator ratios are calculated by normalizing the intensity of NADH peak fluorescence by that of collagen or elastin. Although the fluoresence of the structural proteins elastin and collagen does not vary with tissue oxygenation, their fluorescence vary varies with the site of measurement.
The intrinsic LIF of biological tissue has a single peak spectral profile resembling that of the pure structural proteins which are primarily elastin and collagen. However, this single peak profile is modulated by the attenuation of hemoglobin, especially about 410 nm, to yield a distorted, double-peak spectrum. The second spurious peak at about 470 nm results from the spectral valley created by heavy hemoglobin absorption at about 410 nm. Unfortunately, this second peak overlaps and obscures the peak fluorescence emission of NADH at about 470-490 nm, which may impede ischemia detection techniques that are based on NADH concentration.
The methods and devices of the present invention will enable measurement of several LIF parameters that directly relate to the state of tissue perfusion and/or hemoglobin oxygenation. This offers superior accuracy over the currently available LIF techniques which detect ischemia and hypoxia indirectly by sensing an upsurge in NADH fluorescence. In particular, the methods and devices of the present invention can directly indicate the presence and the level of hypoxia or ischemia. Furthermore, the methods of the present invention utilize novel criteria for discrimination between normal and ischemic or hypoxic tissue.
It is readily apparent that existing LIFS techniques in medicine and industry are affected by modulations of the intrinsic LIF. Thus, there is need for methods and devices for determining the intrinsic laser induced fluorescence while eliminating or minimizing modulating influences in order to provide more accurate and complete characterization of a sample. In particular, there is a need for method and devices for characterization of biological tissue. The present invention addresses these and other needs.
The present invention is embodied in a system and related method for laser-induced fluorescence attenuation spectroscopy (“LIFAS”) in which the attenuation and intrinsic LIF of a sample can be determined. The LIFAS system employs a source, a first sensor, a second sensor and a processor. The source, preferably a laser, emits light to irradiate a sample volume in a sample so that the sample volume produces return light, which preferably includes laser induced fluorescence. The first sensor monitors the return light at a first distance from the sample volume and generates a plurality of signals representing the intensity of the return light in predetermined wavelength bands. The second sensor monitors the return light at a second distance from the sample volume and generates a plurality of signals representing the intensity of the return light, preferably over the same wavelength bands. Where the first and second distances are different, the processor can be used to determine the wavelength-dependent attenuation of the sample using the signals of both sensors. The measured attenuation will typically reflect the effects of both absorption and scattering by the sample. For maximum signal-to-noise ratio, it is preferred that the first and second detectors monitor return light from the sample volume at a location in proximity to the sample volume.
Once the wavelength-dependent light attenuation is determined, the attenuation can be used to restore the intrinsic LIF of the fluorophores of the sample. Once the attenuation and intrinsic fluorescence have been determined, these factors can be used in a variety of applications, including medical diagnosis. In the preferred embodiment, the attenuation and fluorescence are used for the detection of ischemia and hypoxia of biological tissue. Ischemia and hypoxia are detected by monitoring spectral changes in the intrinsic LIF to detect a rise in the concentration of NADH in the tissue. Since ischemia is caused by a decrease in the blood content of the tissue, ischemic tissue will have lower concentrations of hemoglobin. Consequently, in ischemic tissue, absorption by hemoglobin, especially in the 390-450 nm spectral band, will be reduced. Changes in the wavelength of peak light transmission, especially in the 450-500 nm band, can also be used to detect hemoglobin oxygenation and, hence, the presence of hypoxia or ischemia. Finally, multicriteria associative memories (MAM) can be used as an attenuation or fluorescence spectral classifier.
Other features and advantages of the present invention will be apparent from the following description of the preferred embodiments, taken in conjunction with the accompanying drawings, which illustrate, by way of example, the principles of the invention.
FIG. 1 is a schematic diagram of a spectroscopic system in accordance with the invention;
FIG. 2(a) is a schematic diagram of a Laser Induced Fluorescence Attenuation Spectroscopy system (“LIFAS”) in accordance with the present invention having an excitation waveguide and a first and second collection waveguides;
FIG. 2(b) is a schematic diagram of an alternative configuration of the collection waveguides of FIG. 2(a);
FIG. 2(c) is a schematic diagram of yet another alternative configuration of the collection waveguides of FIG. 2(a);
FIG. 3(a) is a schematic diagram of a LIFAS system in accordance with the present invention having a first excitation-collection waveguide and a second collection only waveguide;
FIG. 3(b) is a schematic diagram of an alternative configuration of the collection waveguides of FIG. 3(a);
FIG. 4 is schematic diagram of a LIFAS system for biomedical applications in which excitation radiation is used to induce fluorescence of tissue;
FIGS. 5(a) and (b) are end perspective views of a LIFAS probe having an optical fiber and an optical fiber bundle as the central waveguide;
FIGS. 6(a) and (b) are partial perspective views of an electrical subsystem used to synchronize a LIFAS system with the electrical activity of tissue using electrodes integrated into the optical probe;
FIGS. 7(a) and (b) are schematic diagrams showing the relative positions of the action potential and electrodes integrated into the optical probe; and
FIGS. 7(c) and (d) are the corresponding action potential timing diagrams;
FIG. 8 is a perspective view of a probe incorporating a visible light source for probe positioning and a circular LED array for indicating the direction of contraction propagation;
FIGS. 9(a)-(c) are partial perspective views of three LIFAS probes having waveguides arranged in different geometrical configurations adapted for different applications (top row is an elevation view; middle row is a side view; bottom row is a bottom view);
FIG. 10 is a schematic diagram of a biomedical LIFAS system in accordance with the invention in which a single optical detector is used to measure the return light from two collection fibers;
FIG. 11 18 is a block diagram of the method for determining the attenuation and the intrinsic fluorescence of a sample;
FIG. 12 19 is a graph of the attenuation spectrum measured from normal and ischemic renal cortex of rabbit kidney using LIFAS devices and methods in accordance with the invention;
FIG. 13 20 is a scatter plot of the fluorescence intensity at 480 nm acquired from hypoxic (+), normal (o) and hyperoxic (x) tissue through excitation-collection and collection-only waveguides;
FIG. 14 21 is a graph of the intensity Ico(λ)c of the signal measured by a collection-only waveguide from normal, hyperoxic and hypoxic tissue;
FIG. 15(a) 22(a) is a graph of the modulated LIF spectra of normal and ischemic kidney, and
FIG. 15(b) 22(b) is a graph of the intrinsic LIF spectra of normal and ischemic kidney;
FIGS. 16(a) and (b) 23(a) and (b) are graphs of typical modulated LIF spectra of normal and ischemic kidney, respectively, depicting the difference in the symmetry of the main lobe; and
FIGS. 17(a)-(b) are graphs of the mean LIF intensity of live kidney and heart tissue and
FIGS. 17(c)-(d) are the corresponding LIFAS-derived attenuation spectra.
As shown in the exemplary drawings and, in particular, FIG. 1 thereof, the present invention is embodied in a spectroscopic system 110 and related method for measuring the attenuation and/or optical rotation caused by a sample 114. The spectroscopic system 110 shown in FIG. 1, includes a source 111 that produces radiation 112, which is directed at a sample volume 113 within the sample 114. The source 111 is preferably a laser and the radiation 112 is preferably monochromatic ultraviolet (UV), visible or infrared (IR) radiation 112. Nevertheless, the source 111 can be selected to produce other types of radiation, such as broadband or polarized radiation, useful for a particular application. The spectroscopic system 110 further includes a first sensor 116 displaced by a distance Z1 from the sample volume 113, and a second sensor 118 displaced by a distance Z2 from the sample volume 113, which are used to monitor return radiation 120 from the sample 114. In the preferred embodiment, the return radiation 120 will include fluorescence of the fluorophores of the sample 114.
The sensors 116 and 118 each include an aperture 116a and 118a, respectively, through which the return radiation 120 is observed and collected. The sensors 116 and 118 typically can only observe the events occurring within the volume defined by a solid angle emerging from the aperture of the sensor. This volume is known as the numerical aperture or the field of view of the sensor. Thus, first and second sensors 116 and 118 include numerical apertures 117 and 119, respectively, that are adapted to receive a portion of the return radiation 120 from the sample 114. The sensors 116 and 118 can be tilted at different angles Θ1 and Θ2 and selected to have different numerical apertures 117 and 119 so that the sensors 116 and 118 can selectively monitor return radiation 120 from all or part of the sample volume 113.
The sensors 116 and 118 each generate a signal 124a and 125a, respectively, representing the intensity Ic1(λ) and Ic2(λ) and/or polarization of the return radiation 120. Preferably, the signals 124a and 125a are generated at a plurality of wavelengths within predetermined wavelength bands. The signal 124a from the first sensor 116 and the signal 125a from the second sensor 118 are communicated by signal paths 124 and 125, respectively, to a processor 123. As discussed in additional detail, below, the processor 123 processes the signals 124a and 125a to determine a spectral characteristic of interest, such as the attenuation and/or optical rotation of the return radiation 120 caused by the sample 114.
To determine the attenuation of the return radiation 120 caused by the sample, the sensors 116 and 118 are positioned at non-equivalent distances Z1 and Z2 from the sample volume 113. Preferably, the first and second sensors 116 and 118 will be positioned so that one of the sensors will be in the immediate proximity of the sample volume 113 while the other sensor is positioned at a location adjacent to the first sensor, but displaced slightly further from the sample volume 113. It has been found that this arrangement advantageously improves the signal-to-noise ratio and, hence, measurement accuracy of the spectroscopic system 110.
The attenuation of the return radiation 120 is dependent on the distance traveled by the return radiation 120 through the sample 114. Hence, the signal 124a measured by the first sensor 116 and the signal 125a measured by the second sensor 118 will suffer different attenuation where the distances Z1 and Z2 from the sample volume 113 are not equivalent. The processor 123 can be used to process the signals 124a and 125a to determine the wavelength-dependent attenuation of the sample 114. The attenuation determined by the spectroscopic system 110 will reflect the effects of light absorption and scattering by the sample 114. Where the radiation 112 causes fluorophores in the sample 114 to fluorescence, the attenuation of the sample 114 can be used to determine the intrinsic fluorescence 129 of the fluorophores in the sample volume 113. The methods by which the attenuation and intrinsic LIF are determined are discussed in detail below.
The source 111, shown in FIG. 1, can be any radiation source, such as a laser or lamp emitting excitation radiation 112 at a wavelength capable of interacting with the sample 114. The sensors 116 and 118 will preferably include a detector, which can be as simple as individual light-sensitive diodes with appropriate band pass filters, or more complicated sensors such as an optical spectrum analyzer. Preferably, the sensor is a suitable spectrograph or spectrometer equipped with a suitable sensor. Alternatively, the sensor can include a multispectral CCD camera.
In the preferred embodiment, the source 111 is an XeCl excimer laser emitting monochromatic ultraviolet radiation at 308 nm. Each of the sensors 116 and 118 is a spectrograph (Model FF250, ARIES Inc., Concorde, Mass.) associated with a 1024 element intensified photo diode array (PDA) to image the resolved spectrum. Each PDA is connected to an optical multichannel analyzer (OMA III, EG&G Princeton Applied Research Corporation, Princeton, N.J.). The OMA reads the light spectrum imaged by the PDA to produce the signals 124a and 125a. A 335 nm longpass filter (Schott WG335) is placed in front of the aperture of each of the sensors 116 and 118 to remove any backscattered 308 nm excitation radiation. The processor 123 is a personal computer that is networked to each of the sensors 116 and 118 via the signal paths 124 and 125 to receive the signals 124a and 125a, respectively.
In other applications, such as measuring the optical rotation or anisotropy of a sample, it will be desirable to position the first and second sensors 116 and 118 at equivalent distances Z1 and Z2 from the sample volume 113. Optical rotation is observed in optically active materials. An optically active material is characterized by a lack of symmetry in its molecular or crystalline structure which causes a rotation of the plane of polarization in incident-plane-polarized radiation. The extent to which the plane of polarization is rotated will typically vary from one optically active material to another. In addition, the extent of rotation may depend on the number of molecules in the path of the radiation, the wavelength of the radiation, and the temperature of the material. Anisotropy, on the other hand, is caused be a selective response of the sample to radiation travelling in different directions. In certain biological samples, for example, anisotropy can result from microscopic inhomogeneity in the tissue structure. Use of equivalent distances Z1 and Z2 will minimize the contribution of the path-length-dependent attenuation to the overall attenuation measured by the system 110. Therefore, the optical rotation or anisotropy of the sample can be determined more easily.
The LIFA system 110 shown in FIG. 1 can be adapted to measure optical rotation by utilizing first and second sensors 116 and 118 which are adapted to measure the polarization-dependent intensity of the return radiation. In particular, the first sensor 116 can be adapted to measure a first optical angle φ1 (not shown) yielding the maximum intensity of the first portion of the return radiation 120. Meanwhile, the second sensor 118 can be adapted to measure a second optical angle φ2 (not shown) yielding the maximum intensity of the second portion of the return radiation 120. The optical rotation of the return light 120 will be given by the difference between the angles φ1 and φ2, provided that the system has been properly calibrated. The same sensor is used for determination of the attenuation of the sample will find utility for monitoring the optical rotation. These sensors can be adapted to such measurements by placing a rotatable polarizing filter at each of the apertures 116a and 118a of the first and second sensors 116 and 118, respectively.
An alternative embodiment of the present invention is shown in FIG. 2(a). In this embodiment, the spectroscopic system 110 of FIG. 1 has been adapted as a Laser Induced Fluorescence Attenuation Spectroscopy (“LIFAS”) system 210. In the LIFAS system 210, a source 211 emits laser radiation 212 at an intensity and a wavelength capable of inducing fluorescence of the sample 214. The laser radiation 212 is transmitted through an excitation waveguide 215 to a sample volume 213 within the sample 214 where the laser radiation 212 excites local fluorophores in the sample volume 213 to emit intrinsic fluorescence 229. The intrinsic fluorescence 229 of the fluorophores in the sample volume 213 is modulated, for example, by the absorption and scattering of the local chromophores (not shown) and scatterers (not shown) present in the sample 214, respectively.
Two collection waveguides 221 and 222 having apertures 221a and 222a and numerical apertures 217 and 219 are disposed about the excitation waveguide 215. As shown in FIG. 2(b), the collection waveguides 221 and 222 may be positioned such that their apertures 221a and 222b are laterally displaced from the excitation waveguide 215 by the distances x1′ and x2′ and/or axially displaced from the aperture 215a of the excitation waveguide 215 by the distances y1′ and y2′. Preferably, the lateral distances x1′ and x2′ are small or zero. Meanwhile, the axial distances y1′ and y2′ are preferably selected to be small and unequal, while one of the axial distances is preferably zero. Also, it is desirable to position the apertures 215a, 221a and 222a of the waveguides 215, 221 and 222 in close proximity to or in contact with the sample 214 during use of the LIFAS system 210, as shown in FIG. 2(a).
An alternative configuration of the collection waveguides is shown in FIG. 2(c). In this configuration, the axial distances y1′ and y2′ are both zero. Meanwhile, the lateral distances x1′ and x2′ are selected to be small and unequal. The apertures 240a and 242a of the waveguides 240 and 242 are oblique such that the fields of view 244 and 246 are directed toward the sample volume 213 and to advantageously encompass the bulk of the sample volume 213. As shown in FIG. 2(c), the distances z1′ and z2′ are directed along the respective axes of the numerical apertures 244 and 246 and extend from the surface of the apertures 240a and 242a to the point of intersection of the axes of the numerical apertures 244 and 246, respectively.
The collection waveguide 221 collects a first portion 228 of the return light 220 and transmits the first portion 228 of the return light 220 to a first sensor 216. The first sensor 216 generates a first signal 224a, representing the intensity Ic1(λ) of the first portion 228 of the return light 220 at a plurality of wavelengths within predetermined wavelength bands. Similarly, the collection waveguide 222 collects a second portion 230 of the return light 220 and transmits the second portion 230 of the return light 220 to the second sensor 218. The second sensor 218 generates a second signal 225a representing the intensity Ic2(λ) of the second portion 230 of the return light 220 at a plurality of wavelengths preferably within the same wavelength bands monitored by the first sensor 216.
The processor 223 then processes the first and second signals 224a and 225a to determine the wavelength-dependent attenuation of the sample 214. As discussed in detail, below, once the attenuation is known, either of the signals 224a or 225a can be processed to minimize the effects of attenuation and determine the intrinsic LIF 229 of the fluorophores in the sample volume 213. Alternatively, if the sensors 216 and 218 are selected to monitor the polarization of the first portion 228 and the second portion 230 of the return light 220, the processor 223 can be used to determine the optical rotation of the return light 220 caused by the sample 214.
Preferably, the intensity and wavelength of the laser radiation 212 should be sufficient to create a sample volume 213 that is large enough to have some overlap with the numerical apertures 217 and 219 of the collection waveguides 221 and 222, respectively. The numerical apertures 217 and 219 can be selected to encompass all or parts of the sample volume 213. Furthermore, longpass filters are placed before the inputs of the sensors 216 and 218 to selectively block backscattered excitation radiation.
In the preferred embodiment, the source 211 is an Xe—Cl excimer laser emitting 308 nm ultraviolet excitation radiation 212. The waveguides 215, 221 and 222 are advantageously comprised of optical fibers or optical fiber bundles, which can be integrated into a probe for ease of use and durability. The optical bundle and fibers are made of fused silica which is transparent to ultraviolet radiation. Specifically, a 1.4 mm diameter optical bundle is used as the excitation waveguide 215 while the collection waveguides 221 and 222 are 0.4 mm optical fibers disposed about the excitation bundle. In the preferred probe embodiment, the lateral range x1′ and x2′ are equal to zero while the axial distance y1′ is about 0.6 mm and the axial distance y2′ is about zero. Furthermore, the probe may be configured within, for example, the shaft of a hypodermic needle, so that the in-vivo physiological or pathological properties of biological tissue can be determined.
In the preferred embodiment, each of the sensors 216 and 218 is a spectrograph (Model FF250, ARIES Inc., Concorde, Mass.) associated with a 1024 element intensified photo diode array (PDA). Each PDA is connected to an optical multichannel analyzer (OMA III, EG&G Princeton Applied Research Corporation, Princeton, N.J.) which measures the intensity of the light spectrum imaged by the PDA and produces the signals 224a and 225a. The processor 223 is a personal computer that is networked to each of the sensors 216 and 218 via the signal paths 224 and 225 to receive the signals 224a and 225a, respectively.
The method of determining the attenuation and intrinsic fluorescence of a sample is better understood with reference to the block diagram shown in FIG. 11 18, which illustrates the main steps involved in determining the wavelength-dependent attenuation coefficient α(λ) and the intrinsic fluorescence IT(λ) of a sample in accordance with the current invention. In the embodiment shown in FIG. 2(a), the first and second portions 228 and 230 of the return light 220 experience different attenuation effects due to the unequal path lengths traversed by the return light 220 from the sample volume 213 to the apertures 221a and 222a of the collection waveguides 221 and 222. The first portion 228 of the return light 220 collected by the aperture 221a travels an additional path-length of {y1′-y2′} through the tissue as compared to the second portion 230 of the return light 220 which is collected by the aperture 222a. Hence, the first portion 228 of the return light 220 suffers more path-length-dependent attenuation as compared to the second portion 230 of the return light 220. Thus, the signals 224a and 225a representing the intensity Ic1(λ) and Ic2(λ) at different wavelengths will exhibit differing levels of modulation caused by the attenuation of the sample 214.
In addition, the signals 224a and 225a will also exhibit wavelength-dependent modulations caused by the instrumental effects. The wavelength-dependent modulations due to the instrumental effects can be determined and, in turn, compensated for by conducting a calibration of the LIFAS system 210. System calibration can be performed using light from a standard lamp (Quartz Halogen Lamp, Model No. 63358, Oriel Instruments, Stratford, Conn.) having a predetermined continuous spectrum to measure the wavelength-dependent instrumental effects of the LIFAS system 210. Once these instrumental effects are known, the processor 223 can be adapted to correct the measured intensities Ic1(λ) and Ic2(λ) for modulations caused by the wavelength-dependent instrumental effects. The corrected intensities Ic1(λ)c and Ic2(λ)c representing the intensity of the first and second portions 228 and 230 of the return light 220 at different wavelengths can then be used to determine the attenuation coefficient α(λ) of the sample 214 as described below.
The regions {circle around (1)} and {circle around (2)}, of FIG. 2(a) may be at an effective range, symbolized as “R,” from which the collection waveguides 221 and 222 collect the majority of the first and second portions of return light 228 and 230, respectively. The effective range “R” will vary with the attenuation of the sample. However, the regions {circle around (1)} and {circle around (2)}, are geometrically symmetric with respect to the aperture 215a of the excitation waveguide 215 and, hence, have identical intensity of the intrinsic fluorescence 229 represented by IT(λ). Furthermore, since the lateral and axial distances x1′, x2′ and y1′, y2′ are predetermined by the configuration of the probe (in the preferred embodiment x1′=x2′, y1′>y2′, y2′=0), the wavelength-dependent intensities Ic1(λ)c and Ic2(λ)c can be described by the following equations:
Ic1(λ)c=IT(λ)e−α(λ).(R+y1′) (1)
Ic2(λ)c=IT(λ)e−α(λ).(R+y2′) (2)
Ic1(λ)c=IT(λ)e−α(λ).(R+y1′) (1)
Ic2(λ)c=IT(λ)e−α(λ).(R+y2′) (2)
The attenuation coefficient α(λ) can be calculated independent of the value of “R” from (1) and (2) as follows:
α(λ)={1/{y2′−y1′}}ln{Ic1(λ)c/Ic2(λ)c} (3)
α(λ)={1/{y2′−y1′}}ln{Ic1(λ)c/Ic2(λ)c} (3)
Where the difference {y2′−y1′} is a known constant, “e” is the natural exponential function and “ln” is the natural logarithm. It will be appreciated by those of ordinary skill in the art that the natural exponential and logarithm can be replaced by the common exponential and logarithm to the base 10, respectively. Similarly, for the probe configuration in FIG. 2(c), the attenuation coefficient can be calculated as follows:
α(λ)={1/{z2′−z1′}}ln{Ic1(λ)c/Ic2(λ)c} (4)
α(λ)={1/{z2′−z1′}}ln{Ic1(λ)c/Ic2(λ)c} (4)
Once the attenuation coefficient α(λ) is determined, the intrinsic fluorescence, IT(λ), can be restored from either of the signals Ic1(λ)c or Ic2(λ)c (preferably Ic2(λ)c where y2′<<y1′) by assuming an average effective range “R” from which most of the intrinsic fluorescence is collected. For biological tissue, the constant “R” is approximately about 0.2 mm at 308 nm excitation radiation. Therefore, the intrinsic fluorescence IT(λ) can be obtained by substituting the measured Ic2(λ)c into equation (2) and solving for IT(λ) using the constant R and the known value y2′:
IT(λ)=Ic2(λ)ceα(λ).(R+y2′) (5)
IT(λ)=Ic2(λ)ceα(λ).(R+y2′) (5)
Whether the measured attenuation accounts for absorption and/or scattering is mainly determined by the wavelength band of interest and the nature of the sample. The optical properties of biological tissue and the effects of tissue on LIF are greatly different for the wavelengths below and above approximately 600 nm. Below about 600 nm, the optical attenuation of biological tissue is primarily due to absorption and, hence, the attenuation coefficient α(λ) will represent absorptivity α(λ) a (λ). Absorptivity is a property of a substance, while absorbance is a property of a particular sample of a substance. Therefore, absorbance will vary with the concentration of the substance (e.g., hemoglobin) and geometry of the tip of the probe. Thus, for samples such as biological tissue where the attenuation of the sample is primarily due to absorption, the absorbance A(λ) and the percent transmittance %T(λ) of the sample can be calculated as follows:
A(λ)=log{Ic2(λ)c/Ic1(λ)c} (6)
%T(λ)=100·{Ic1(λ)c/Ic2(λ)c} (7)
A(λ)=log{Ic2(λ)c/Ic1(λ)c} (6)
%T(λ)=100·{Ic1(λ)c/Ic2(λ)c} (7)
In an alternative embodiment of the LIFAS system 310, shown in FIG. 3(a), the source 311 emits laser radiation 312 at a wavelength and intensity capable of inducing fluorescence of the sample 314. The laser radiation 312 is reflected by a dichroic mirror 326 into an excitation-collection waveguide 321, which transmits the laser radiation 312 to the sample volume 313 where the laser radiation 312 excites local fluorophores to emit intrinsic fluorescence 329. Furthermore, the intensity of the laser 312 should be sufficient to create a sample volume 313 that overlaps with the numerical aperture 319 of the collection-only waveguide 322. The dimensions of the sample volume 313 will also depend on the numerical aperture of the excitation-collection waveguide 321, on the wavelength and intensity of the excitation radiation 312 and on the optical properties of the sample 314. The intrinsic fluorescence 329 is modulated, for example, by the absorption and scattering of the local chromophores (not shown) and scatterers (not shown) of the sample 314.
The excitation-collection waveguide 321 collects a first portion 328 of the return light 320 directly from the sample volume 313. The first portion 328 of the return light 320 is transmitted through the dichroic mirror 326 to the first sensor 316. The first sensor 316 generates a first signal 324a representing the intensity Ixc(λ) of the first portion 328 of the return light 320 at a plurality of wavelengths within a predetermined wavelength band.
As shown in FIG. 3(a), the collection-only waveguide 322 may be positioned such that the aperture 322a is laterally displaced from the excitation-collection waveguide 321 by the distance x3 and axially displaced from the aperture 321a of the excitation-collection waveguide 321 by the range y3. Preferably, the lateral distance x3 is zero while the axial distance y3 is non-zero. Also, the apertures 321a and 322a of the waveguides 321 and 322 are preferably positioned in close proximity to or in contact with the sample 314 during use of the LIFAS system 310, as shown in FIG. 3(a). Meanwhile, the numerical aperture 319 of the collection-only waveguide 322 is selected to include at least a portion of the sample volume 313.
The collection-only waveguide 322 collects a second portion 330 of the return light 320 which is transmitted to a second sensor 318. The second sensor 318 generates a second signal 325a representing the intensity Ico(λ) of the second portion 330 of the return light 320 at a plurality of wavelengths preferably within the same wavelength bands as the signal 324a generated by the first sensor 316. Furthermore, a longpass filter is placed in front of the aperture of each of the sensors 316 and 318 to selectively block backscattered excitation radiation.
In the embodiment shown in FIG. 3(a), the first and second portions 328 and 330 of the return light 320 experience different attenuation effects due to the unequal pathlengths traversed by the return light 320 from the sample volume 313 to the apertures 321a and 322a of the waveguides 321 and 322, respectively. The second portion 330 of the return light 220 collected by the aperture 322a travels an additional path-length through the tissue as compared to the first portion 328 of the return light 320 which is collected by the aperture 321a directly from the sample volume 313. Hence, the first portion 328 of the return light 320 suffers less path-length-dependent attenuation as compared to the second portion 330 of the return light 320. Thus, the signals 324a and 325a representing intensity Ixc(λ) and Ico(λ) at different wavelengths will exhibit different levels of modulation caused by the sample 314.
The signals 324a and 325a will also exhibit wavelength-dependent modulations caused by the instrumental effects. The wavelength-dependent modulations due to instrumental effects can be determined and, in turn, compensated for by conducting a calibration of the LIFAS system 310. System calibration is performed using light from a standard lamp (Qaurtz Halogen Lamp, Model No. 63358, Oriel Instruments, Stratford, Conn.) having a predetermined continuous spectrum to measure the wavelength-dependent instrumental effects of the LIFAS system 310. Once these instrumental effects are known, the processor 323 can be adapted to correct the measured intensities Ixc(λ) and Ico(λ) for modulations caused by the wavelength-dependent instrumental effects. The corrected intensities Ixc(λ)c and Ico(λ)c representing the intensity of the first and second portions 328 and 330 of the return light 320 at different wavelengths can then be used by the processor 323 to determine the wavelength-dependent attenuation α(λ) of the sample 314. As discussed in detail, below, once the attenuation is known, either of the signals 324a or 325a, preferably 324a, can be corrected for the effects of attenuation to restore the intrinsic LIF 329 of the fluorophores in the sample volume 313.
In the preferred embodiment, the source 311 is an Xe—Cl excimer laser emitting ultraviolet excitation radiation at a wavelength of 308 nm. The waveguides 321 and 322 are advantageously comprised of optical fibers or optical fiber bundles, which can be integrated into a probe for ease of use and durability. A 1.4 mm diameter optical bundle and a 0.4 mm optical fiber are used as the excitation-collection and the collection-only waveguides, respectively. Preferably, the collection-only waveguide is a plurality of 0.4 mm optical fibers disposed about the periphery of the excitation-collection waveguide. The optical bundle and fibers are made of fused silica which is transparent to the 308 nm ultraviolet radiation. Furthermore, the probe may be configured within, for example, the shaft of a hypodermic needle, so that the in-vivo physiological or pathological properties of biological tissue can be determined. Each of the sensors 316 and 318 is a spectrograph (Model FF250, ARIES Inc., Concorde, Mass.) associated with a 1024 element intensified photo diode array (PDA) to image the resolved spectrum. Each PDA is connected to an optical multichannel analyzer (OMA III, EG&G Princeton Applied Research Corporation, Princeton, N.J.) which measures the intensity of the light spectrum imaged by the PDA and produce the signals 324a and 325a. The processor 323 is a personal computer that is networked to each of the sensors 316 and 318 via the signal paths 324 and 325 to receive the signals 324a and 325a, respectively.
The method of determining the attenuation coefficient α(λ) and the intrinsic fluorescence IT(λ) of a sample using the embodiment of FIG. 3(a) in accordance with the current invention is as follows. In the embodiment shown in FIG. 3(a), “D” represents the effective range, from which the collection waveguide 321 collects a majority of the portion 328 of the return light 320. The portion 328 of the return light 320 is collected directly from the sample volume 313 by the excitation-collection waveguide 321. Therefore, the wavelength-dependent intensity Ixc(λ)c of the portion 328 of the return light 320 collected by the excitation-collection waveguide 321 will be substantially similar to the wavelength-dependent intensity of the return light 320, represented as Io(λ). However, the return light 320 with the intensity Io(λ) will suffer additional wavelength-dependent attenuation as it travels the extra path-length to reach the aperture 322a and is collected as the second portion 330 of the return light 320 with the intensity Ico(λ)c. The lateral and axial distances x3 and y3 will be predetermined by the configuration of the waveguides 321 and 322. In the preferred embodiment, the lateral distance x3=0 and the axial distance y3>0. Thus, the wavelength-dependent intensity Ico(λ)c can be approximated by the following equations:
Ixc(λ)c≈Io(λ)=IT(λ)e−α(λ)·D (8)
Ico(λ)c≈Io(λ)e−α(λ)·y3 (9)
≈Ixc(λ)ce−α(λ)·y3 (9)
α(λ)={1/y3}ln{I cx xc(λ)c/Ico(λ)c} (10)
Similarly, for the alternative probe configuration shown in FIG. 3(b), where the lateral distance x3′>0 and the axial distance y3′=0, the attenuation coefficient can be approximated as follows:
α(λ)={1/x3′}ln{Ixc(λ)c/Ico(λ)c} (11)
Once the attenuation coefficient α(λ) is determined, the intrinsic fluorescence, IT(λ), can be restored from either of the signals Ixc(λ)c or Ico(λ)c, preferably Ixc(λ)c, by assuming an average effective range “D” from which most of the intrinsic fluorescence is collected. For biological tissue, the constant “D” is approximately about 0.2 mm at 308 nm excitation radiation. By substituting the measured Ixc(λ)c into equation (7) and solving for IT(λ):
IT(λ)=Ixc(λ)ceα(λ).D (12)
Ixc(λ)c≈Io(λ)=IT(λ)e−α(λ)·D (8)
Ico(λ)c≈Io(λ)e−α(λ)·y3 (9)
≈Ixc(λ)ce−α(λ)·y3 (9)
α(λ)={1/y3}ln{I cx xc(λ)c/Ico(λ)c} (10)
Similarly, for the alternative probe configuration shown in FIG. 3(b), where the lateral distance x3′>0 and the axial distance y3′=0, the attenuation coefficient can be approximated as follows:
α(λ)={1/x3′}ln{Ixc(λ)c/Ico(λ)c} (11)
Once the attenuation coefficient α(λ) is determined, the intrinsic fluorescence, IT(λ), can be restored from either of the signals Ixc(λ)c or Ico(λ)c, preferably Ixc(λ)c, by assuming an average effective range “D” from which most of the intrinsic fluorescence is collected. For biological tissue, the constant “D” is approximately about 0.2 mm at 308 nm excitation radiation. By substituting the measured Ixc(λ)c into equation (7) and solving for IT(λ):
IT(λ)=Ixc(λ)ceα(λ).D (12)
As discussed in connection with the previous embodiment, the measured attenuation may account for absorption and/or scattering depending on the wavelength band of interest and the nature of the sample. Below about 600 nm, the optical attenuation of biological tissue is primarily due to absorption and, hence, the attenuation coefficient α(λ) will represent absorptivity α(λ) a(λ). Also, the absorbance A(λ) and the percent transmittance %T(λ) of such samples can be calculated as follows:
A(λ)=log{Ixc(λ)c/Ico(λ)c} (13)
%T(λ)={Ico(λ)c/Ixc(λ)c}·100 (14)
A(λ)=log{Ixc(λ)c/Ico(λ)c} (13)
%T(λ)={Ico(λ)c/Ixc(λ)c}·100 (14)
In another alternative embodiment shown in FIG. 4, a LIFAS system 410 in accordance with the present invention has been adapted for biomedical applications. In this particular embodiment, the LIFAS system 410 has been adapted to determine the optical attenuation of biological tissue. The laser 411 emits radiation 412 at a wavelength capable of exciting the tissue 414 to emit fluorescence. The radiation 412 is directed through an iris 440 at a dichroic mirror 442 which reflects the radiation 412 onto a lens 444 which focuses the radiation 412 onto the proximal tip 445 of an optical fiber 446. The adjustable iris 440 is advantageously used to reduce the energy of the radiation 412. Alternatively, the adjustable iris 440 can be replaced by any suitable attenuator.
The probe 448 includes a central optical fiber 446 that is used as the excitation-collection fiber and peripheral optical fibers 450a-h are used as the collection-only fibers. The distal end of the optical fibers 446 and 450a-h are incorporated into the optical probe 448. The aperture 448a the optical fiber probe 448 is placed in proximity to the tissue 414 so that the aperture 446a of the excitation-collection fiber 446 and apertures 451a-h of the collection-only fibers 450a-h are in contact with the tissue 414. As shown in a partial perspective view in FIG. 5(a), the optical fiber probe 448 includes a central optical fiber 446 and a plurality of optical fibers 450a-h disposed about the periphery of the central optical fiber 446. The apertures 451a-h of the distal ends of the collection-only fibers 450a-h are axially displaced by a small distance y3 with respect to the aperture 446a of the excitation-collection fiber 446. The return light 420 collected by apertures 451a-h of the collection-only fibers 450a-h pool into the aperture 418a of the sensor 418. It will be appreciated by those in the art that the optical fibers 446 and 450a-h can advantageously be replaced by optical fiber bundles in order to obtain greater flexibility and durability. For example, as shown in FIG. 5(b), the central optical fiber 446 can be replaced with an optical fiber bundle 454.
The excitation radiation 412 is transmitted through the optical fiber 446 to the tissue 414 to induce intrinsic fluorescence of the fluorophores of the tissue 414. The intrinsic fluorescence is modulated, for example, by the chromophores and/or scatterers of the tissue 414. A first portion 428 of the return light 420 is collected by the optical fiber 446 from the tissue volume that is directly irradiated by the excitation radiation 412 and transmitted through the optical fiber 446 to a first lens 444 where the return light is directed through the dichroic mirror 442 and then focused by a second lens 449 onto the aperture 416a of a first sensor 416. Similarly, the collection-only optical fibers 450a-h collect a second portion 430 of the return light 420 and transmit the second portion 430 of the return light 420 to the second sensor 418. Preferably, longpass filters are placed in front of the apertures 416a and 418a of the sensors 416 and 418 to selectively block backscattered excitation radiation. A first signal 424a and a second signal 425a representing the intensity of the first and second portions 428 and 430, respectively, of the return light 420 are generated by the first and second sensors 416 and 418 and transmitted via signal paths 424 and 425 to the processor 423. The processor 423 uses the first and second signals 424a and 425a generated by the detectors 416 and 418 to determine the wavelength-dependent attenuation of the sample 414 using equations (8), (9) and (10) as described in the previous embodiment.
In a particularly preferred embodiment of the LIFAS probe 448 shown in FIG. 8, an illumination source 490 emitting visible light 492 is mounted on the probe 448 to act as a spotlight for the operator. Because room illumination can contaminate the spectral measurements of the system 410 by adding background light, use of the illumination source 490 will allow the operator to see and accurately position the probe 448 under low-light conditions. The illumination source 490 is configured to illuminate the sample at all times, except when the LIFAS system is monitoring return light from the sample 414.
The biological electrical signal arising in nerves or contractile tissue, such as muscle, is known as the “action potential” and is caused by sudden changes in the ion conductivity of the cell membrane. The occurrence of an action potential in contractile tissue initiates a contraction. For example, in cardiac tissue, the action potential propagates and spreads in a wave-like manner to induce a local myocardial contraction wherever it travels.
An action potential propagating in the tissue local to the aperture 448a of the probe 448 can be detected by the electrode 464 which is incorporated into the probe 448 as shown, for example, in FIG. 6(a). Voltage alternations caused by the occurrence of the action potential are picked up by the electrode 464 in reference to the common electrode 466 and are transmitted to the amplifier 460. The common electrode 466 provides the electrical ground for the amplifier 460 by maintaining contact with the tissue of interest 414 or the whole body. As discussed in connection with FIG. 7, below, the amplified action potential 468 is transmitted to the processor 423 to trigger the acquisition process of the LIFAS system 410 at a pre-selected phase of the tissue contraction or of the cardiac cycle, whichever is applicable.
In an alternative probe arrangement, a plurality of electrodes or fibers with a conductive coating can be distributed circumferentially about the tip of the optical fiber probe 448. For example, as shown in FIG. 6(b), the probe 448 can be equipped with three electrodes 470, 472 and 474 arranged in a triangular configuration. The action potentials measured by each of the electrodes 470, 472 and 474 are amplified through separate channels of the amplifier 460 and transmitted to the processor 423. As illustrated in FIG. 7, the processor 423 processes the received signals to determine the direction of propagation of the contraction vector 462. In particular, the processor detects the phase lead/lag between the action potentials collected by the electrodes 470, 472 and 474 to determine the orientation of the contraction vector 462 with respect to the location of the electrodes 470, 472 and 474.
For example, the contraction vector 462 shown in FIG. 7(a) is propagating from the tissue site 476a to the site 478a and, hence, as shown in FIG. 7(c), the action potential 474a arrives before the action potential 472a which in turn arrives before the action potential 470a. Moreover, the phase difference or time delay between a pair of action potentials indicates how the contraction vector 462 is centered between the location of the corresponding pair of electrodes. For example, as shown in FIG. 7(b), the contraction vector 462 propagates from the tissue site 476b to the site 478b. As a result, the corresponding time of arrival of action potentials 470b, 472b and 474b, as shown in FIG. 7(d), will vary. The processor 423 processes the signals and indicates the direction of the propagation of the contraction to the system operator. The direction of propagation can be indicated, for example, by a circular array 496 of light emitting diodes (LED) 498 mounted circumferentially on the probe 448, as shown in FIG. 8. The processor 423 transmits a signal to the LED array 496 so that, for example, only the LED element pointing in the direction of contraction propagation would glow.
It will be appreciated that the amplifier 460 can be replaced by any device that can measure the electrical activity of biological tissue such as a differential amplifier, an electrocardiogram (ECG), an electromyogram (EMG), an electroencephalogram (EEG), depending on the LIFAS application. Furthermore, it will be appreciated that optical fibers with a metallic or electrically conductive coating can be used in place of one or all of the electrode 464, 470, 472 or 474 to measure the action potential of the tissue. It should be noted that, conventional ECG is generally not suitable for triggering the acquisition of LIFS or LIFAS systems, since it does not accurately indicate the instantaneous state of myocardial contraction at the sample volume. However, customary ECG using limb or chest leads can be used to trigger data acquisition of the LIFAS system 410 where the sample 414 is non-contractile tissue.
In the LIFAS system 410 shown in FIG. 4, the light source 411 is preferably a lamp or a laser that emits ultraviolet, visible or infrared radiation. In the preferred embodiment, the source 411 is an XeCl excimer laser emitting pulses of ultraviolet excitation radiation at 308 nm. Where ultraviolet radiation is used, it is advisable that the optical components used in the acquisition system be made of synthetic quartz (fused silica) to ensure maximal ultraviolet transmission and minimal instrumental fluorescence. Alternatively, a nitrogen laser, a helium-cadmium laser, a frequency-multiplied laser, a solid-state laser, an arc lamp or a light-emitting diode can be used as the light source 411. The energy of the excitation light 412 is typically between 0.001-10 m Joules. However, it will be appreciated that the selected energy level should be low enough to avoid tissue ablation and/or photobleaching while still being adequate to produce detectable LIF.
In the preferred embodiment, the sensors 416 and 418 are each comprised of a spectrograph (Model FF250, ARIES Inc., Concorde, Mass.) associated with a 1024 element intensified photo diode array (PDA) detector. An optional low fluorescence, long-pass filter (not shown) with a cutoff wavelength above 308 nm, preferably 335 nm (Schott WG335), is placed before the entrance slit of each spectrograph to selectively block any backscattered excitation radiation from reaching the sensors 416 and 418. The entrance slit of the spectrograph preferably has a width of 100 micrometers. The spectrograph uses a 150 lines per millimeter diffraction grating to disperse the incoming return light 420 into its spectral components.
The spectrum formed by the spectrograph is imaged by a detector, preferably an intensified linear photodiode array (Model 1420, EG&G Princeton Applied Research Corporation, Princeton, N.J.) facing the output port of the spectrograph. The photodiode array generates a plurality of electrical signals representing the intensity of the return light 420 at wavelengths within predetermined wavelength bands. Alternatively, the sensors can be constructed of any suitable materials, such as individual light-sensitive diodes with appropriate band-pass filters for the analysis of spectral bands of the return light or an optical spectrum analyzer (“OSA”) for analysis of a broader spectrum. Selection of the return light monitoring device will depend on a variety of factors, including cost, accuracy, resolution, and whether the user is interested in monitoring a single wavelength, a wavelength band or an entire spectrum.
Although in the preferred embodiments shown in FIGS. 4 and 5, the optical fiber probe includes a central excitation-collection optical fiber or optical fiber bundle with a plurality of collection-only optical fibers disposed around its periphery, it will be appreciated by those of ordinary skill in the art that the probe can take many forms. Furthermore, it will be appreciated that the central optical fiber can be used as the collection-only waveguide while all or some of the peripheral fibers can be used for excitation-collection or collection-only. The latter arrangement is preferred when testing highly-attenuating samples to achieve a better signal-to-noise ratio.
FIG. 9 shows three alternative geometrical configurations of the collection-only optical fibers 950 450′a-h about the excitation-collection waveguide 946 446′. In these embodiments, it is desirable to couple each of the collection-only waveguides 950 450′a-h to a separate sensor so that the intensity of each portion of the return light collection by each fiber can be monitored. In FIG. 9(a), the collection-only waveguides 950 450′a-h are arranged about the excitation-collection waveguide 946 446′so that their apertures have a helical configuration. Because the aperture of each successive collection-only waveguide is shifted axially away from the aperture 947 447′of the excitation-collection waveguide 946 446′, the return light collected by each of the collection-only waveguides 950 450′a-h will be attenuated in varying degrees. Use of a probe arrangement having a plurality of collection distances will be useful in measuring the polarization and/or the attenuation of, especially, a sample having a higher sensitivity to attenuation due to absorption. Furthermore, a probe incorporating a plurality of collection distances have has application to a larger variety of samples. For example, where the sample is highly attenuating, the collection-only waveguides having apertures close to the excitation site can be used to collect the return light. Where the sample is lightly attenuating, the return light collected by the waveguides having apertures that are further from the excitation site will be useful in determining the attenuation.
In FIG. 9(b), the collection-only waveguides 950 450′a-c are displaced laterally with respect to the excitation-collection waveguide 946 446′. Such a probe configuration will be useful in measuring the polarization and/or the attenuation of the sample where the sample has a higher sensitivity to attenuation due to scattering. The return light collected by the waveguide 950 450′c will be useful in measuring attenuation of a lightly attenuating sample. On the other hand, the return light measured by the closest waveguide 950 450′a will be useful in measuring the attenuation of a heavily-attenuating sample.
In FIG. 9(c), the collection-only waveguides 950 450′a-c are both axially and laterally displaced with respect to the excitation-collection waveguide 946 446′. This configuration combines the advantages of both of the aforementioned configurations shown in FIGS. 9(a) and 9(b).
In an alternative embodiment of the LIFAS system of FIG. 4, shown in FIG. 10, a single sensor 1016 and an associated optical multiplexer 1080 are utilized. The multiplexer 1080 is used to switch the input of the sensor 1016 between the excitation-collection optical path (1046, 1044, 1042, 1049, 1046′) and the collection-only optical path (1050) such that the return light from each pathway is measured sequentially. The processor 1023 sends trigger signals to the source 1011, the sensor 1016 and the optical multiplexer 1080 to synchronize their actions. If the source 1011 is a pulsed laser, two or more radiation pulses are typically required to acquire a single attenuation measurement using the multiplexed system 1010. A single laser pulse can be used if the laser pulse lasts long enough to sustain the emission of return light 1020 during the minimum period of time required by the optical multiplexer 1080 and associated sensor 1016 to acquire the spectral measurements from both the excitation-collection and the collection only optical paths. The preferred embodiment of the LIFAS system 1010 is similar to that of 410, except that the system 1010 utilizes an electromagnetic dual port shutter as the optical multiplexer 1080 associated with a single sensor 1016 in a configuration where the portion 1028 and the portion 1030 of the return light 1020 are measured sequentially.
Diagnosis of Hypoxia and Ischemia
The LIFAS methods and devices of the present invention can be used advantageously for the in-vivo diagnosis of hypoxia and ischemia of biological tissue. Hypoxia is a deficiency in the amount of oxygen reaching the tissue, e.g., due to pneumonia, whereas, ischemia is a localized reduction in arterial blood perfusion, e.g., due to a narrowing of arteries by spasm or disease. Ischemia can also result from hemorrhage of an arterial wound or during surgical procedure that temporarily interrupts the blood flow to a body region. The present invention describes new criteria and methods for the discrimination between normal, ischemic and hypoxic biological tissue, including, in particular renal and myocardial tissue, as follows.
Utilizing LIFAS methods and devices, it has been found that ischemic (or hypoxic) tissue exhibits a lower laser induced fluorescence attenuation (“LIFA”) than normal tissue of the same type. Since LIFA is an absolute quantity, its magnitude can be directly compared with predetermined standard values. Similarly, in absorption-dominant media, the absorbance or percent transmittance can also be utilized. It has been found that, although the LIFA of ischemic tissue is lower than the LIFA of normal tissue over all wavelengths, their difference is most prominent between 350 and 450 nm.
The LIFAS-derived LIFA spectra of normal and ischemic rabbit kidney are shown in FIG. 12 19. The LIFA spectra shown in FIG. 12 19 are acquired using a LIFAS system employing 308 nm excitation radiation produced by an XeCl excimer laser. This LIFAS system uses a 335 nm longpass filter (Schott WG335) to cutoff backscattered excitation radiation form the collected return light. Hence, for this particular LIFAS system the LIFA values below 350 nm are not reliable. For biological tissue, the LIFA values in the wavelength band about 480 nm have the highest signal-to-noise ratio and hence measurement accuracy. As shown in FIG. 12 19, the LIFA of ischemic tissue is lower than the LIFA of normal tissue over the entire spectrum and is particularly low in the region from 350 to 450 nm.
As demonstrated in FIG. 12 19, the LIFA, absorbance or percent transmittance at a predetermined wavelength or wavelength bands can be used for the detection of ischemia or hypoxia. Furthermore, predictive models, spectral recognition techniques and associated classifiers can be applied to identify whether a given LIFA, absorbance or percent transmittance spectrum has been acquired from normal, ischemic or hypoxic tissue. The classifiers can be initially trained with LIFA, at a predetermined wavelength or wavelength bands acquired from tissue with a known state of perfusion or oxygenation.
Another parameter found to be useful in the classification of normal, ischemic and hypoxic tissue, is the intensity of return light from a pair of LIFAS collection pathways (i.e. [Ic1(λ)c, Ic2(λ)c] or [Ixc(λ)c, Ico(λ)c] for the LIFAS embodiments described above. ). For example, FIG. 13 20 shows the [Ixc(λ)c, Ico(λ)c] pair at λ=480 nm, symbolized as [Ixc(480)c, Ico(480)c], measured from hyper-oxygenated (x), normal (o) and oxygen deficient (+) rabbit kidney. The [Ixc(480)c, Ico(480)c] from normal and oxygen deficient tissue tend to cluster in two linearly separable regions of the two dimensional Ixc(λ)c−Ico(λ)c space. Thus, a simple linear or nonlinear classifier function can be trained on a set of [Ixc(λ)c, Ico(λ)c] pairs measured using a LIFAS system from normal, ischemic and hypoxic tissue. Other classifiers such as artificial neural networks (ANN) are also being used. The trained classifier function can then be used to classify an unknown [Ixc(λ)c, Ico(λ)c] pair as normal, ischemic or hypoxic. A “nearest neighbor” (NN) classifier has been found to perform satisfactorily. The NN classifier checks the proximity of an unknown [Ixc(480)c, Ico(480)c] pair to clusters of predetermined [Ixc(480)c, Ico(480)c] pairs measured from known normal, ischemic and hypoxic tissue. Other classifiers such as artificial neural networks (ANN) can also be utilized. For myocardial and renal tissue it has been found that it is preferable to use [Ixc(λ)c, Ico(λc)] measured at 480 nm, to optimize signal-to-noise ratio. However, [Ixc(λ)c, Ico(λ)c] at other single or multiple pre-selected wavelengths can also be used.
An additional parameter for the classification of normal, ischemic and hypoxic tissue, is the wavelength of the peak transmittance of the tissue, symbolized hereafter as λmax-T, especially in the 450-500 nm band. An alternative to λmax-T is the wavelength of the peak Ico(λ)c in the 450-500 nm band, symbolized hereafter as λmax-co. Both λmax-T and λmax-co shift towards shorter wavelengths as the hemoglobin in the tissue becomes deoxygenated. For example, FIG. 14 21 shows Ico(λ)c spectra that are acquired using the LIFAS system shown in FIG. 10 employing 308 nm excitation radiation produced by and XeCl excimer laser. It should be noted that the λmax-co of normal tissue shifts to a shorter wavelength as the tissue becomes hypoxic; whereas the λmax-co of normal tissue shifts to a longer wavelength as the tissue becomes hyperoxic. Specifically, λmax-co varies between about 480 and 500 nm as blood or hemoglobin oxygenation varies between deoxygenated to oxygenated, respectively. A separation border can be identified at about 489.5 nm to separate λmax-co of normal tissue (peaks above 489.5 nm) from hypoxic/ischemic tissue (peaks below 489.5 nm). A simple classifier can be trained to identify tissue as hypoxic if its λmax-co is below 489.5, and vice versa. The degree of hypoxia is determined from the magnitude of the shift in λmax-co from the normal value, the smaller the shift the subtle the hypoxia.
The presence of renal or myocardial ischemia can be detected from the shape of the main lobe of the common LIF (e.g. Ixc(λ)c) spectrum in the wavelength band 350-450 nm. The common LIF can be acquired via an excitation-collection waveguide of a LIFAS or a conventional LIFS system. For example, FIGS. 16 23(a) and (b) show typical LIF spectra acquired from normal and ischemic rabbit kidneys at an excitation wavelength of 308 nm. As shown in FIG. 16 23(b), the shape of the main lobe of the LIF acquired from normal tissue is skewed to the right (a positive skewness value). However, the shape of the main lobe of the LIF acquired from ischemic tissue is almost symmetric (a very small skewness value).
Skewness can be measured by a single parameter which indicates the degree of asymmetry of a lobe or curve around its mean value. For a symmetrical lobe the skewness is zero, however for an asymmetrical lobe the skewness can be either positive or negative depending on the shape. The skewness “S” is given by:
where x is the intensity of the fluorescence at the wavelength λ,x is the mean intensity of the lobe, λ is the wavelength and N is the number of wavelength measurements in the lobe.
where x is the intensity of the fluorescence at the wavelength λ,
Therefore, tissue ischemia can be detected by monitoring the skewness of the main lobe of a common (i.e. modulated) LIF acquired using an excitation-collection fiber from the tissue. A zero or negative skewness value indicates that the LIF spectra is acquired from ischemic tissue, while a positive skewness will indicate normally perfused tissue. The bottom of the central spectral valley is considered as the baseline for the definition of the main lobe as indicated in FIG. 16 23.
The intrinsic LIF of normal biological tissue will have a spectrum with a single peak resembling that of the main tissue fluorophores, collagen and elastin. However, in the event of ischemia or hypoxia the intrinsic LIF develops a secondary peak or a hump at about 470-490 nm which is associated with the peak fluorescence emission of NADH. The appearance of this hump in an intrinsic LIF spectrum is a direct indication of oxygen deficiency resulting from hypoxia or ischemia. Unfortunately, this NADH-related hump is not readily detectable in common LIF spectra because of an overlapping spurious hump created by an intensity dip associated with peak hemoglobin absorption at about 410 nm. For example, in common and intrinsic LIF spectrum of normal and ischemic rabbit myocardium shown in FIGS. 15(a) and (b), respectively, the intrinsic LIF spectrum of normal kidney does not exhibit the second hump created by the spectral valley associated with hemoglobin absorption. To the contrary, the intrinsic fluorescence of hypoxic myocardium exhibits a secondary hump indicating high NADH concentration. Accordingly, ischemia or hypoxia can be detected from a LIFAS-derived intrinsic LIF spectrum by assessing its NADH-related secondary hump either visually or through simple qualitative analysis. The magnitude of the NADH hump will indicate the level of oxygen deficiency caused by hypoxia or ischemia while its absence indicate normal oxygenation.
Classification using Chemometric Models
Current ischemia or hypoxia detection techniques use predetermined ratios of spectral intensities at wavelengths associated with NADH, elastin and collagen to discriminate normal from abnormal tissue. However, the magnitude of the intensity does not fully characterize spectral changes associated with ischemia or hypoxia. Instead, it is desirable to undertake spectral classification based on the shape of wavelength bands or the whole spectrum.
The introduction of the LIFAS methods and devices of the present invention enables the application of a new modeling approach for the measurement of ischemia and hypoxia. The approach relies on methods of multivariate linear regression (MLR), principle component regression (PCR) and the method of partial least squares (PLS). These modeling methods are well-established chemometric techniques used in the field of analytical chemistry to estimate the concentration of a material in a mixture from absorption spectra of the mixture. The algorithm and theoretical basis for PLS predictive modeling can be found in Brereton, R. G. Chemometrics: Applications of Mathematics and Statistics to Laboratory Systems, New York: Ellis Horwood, 1990. A basic overview of the PLS regression can be found in Gerald and Kowalski, “Partial Least-Squares Regression: A Tutorial” Analytical Chimica Acta 185 (1986): 1-17.
In the preferred embodiment, the MLR, PCR and the PLS models are trained with LIFA or absorbance spectra as their input and the concentration of both oxygenated and deoxygenated hemoglobin as their outputs. The blood content (i.e. quantity of blood) in the tissue is determined by combining the concentrations of both oxygenated and deoxygenated hemoglobin. The MLR, PCR and the PLS models are trained with LIFA spectra from normal, hypoxic or ischemic rabbit heart and kidney.
Once a model is trained, it can be used to predict the concentrations of oxygenated and deoxygenated hemoglobin if given a LIFA spectrum measured from tissue with unknown oxygenation. The presence and level of hypoxia can be determined by comparing the latter-predicted concentrations values to those known values previously measured from normal tissue. Hypoxic tissue has less oxygenated and more deoxygenated hemoglobin concentrations than normal tissue. Similarly, the presence and level of ischemia can be determined by combining the predicted concentrations to determine the total blood content and then comparing the total blood content to known values of blood content measured in normal tissue. Ischemic tissue will have a lower blood content than normally perfused tissue. The PLS model was found to have the optimal accuracy in detecting the presence and level of ischemia and hypoxia.
Although LIFA or absorbance spectra are the optimal input to the MLR, PCR or PLS models for concentration prediction, it will be appreciated that modulated LIF, or percent transmittance spectra can also be used due to the fact that, even though common LIF represent fluorescence information, the LIF spectra are modulated by wavelength-dependent tissue attenuation.
The MAM Classifier
In accordance with the invention, a new mathematical classifier has been developed and applied to categorize spectral data for ischemia or hypoxia detection. The recent multicriteria associative memories (MAM) technique is modified to perform as a data classifier. Similar to existing classifiers, the MAM requires initial training on a set of input-output data pairs. The training process of the MAM classifier involves the calculation of the weights matrix M(η) from the input-output data set using the following learning rule:
M(η)=ηRST[ηSST+(1−η)I]−1 (17)
The matrices “S” and “R” holds the input and output training vectors as their columns, respectively. The superscripts T and −1 indicate matrix transpose and inversion, respectively, and “I” is the identity matrix. The parameter η is initially set to 0.98; however, it can assume any value between 0 and 1 depending on the noise of the system. Following the training stage, the output “r” for an unknown input “s” can be readily calculated from the dot product:
r=M(η).s (18)
Finally, an appropriate transfer function is used to assign the output “r” into one of several predetermined classification categories.
M(η)=ηRST[ηSST+(1−η)I]−1 (17)
The matrices “S” and “R” holds the input and output training vectors as their columns, respectively. The superscripts T and −1 indicate matrix transpose and inversion, respectively, and “I” is the identity matrix. The parameter η is initially set to 0.98; however, it can assume any value between 0 and 1 depending on the noise of the system. Following the training stage, the output “r” for an unknown input “s” can be readily calculated from the dot product:
r=M(η).s (18)
Finally, an appropriate transfer function is used to assign the output “r” into one of several predetermined classification categories.
In the present invention, the MAM classifier is initially trained with LIFA (or absorbance) spectra acquired from normal or ischemic tissue as the training inputs. The corresponding normal or ischemic state can be encoded as, for example, “−1” or “1,” respectively and used as the training outputs. Therefore, the training LIFA spectra are placed as columns of the input matrix “S” while their corresponding state-coded values are arranged in the same order as elements of the output row vector “R.” The number of columns in “S” and elements in “R” are equal to the number of available training sets. A trained MAM matrix can determine whether an unknown LIFA spectrum “s?” has been acquired from normal or ischemic tissue by calculating the dot product r?=M(η), s? and passing the scalar result “r?” to a hard limit transfer function. The hard limit transfer function then converts any negative or positive values of “r?” into “0” or “1” indicating a normal or ischemic classification, respectively.
In a similar fashion, the MAM classifier can be applied for the detection of hypoxia and the discrimination between normal, ischemic and hypoxic tissue. It should be apparent that common or intrinsic LIF spectra can replace LIFA spectra as the classifier input. In addition, this input can be an entire spectrum, a re-sampled version of a spectrum or a set of statistical parameters or features characterizing a spectrum. Similarly, actual ischemia or hypoxia levels can be used as the classifier outputs instead of the binary coded output values employed in the above demonstration. In this case a linear transfer function may be used to categorize the output “r” of the MAM classifier.
The MAM technique outperformed the commonly-used artificial neural network (ANN) classifier in accurately classifying LIF/LIFA spectra resulting from normal and ischemic tissue. The superiority of the MAM classifier is most probably due to its insensitivity to spectral noise that might be present in LIF/LIFA spectra measured from biological systems. Although the foregoing MAM classifier is currently applied to discriminate spectral data for the purpose of ischemia or hypoxia detection, it is understood that those skilled in the art may apply it in various ways for different classification purposes.
Tissue Characterization
It will also be appreciated that the LIFAS devices and methods can be applied to tissue characterization, i.e., to differentiate between normal and diseased tissue, for tissue diagnostics and malignancy detection. Current LIFS techniques use the intensity spectrum of modulated LIF to identify malignant (cancerous and pre-cancerous) tissue and classify its type. LIFAS techniques offer a unique tissue characterizing capability not offered by conventional LIFS, based upon measurement of the attenuation spectrum.
A simple demonstration of LIFAS diagnostic capability is shown in FIGS. 17(a)-(d). Although normal kidney and heart tissue are different in nature, their common LIF spectra, shown in FIGS. 17(a) and (b) are almost identical and, hence, are not so useful for classification purposes. However, heart and kidney LIFA spectra, shown in FIGS. 17(c) and d are different in terms of both shape and peak attenuation values. Thus, LIFAS techniques offer better tissue identification power than conventional LIFS techniques.
Other biomedical applications of the LIFAS methods and devices will include laser removal of decorative tattoos, detection of the in-vivo glucose level, assessment of the degree of burn trauma, detection of atherosclerotic plaque, angioplasty, measurement of acidity or alkalinity, pH measurement, the analysis of biochemical fluids, and the like. For example, measurement of the in vivo skin absorption using LIFAS methods and devices in accordance with the present invention can aid in the selection of optimal laser wavelengths for removing tattoos of different colors. Furthermore, since LIFAS techniques can be used to determine absorbance from a hypodermic sample volume, the skin color and the depth of the tattoo dye can be more accurately characterized than in surface reflectance techniques. Similarly, burn injury assessment can be accomplished by using LIFAS techniques to measure the depth of burn by probing for the presence of blood perfusion at varying locations within the tissue. LIFAS techniques can also be used to determine the absorbance or turbidity of a liquid in-situ without the necessity of extracting a sample for use in a spectrometer.
It will be understood by those of ordinary skill in the art that, although the LIFAS system and method is shown in the exemplary method as applied to biological tissue, it is also readily applicable to chemical and industrial material. For example, LIFAS devices and methods can be used to measure the absorbance and/or turbidity of materials and mixtures in medical, food, beverage, detergent, plastic, glass, oil, paint, textile, and semiconductor applications. Furthermore, the concentration of the pure components of the mixture can be determined from the absorbence spectrum using chemometric techniques such as multivariate regression (MLR), partial least squares (PLS) or artificial neural networks described above.
Although the foregoing discloses preferred embodiments of the present invention, it is understood that those skilled in the art may make various changes to the preferred embodiments without departing from the scope of the invention. The invention is defined only by the following claims.
Claims (54)
1. A spectroscopic method of analyzing a sample, comprising:
irradiating a sample with radiation to produce fluorescence from the sample, wherein the fluorescence is modulated by the sample;
monitoring a first portion of the modulated fluorescence at a first distance from the sample;
monitoring a second portion of the modulated fluorescence at a second distance from the sample, the second distance being different from the first distance; and
comparing the first and second portions of the modulated fluorescence to each other to determine a modulation characteristic of the sample.
2. The method of claim 1 , wherein the radiation comprises substantially monochromatic light.
3. The method of claim 1 , wherein the radiation comprises laser light.
4. The method of claim 1 , wherein irradiating the sample comprises directing radiation at the sample using a waveguide.
5. The method of claim 4 , wherein the waveguide is an optical fiber.
6. The method of claim 4 , wherein the waveguide is an optical fiber bundle.
7. The method of claim 1 , wherein monitoring of the modulated fluorescence comprises:
collecting a portion of the modulated fluorescence; and
determining the intensity of the collected portion of modulated fluorescence.
8. The method of claim 7 , wherein the first portion of the modulated fluorescence is collected with a first waveguide and the second portion of the modulated fluorescence is collected with a second waveguide.
9. The method of claim 8 , wherein the first waveguide is an optical fiber.
10. The method of claim 8 , wherein the first waveguide is an optical fiber bundle.
11. The method of claim 8 , wherein the second waveguide is an optical fiber.
12. The method of claim 8 , wherein the second waveguide is an optical fiber bundle.
13. The method of claim 1 , wherein irradiating the sample comprises directing radiation to the sample using a first waveguide and wherein the fluorescence is monitored using the first waveguide.
14. The method of claim 7 , wherein the intensity of the collected portion of the fluorescence is determined with a sensor.
15. The method of claim 7 , wherein the intensity of the first portion of the modulated fluorescence is determined with a sensor.
16. The method of claim 7 , wherein the intensity of the second portion of the modulated fluorescence is determined with a sensor.
17. The method of claim 7 , wherein the intensity of the first portion of the modulated fluorescence is determined with a first sensor and the intensity of the second portion of the modulated fluorescence is determined with a second sensor.
18. The method of claim 7 , wherein the first and second portions of the modulated fluorescence are measured consecutively.
19. The method of claim 7 , wherein the first and second portions of the modulated fluorescence are measured simultaneously.
20. The method of claim 11 1, wherein the method further includes determining the intrinsic fluorescence of the sample.
21. The method of claim 1 , wherein the sample is biological material.
22. The method of claim 21 , wherein the biological material is living tissue.
23. The method of claim 21 , wherein the method further includes determining a physiological property of the biological material using the modulation characteristic.
24. The method of claim 21 , wherein the method further includes determining a pathological property of the biological material using the modulation characteristic.
25. The method of claim 22 , wherein the method further includes determining a physiological property of the living tissue using the modulation characteristic.
26. The method of claim 25 , wherein the physiological property of the tissue is tissue oxygenation.
27. The method of claim 22 , wherein the method further includes determining a pathological property of the tissue using the modulation characteristic.
28. The method of claim 27 , wherein the pathological property of the tissue is the malignant condition of the tissue.
29. The method of claim 1 , wherein either but not both of the distances is substantially zero.
30. A spectroscopic method of analyzing a sample, comprising:
irradiating a sample with radiation to produce return radiation from the sample, wherein the return radiation is modulated by the sample;
monitoring a first portion of the modulated return radiation at a first distance from the sample;
monitoring a second portion of the modulated return radiation at a second distance from the sample;
processing the first and second portions of the modulated return radiation to determine a modulation characteristic of the sample,
wherein the return radiation is modulated by attenuation.
31. The method of claims 30, wherein the return radiation is attenuated by scattering.
32. The method of claim 30 , wherein the return radiation is attenuated by adsorption.
33. The method of claim 30 , wherein the modulation characteristic of the sample is attenuation.
34. The method of claim 30 , wherein the modulation characteristic of the sample is absorption.
35. The method of claim 34 , wherein the method further includes determining transmittance.
36. The method of claim 30 , wherein the modulation characteristic of the sample is optical rotation.
37. A spectroscopic method of analyzing a sample, comprising:
irradiating a sample with radiation to produce return radiation from the sample, wherein the return radiation is modulated by the sample;
monitoring a first portion of the modulated return radiation at a first distance from the sample;
monitoring a second portion of the modulated return radiation at a second distance from the sample;
processing the first and second portions of the modulated return radiation to determine a modulation characteristic of the sample;
wherein the sample is biological material;
wherein the method further includes determining a physiological property of the tissue using the modulation characteristic; and
wherein the physiological property of the tissue is hypoxia.
38. A spectroscopic method for determining the oxygenation of a biological material, comprising:
irradiating a sample of a biological material with radiation to produce fluorescence from the sample, wherein the fluorescence is modulated by attenuation of the sample;
monitoring a first portion of the modulated fluorescence at a first distance from the sample;
monitoring a second portion of the modulated fluorescence at a second distance from the sample, the second distance being different from the first distance;
comparing the first and second portions of the modulated fluorescence to each other to determine the attenuation of the sample; and
determining oxygenation of the sample using the attenuation of the sample.
39. A spectroscopic method for determining the oxygenation of a biological material, comprising:
irradiating a sample of a biological material with radiation to produce return radiation from the sample, wherein the return radiation is modulated by attenuation of the sample;
monitoring a first portion of the modulated return radiation at a first distance from the sample;
monitoring a second portion of the modulated return radiation at a second distance from the sample;
processing the first and second portions of the modulated return radiation to determine the attenuation of the sample;
determining oxygenation of the sample using the attenuation of the sample;
wherein the oxygenation of the sample is determined by comparing the attenuation of the sample to the attenuation of a sample having a known level of oxygenation.
40. A spectroscopic method for determining the concentration of hemoglobin in a biological material, comprising:
irradiating a sample of biological material with radiation to produce fluorescence from the sample, wherein the fluorescence is modulated by attenuation of the sample;
monitoring a first portion of the modulated fluorescence at a first distance from the sample;
monitoring a second portion of the modulated fluorescence at a second distance from the sample, the second distance being different from the first distance;
comparing the first and second portions of the modulated fluorescence to each other to determine the attenuation of the sample; and
determining the concentration of hemoglobin in the sample using the attenuation of the sample.
41. A spectroscopic method for determining the concentration of hemoglobin in a biological material, comprising:
irradiating a sample of a biological material with radiation to produce return radiation from the sample, wherein the return radiation is modulated by attenuation of the sample;
monitoring a first portion of the modulated return radiation at a first distance from the sample;
monitoring a second portion of the modulated return radiation at a second distance from the sample;
determining the concentration hemoglobin in the sample using the attenuation of the sample;
wherein the concentration of hemoglobin is determined by comparing the attenuation of the sample to the attenuation of a sample having a known concentration of hemoglobin.
42. A method for determining a physiological characteristic of a biological material, comprising:
irradiating a sample of biological material with radiation to produce fluorescence from the sample, wherein the fluorescence is modulated by the sample;
monitoring a first portion of the modulated fluorescence at a first distance from the sample;
monitoring a second portion of the modulated fluorescence at a second distance from the sample, the second distance being different from the first distance; and
comparing the first and second portions of the modulated fluorescence to each other, using a predictive model, to determine a physiological characteristic of the sample.
43. A method for determining a physiological characteristic of a biological material, comprising:
irradiating a sample of a biological material with radiation to produce return radiation from the sample, wherein the return radiation is modulated by the sample;
monitoring a first portion of the modulated return radiation at a first distance from the sample;
monitoring a second portion of the modulated return radiation at a second distance from the sample;
processing the first and second portions of the modulated return radiation, using a predictive model, to determine a physiological characteristic of the sample;
wherein the predictive model is a multivariate linear regression.
44. A method for determining a physiological characteristic of biological material, comprising:
irradiating a sample of biological material with radiation to produce fluorescence from the sample, wherein the fluorescence is modulated by the sample;
monitoring a first portion of the modulated fluorescence at a first distance from the sample;
monitoring a second portion of the modulated fluorescence at a second distance from the sample, the second distance being different from the first distance;
comparing the first and second portions of the modulated fluorescence to each other to determine a modulation characteristic of the sample; and
processing the modulation characteristic, using a predictive model, to determine a physiological characteristic of the sample.
45. A method for determining a physiological characteristic of a biological material, comprising:
irradiating a sample of a biological material with radiation to produce return radiation for the sample, wherein the return radiation is modulated by the sample;
monitoring a first portion of the modulated return radiation at a first distance from the sample;
monitoring a second portion of the modulated return radiation at a second distance from the sample;
processing the first and second portions of the modulated return radiation, using a predictive model, to determine a physiological characteristic of the sample;
wherein the predictive model is a multicriteria associative memory classifier.
46. Apparatus for analyzing a sample, comprising:
a source adapted to emit radiation that is directed at a sample to produce fluorescence from the sample, wherein the fluorescence is modulated by the sample;
a first sensor adapted to monitor the fluorescence at a first distance from the sample and generate a first signal indicative of the intensity of the fluorescence;
a second sensor adapted to monitor the fluorescence at a second distance from the sample and generate a second signal indicative of the intensity of the fluorescence, the second distance being different from the first distance; and
a processor associated with the first sensor and the second sensor and adapted to compare the first and second signals to each other to determine a modulation characteristic of the sample.
47. The apparatus of claim 46 , wherein fiber optics transmit the fluorescence to the sensors.
48. Apparatus for analyzing a sample, comprising:
a source adapted to emit radiation that is directed at a sample volume in a sample to produce fluorescence from the sample, such fluorescence including modulated fluorescence resulting from modulation by the sample;
a first sensor adapted to monitor the fluorescence at a first distance from the sample volume and generate a first signal indicative of the intensity of the fluorescence;
a second sensor adapted to monitor the fluorescence at a second distance from the sample volume and generate a second signal indicative of the intensity of the fluorescence, the second distance being different from the first distance; and
a processor associated with the first sensor and the second sensor and adapted to compare the first and second signals to each other to determine a modulation characteristic of the sample.
49. Apparatus for determining a modulation characteristic of a biological material, comprising:
a source adapted to emit excitation light;
a first waveguide disposed at a first distance from the sample adapted to transmit the excitation light from the light source to the biological material to cause the biological material to produce fluorescence, and adapted to collect a first portion of the fluorescence;
a first sensor, associated with the first waveguide, adapted to measure the intensity of the first portion of the fluorescence and generate a first signal indicative of the intensity of the first portion of the fluorescence;
a second waveguide disposed at a second distance from the sample adapted to collect a second portion of the fluorescence, the second distance being different from the first distance;
a second sensor, associated with the second waveguide, adapted to measure the intensity of the second portion of the fluorescence and generate a second signal indicative of the intensity of the second portion of the fluorescence; and
a processor adapted to compare the first and second signals to each other to determine a modulation characteristic of the biological material.
50. Apparatus for analyzing a sample, comprising:
a source adapted to emit radiation that is directed at a sample volume in a sample to produce fluorescence from the sample, such fluorescence including modulated fluorescence resulting from modulation by the sample;
a first sensor, displaced by a first distance from the sample volume adapted to monitor the fluorescence and generate a first signal indicative of the intensity of the fluorescence; and
a second sensor, displaced by a second distance from the sample volume adapted to monitor the fluorescence and generate a second signal indicative of the intensity of fluorescence, the second distance being different from the first distance; and
a processor associated with the first sensor and the second sensor and adapted to compare the first and second signals to each other to determine a physiological property of the sample.
51. Apparatus for determining a physiological property of a biological material, comprising:
a source adapted to emit excitation light;
a first waveguide disposed at a first distance from the sample, and adapted to transmit the excitation light from the light source to the biological material to cause the biological material to produce fluorescence, and further adapted to collect a first portion of the fluorescence;
a first sensor, associated with the first waveguide, for measuring the intensity of the first portion of the fluorescence and generating a first signal representative of the intensity of the first portion;
a second waveguide disposed at a second distance from the sample, and adapted to collect a second portion of the fluorescence, the second distance being different from the first distance;
a second sensor, associated with the first waveguide, for measuring the intensity of the second portion of the fluorescence and generating a second signal representative of the intensity of the second portion; and
a processor adapted to compare the first and second signals to each other to determine a physiological property of the biological material.
52. A spectroscopic method of analyzing a sample, comprising:
irradiating a sample with radiation to produce fluorescence from the sample, wherein the fluorescence is modulated by the sample;
monitoring a first portion of the modulated fluorescence at a first distance from the sample;
monitoring a second portion of the modulated fluorescence at a second distance from the sample, the second distance being different from the first distance;
comparing the first and second portions of the modulated fluorescence to each other to determine a modulation characteristic of the sample;
wherein the sample is a biological material tissue;
wherein the method further includes determining a physiological property of the tissue using the modulation characteristic; and
wherein the physiological property of the tissue is ischemia.
53. A method for determining a physiological characteristic of a biological material, comprising:
irradiating a sample of a biological material with radiation to produce fluorescence from the sample, wherein the fluorescence is modulated by the sample;
monitoring a first portion of the modulated fluorescence at a first distance from the sample;
monitoring a second portion of the modulated fluorescence at a second distance from the sample, the second distance being different from the first distance; and
comparing the first and second portions of the modulated fluorescence to each other, using a predictive model, to determine a physiological characteristic of the sample; ,
wherein the predictive model is multivariate.
54. A spectroscopic method of analyzing a sample, comprising:
irradiating a sample with radiation to produce fluorescence from the sample, wherein the fluorescence is modulated by the sample;
monitoring a first portion of the modulated fluorescence at a first angle from the sample;
monitoring a second portion of the modulated fluorescence at a second angle from the sample; and
comparing the first and second portions of the modulated fluorescence to each other to determine a modulation characteristic of the sample.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/056,335 USRE39672E1 (en) | 1997-07-07 | 2002-01-23 | Method and devices for laser induced fluorescence attenuation spectroscopy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/889,017 US6124597A (en) | 1997-07-07 | 1997-07-07 | Method and devices for laser induced fluorescence attenuation spectroscopy |
US10/056,335 USRE39672E1 (en) | 1997-07-07 | 2002-01-23 | Method and devices for laser induced fluorescence attenuation spectroscopy |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/889,017 Reissue US6124597A (en) | 1997-07-07 | 1997-07-07 | Method and devices for laser induced fluorescence attenuation spectroscopy |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE39672E1 true USRE39672E1 (en) | 2007-06-05 |
Family
ID=25394356
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/889,017 Expired - Lifetime US6124597A (en) | 1997-07-07 | 1997-07-07 | Method and devices for laser induced fluorescence attenuation spectroscopy |
US09/605,176 Expired - Fee Related US6697657B1 (en) | 1995-06-06 | 2000-06-28 | Method and devices for laser induced fluorescence attenuation spectroscopy (LIFAS) |
US10/056,335 Expired - Lifetime USRE39672E1 (en) | 1997-07-07 | 2002-01-23 | Method and devices for laser induced fluorescence attenuation spectroscopy |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/889,017 Expired - Lifetime US6124597A (en) | 1997-07-07 | 1997-07-07 | Method and devices for laser induced fluorescence attenuation spectroscopy |
US09/605,176 Expired - Fee Related US6697657B1 (en) | 1995-06-06 | 2000-06-28 | Method and devices for laser induced fluorescence attenuation spectroscopy (LIFAS) |
Country Status (6)
Country | Link |
---|---|
US (3) | US6124597A (en) |
EP (2) | EP0995095B1 (en) |
JP (1) | JP2001509589A (en) |
AU (1) | AU752061B2 (en) |
DE (1) | DE69829664D1 (en) |
WO (1) | WO1999002956A2 (en) |
Cited By (292)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060188869A1 (en) * | 2005-01-13 | 2006-08-24 | Whitehead Institute For Biomedical Research | Method and apparatus for UV imaging |
US20060258926A1 (en) * | 1999-01-25 | 2006-11-16 | Ali Ammar A | Systems and methods for acquiring calibration data usable in a pulse oximeter |
US20060270921A1 (en) * | 2001-06-29 | 2006-11-30 | Weber Walter M | Sine saturation transform |
US20070249918A1 (en) * | 1991-03-07 | 2007-10-25 | Diab Mohamed K | Signal processing apparatus |
US20070265514A1 (en) * | 2006-05-15 | 2007-11-15 | Kiani Massi E | Systems and methods for calibrating minimally invasive and non-invasive physiological sensor devices |
US20080027294A1 (en) * | 2003-08-28 | 2008-01-31 | Ammar Al-Ali | Physiological parameter tracking system |
US20080036752A1 (en) * | 1997-04-14 | 2008-02-14 | Diab Mohamed K | Signal processing apparatus and method |
US20080039735A1 (en) * | 2006-06-06 | 2008-02-14 | Hickerson Barry L | Respiratory monitor display |
US20080064936A1 (en) * | 2001-07-02 | 2008-03-13 | Ammar Al-Ali | Low power pulse oximeter |
US20080071153A1 (en) * | 2006-09-20 | 2008-03-20 | Ammar Al-Ali | Duo connector patient cable |
US20080071155A1 (en) * | 2006-09-20 | 2008-03-20 | Kiani Massi E | Congenital heart disease monitor |
US20080091093A1 (en) * | 2006-10-12 | 2008-04-17 | Ammar Al-Ali | Perfusion index smoother |
US20080094228A1 (en) * | 2006-10-12 | 2008-04-24 | Welch James P | Patient monitor using radio frequency identification tags |
US20080103375A1 (en) * | 2006-09-22 | 2008-05-01 | Kiani Massi E | Patient monitor user interface |
US20080197301A1 (en) * | 2006-12-22 | 2008-08-21 | Diab Mohamed K | Detector shield |
USD609193S1 (en) | 2007-10-12 | 2010-02-02 | Masimo Corporation | Connector assembly |
USD614305S1 (en) | 2008-02-29 | 2010-04-20 | Masimo Corporation | Connector assembly |
USRE41317E1 (en) | 1998-10-15 | 2010-05-04 | Masimo Corporation | Universal modular pulse oximeter probe for use with reusable and disposable patient attachment devices |
US7734320B2 (en) | 1999-12-09 | 2010-06-08 | Masimo Corporation | Sensor isolation |
USD621516S1 (en) | 2008-08-25 | 2010-08-10 | Masimo Laboratories, Inc. | Patient monitoring sensor |
US7822452B2 (en) | 2004-08-11 | 2010-10-26 | Glt Acquisition Corp. | Method for data reduction and calibration of an OCT-based blood glucose monitor |
USRE41912E1 (en) | 1998-10-15 | 2010-11-02 | Masimo Corporation | Reusable pulse oximeter probe and disposable bandage apparatus |
US7873497B2 (en) | 2000-06-05 | 2011-01-18 | Masimo Corporation | Variable indication estimator |
US7880626B2 (en) | 2006-10-12 | 2011-02-01 | Masimo Corporation | System and method for monitoring the life of a physiological sensor |
US7880606B2 (en) | 2002-01-24 | 2011-02-01 | Masimo Corporation | Physiological trend monitor |
US7919713B2 (en) | 2007-04-16 | 2011-04-05 | Masimo Corporation | Low noise oximetry cable including conductive cords |
US7937130B2 (en) | 1991-03-07 | 2011-05-03 | Masimo Corporation | Signal processing apparatus |
US7941199B2 (en) | 2006-05-15 | 2011-05-10 | Masimo Laboratories, Inc. | Sepsis monitor |
US7990382B2 (en) | 2006-01-03 | 2011-08-02 | Masimo Corporation | Virtual display |
US8000761B2 (en) | 1999-12-09 | 2011-08-16 | Masimo Corporation | Resposable pulse oximetry sensor |
US8019400B2 (en) | 1994-10-07 | 2011-09-13 | Masimo Corporation | Signal processing apparatus |
US8028701B2 (en) | 2006-05-31 | 2011-10-04 | Masimo Corporation | Respiratory monitoring |
US8036727B2 (en) | 2004-08-11 | 2011-10-11 | Glt Acquisition Corp. | Methods for noninvasively measuring analyte levels in a subject |
US8048040B2 (en) | 2007-09-13 | 2011-11-01 | Masimo Corporation | Fluid titration system |
US8050728B2 (en) | 2005-03-01 | 2011-11-01 | Masimo Laboratories, Inc. | Multiple wavelength sensor drivers |
US8118620B2 (en) | 2007-10-12 | 2012-02-21 | Masimo Corporation | Connector assembly with reduced unshielded area |
US8175672B2 (en) | 1999-04-12 | 2012-05-08 | Masimo Corporation | Reusable pulse oximeter probe and disposable bandage apparatii |
US8203704B2 (en) | 2008-08-04 | 2012-06-19 | Cercacor Laboratories, Inc. | Multi-stream sensor for noninvasive measurement of blood constituents |
US8204566B2 (en) | 2004-08-11 | 2012-06-19 | Glt Acquisition Corp. | Method and apparatus for monitoring blood constituent levels in biological tissue |
US8203438B2 (en) | 2008-07-29 | 2012-06-19 | Masimo Corporation | Alarm suspend system |
US8219172B2 (en) | 2006-03-17 | 2012-07-10 | Glt Acquisition Corp. | System and method for creating a stable optical interface |
US8229533B2 (en) | 1991-03-21 | 2012-07-24 | Masimo Corporation | Low-noise optical probes for reducing ambient noise |
US8255026B1 (en) | 2006-10-12 | 2012-08-28 | Masimo Corporation, Inc. | Patient monitor capable of monitoring the quality of attached probes and accessories |
US8265723B1 (en) | 2006-10-12 | 2012-09-11 | Cercacor Laboratories, Inc. | Oximeter probe off indicator defining probe off space |
US8274360B2 (en) | 2007-10-12 | 2012-09-25 | Masimo Corporation | Systems and methods for storing, analyzing, and retrieving medical data |
US8310336B2 (en) | 2008-10-10 | 2012-11-13 | Masimo Corporation | Systems and methods for storing, analyzing, retrieving and displaying streaming medical data |
US8337403B2 (en) | 2004-03-04 | 2012-12-25 | Masimo Corporation | Patient monitor having context-based sensitivity adjustments |
US8346330B2 (en) | 2008-10-13 | 2013-01-01 | Masimo Corporation | Reflection-detector sensor position indicator |
US8353842B2 (en) | 2005-02-18 | 2013-01-15 | Masimo Corporation | Portable patient monitor |
US8355766B2 (en) | 2007-10-12 | 2013-01-15 | Masimo Corporation | Ceramic emitter substrate |
US8374665B2 (en) | 2007-04-21 | 2013-02-12 | Cercacor Laboratories, Inc. | Tissue profile wellness monitor |
US8401602B2 (en) | 2008-10-13 | 2013-03-19 | Masimo Corporation | Secondary-emitter sensor position indicator |
US8399822B2 (en) | 1999-08-26 | 2013-03-19 | Masimo Corporation | Systems and methods for indicating an amount of use of a sensor |
US8414499B2 (en) | 2006-12-09 | 2013-04-09 | Masimo Corporation | Plethysmograph variability processor |
US8418524B2 (en) | 2009-06-12 | 2013-04-16 | Masimo Corporation | Non-invasive sensor calibration device |
US8423106B2 (en) | 2004-07-07 | 2013-04-16 | Cercacor Laboratories, Inc. | Multi-wavelength physiological monitor |
US8428967B2 (en) | 2009-09-14 | 2013-04-23 | Cercacor Laboratories, Inc. | Spot check monitor credit system |
US8430817B1 (en) | 2009-10-15 | 2013-04-30 | Masimo Corporation | System for determining confidence in respiratory rate measurements |
US8437825B2 (en) | 2008-07-03 | 2013-05-07 | Cercacor Laboratories, Inc. | Contoured protrusion for improving spectroscopic measurement of blood constituents |
US8447374B2 (en) | 2002-12-04 | 2013-05-21 | Ceracor Laboratories, Inc. | Systems and methods for determining blood oxygen saturation values using complex number encoding |
US8473020B2 (en) | 2009-07-29 | 2013-06-25 | Cercacor Laboratories, Inc. | Non-invasive physiological sensor cover |
US8471713B2 (en) | 2009-07-24 | 2013-06-25 | Cercacor Laboratories, Inc. | Interference detector for patient monitor |
US8532728B2 (en) | 1999-03-25 | 2013-09-10 | Masimo Corporation | Pulse oximeter probe-off detector |
US8532727B2 (en) | 1999-01-25 | 2013-09-10 | Masimo Corporation | Dual-mode pulse oximeter |
US8548548B2 (en) | 2002-03-25 | 2013-10-01 | Masimo Corporation | Physiological measurement communications adapter |
US8548550B2 (en) | 2005-11-29 | 2013-10-01 | Cercacor Laboratories, Inc. | Optical sensor including disposable and reusable elements |
US8560034B1 (en) | 1993-10-06 | 2013-10-15 | Masimo Corporation | Signal processing apparatus |
US8571618B1 (en) | 2009-09-28 | 2013-10-29 | Cercacor Laboratories, Inc. | Adaptive calibration system for spectrophotometric measurements |
US8571619B2 (en) | 2009-05-20 | 2013-10-29 | Masimo Corporation | Hemoglobin display and patient treatment |
US8571617B2 (en) | 2008-03-04 | 2013-10-29 | Glt Acquisition Corp. | Flowometry in optical coherence tomography for analyte level estimation |
US8588880B2 (en) | 2009-02-16 | 2013-11-19 | Masimo Corporation | Ear sensor |
US8584345B2 (en) | 2010-03-08 | 2013-11-19 | Masimo Corporation | Reprocessing of a physiological sensor |
US8600467B2 (en) | 2006-11-29 | 2013-12-03 | Cercacor Laboratories, Inc. | Optical sensor including disposable and reusable elements |
US8641631B2 (en) | 2004-04-08 | 2014-02-04 | Masimo Corporation | Non-invasive monitoring of respiratory rate, heart rate and apnea |
US8655807B2 (en) | 2010-04-05 | 2014-02-18 | Applied Research Associates, Inc. | Methods for forming recognition algorithms for laser-induced breakdown spectroscopy |
US8652060B2 (en) | 2007-01-20 | 2014-02-18 | Masimo Corporation | Perfusion trend indicator |
US8666468B1 (en) | 2010-05-06 | 2014-03-04 | Masimo Corporation | Patient monitor for determining microcirculation state |
US8670811B2 (en) | 2009-06-30 | 2014-03-11 | Masimo Corporation | Pulse oximetry system for adjusting medical ventilation |
US8676286B2 (en) | 2003-07-08 | 2014-03-18 | Cercacor Laboratories, Inc. | Method and apparatus for reducing coupling between signals in a measurement system |
US8682407B2 (en) | 2004-07-09 | 2014-03-25 | Masimo Corporation | Cyanotic infant sensor |
US8688183B2 (en) | 2009-09-03 | 2014-04-01 | Ceracor Laboratories, Inc. | Emitter driver for noninvasive patient monitor |
US8690799B2 (en) | 2009-10-15 | 2014-04-08 | Masimo Corporation | Acoustic respiratory monitoring sensor having multiple sensing elements |
US8712494B1 (en) | 2010-05-03 | 2014-04-29 | Masimo Corporation | Reflective non-invasive sensor |
US8718737B2 (en) | 1997-04-14 | 2014-05-06 | Masimo Corporation | Method and apparatus for demodulating signals in a pulse oximetry system |
US8723677B1 (en) | 2010-10-20 | 2014-05-13 | Masimo Corporation | Patient safety system with automatically adjusting bed |
US8721541B2 (en) | 1998-06-03 | 2014-05-13 | Masimo Corporation | Physiological monitor |
US8721542B2 (en) | 2004-03-08 | 2014-05-13 | Masimo Corporation | Physiological parameter system |
US8740792B1 (en) | 2010-07-12 | 2014-06-03 | Masimo Corporation | Patient monitor capable of accounting for environmental conditions |
US8755872B1 (en) | 2011-07-28 | 2014-06-17 | Masimo Corporation | Patient monitoring system for indicating an abnormal condition |
US8764671B2 (en) | 2007-06-28 | 2014-07-01 | Masimo Corporation | Disposable active pulse sensor |
US8771204B2 (en) | 2008-12-30 | 2014-07-08 | Masimo Corporation | Acoustic sensor assembly |
US8781544B2 (en) | 2007-03-27 | 2014-07-15 | Cercacor Laboratories, Inc. | Multiple wavelength optical sensor |
US8781549B2 (en) | 2003-01-24 | 2014-07-15 | Cercacor Laboratories, Inc. | Noninvasive oximetry optical sensor including disposable and reusable elements |
US8781543B2 (en) | 1995-06-07 | 2014-07-15 | Jpmorgan Chase Bank, National Association | Manual and automatic probe calibration |
US8801613B2 (en) | 2009-12-04 | 2014-08-12 | Masimo Corporation | Calibration for multi-stage physiological monitors |
US8821415B2 (en) | 2009-10-15 | 2014-09-02 | Masimo Corporation | Physiological acoustic monitoring system |
US8821397B2 (en) | 2010-09-28 | 2014-09-02 | Masimo Corporation | Depth of consciousness monitor including oximeter |
US8830449B1 (en) | 2011-04-18 | 2014-09-09 | Cercacor Laboratories, Inc. | Blood analysis system |
US8840549B2 (en) | 2006-09-22 | 2014-09-23 | Masimo Corporation | Modular patient monitor |
US8852094B2 (en) | 2006-12-22 | 2014-10-07 | Masimo Corporation | Physiological parameter system |
US8870792B2 (en) | 2009-10-15 | 2014-10-28 | Masimo Corporation | Physiological acoustic monitoring system |
US8897847B2 (en) | 2009-03-23 | 2014-11-25 | Masimo Corporation | Digit gauge for noninvasive optical sensor |
US8911377B2 (en) | 2008-09-15 | 2014-12-16 | Masimo Corporation | Patient monitor including multi-parameter graphical display |
US8920317B2 (en) | 2003-07-25 | 2014-12-30 | Masimo Corporation | Multipurpose sensor port |
US8989831B2 (en) | 2009-05-19 | 2015-03-24 | Masimo Corporation | Disposable components for reusable physiological sensor |
US8996085B2 (en) | 2005-10-14 | 2015-03-31 | Masimo Corporation | Robust alarm system |
US9042967B2 (en) | 2008-05-20 | 2015-05-26 | University Health Network | Device and method for wound imaging and monitoring |
US9066666B2 (en) | 2011-02-25 | 2015-06-30 | Cercacor Laboratories, Inc. | Patient monitor for monitoring microcirculation |
US9072474B2 (en) | 2003-11-05 | 2015-07-07 | Masimo Corporation | Pulse oximeter access apparatus and method |
US9095316B2 (en) | 2011-04-20 | 2015-08-04 | Masimo Corporation | System for generating alarms based on alarm patterns |
US9106038B2 (en) | 2009-10-15 | 2015-08-11 | Masimo Corporation | Pulse oximetry system with low noise cable hub |
US9107625B2 (en) | 2008-05-05 | 2015-08-18 | Masimo Corporation | Pulse oximetry system with electrical decoupling circuitry |
US9131881B2 (en) | 2012-04-17 | 2015-09-15 | Masimo Corporation | Hypersaturation index |
US9138180B1 (en) | 2010-05-03 | 2015-09-22 | Masimo Corporation | Sensor adapter cable |
US9153112B1 (en) | 2009-12-21 | 2015-10-06 | Masimo Corporation | Modular patient monitor |
US9161696B2 (en) | 2006-09-22 | 2015-10-20 | Masimo Corporation | Modular patient monitor |
US9176141B2 (en) | 2006-05-15 | 2015-11-03 | Cercacor Laboratories, Inc. | Physiological monitor calibration system |
US9195385B2 (en) | 2012-03-25 | 2015-11-24 | Masimo Corporation | Physiological monitor touchscreen interface |
US9192351B1 (en) | 2011-07-22 | 2015-11-24 | Masimo Corporation | Acoustic respiratory monitoring sensor with probe-off detection |
US9192329B2 (en) | 2006-10-12 | 2015-11-24 | Masimo Corporation | Variable mode pulse indicator |
US20150355091A1 (en) * | 2010-09-28 | 2015-12-10 | Authentix, Inc. | Determining the Quantity of a Taggant in a Liquid Sample |
US9211095B1 (en) | 2010-10-13 | 2015-12-15 | Masimo Corporation | Physiological measurement logic engine |
US9218454B2 (en) | 2009-03-04 | 2015-12-22 | Masimo Corporation | Medical monitoring system |
US9245668B1 (en) | 2011-06-29 | 2016-01-26 | Cercacor Laboratories, Inc. | Low noise cable providing communication between electronic sensor components and patient monitor |
US9307928B1 (en) | 2010-03-30 | 2016-04-12 | Masimo Corporation | Plethysmographic respiration processor |
US9323894B2 (en) | 2011-08-19 | 2016-04-26 | Masimo Corporation | Health care sanitation monitoring system |
USD755392S1 (en) | 2015-02-06 | 2016-05-03 | Masimo Corporation | Pulse oximetry sensor |
US9326712B1 (en) | 2010-06-02 | 2016-05-03 | Masimo Corporation | Opticoustic sensor |
US9341565B2 (en) | 2004-07-07 | 2016-05-17 | Masimo Corporation | Multiple-wavelength physiological monitor |
US9386961B2 (en) | 2009-10-15 | 2016-07-12 | Masimo Corporation | Physiological acoustic monitoring system |
US9392945B2 (en) | 2012-01-04 | 2016-07-19 | Masimo Corporation | Automated CCHD screening and detection |
US9408542B1 (en) | 2010-07-22 | 2016-08-09 | Masimo Corporation | Non-invasive blood pressure measurement system |
US9436645B2 (en) | 2011-10-13 | 2016-09-06 | Masimo Corporation | Medical monitoring hub |
US9445759B1 (en) | 2011-12-22 | 2016-09-20 | Cercacor Laboratories, Inc. | Blood glucose calibration system |
US9474474B2 (en) | 2013-03-14 | 2016-10-25 | Masimo Corporation | Patient monitor as a minimally invasive glucometer |
US9480435B2 (en) | 2012-02-09 | 2016-11-01 | Masimo Corporation | Configurable patient monitoring system |
US9510779B2 (en) | 2009-09-17 | 2016-12-06 | Masimo Corporation | Analyte monitoring using one or more accelerometers |
US9517024B2 (en) | 2009-09-17 | 2016-12-13 | Masimo Corporation | Optical-based physiological monitoring system |
US9532722B2 (en) | 2011-06-21 | 2017-01-03 | Masimo Corporation | Patient monitoring system |
US9560996B2 (en) | 2012-10-30 | 2017-02-07 | Masimo Corporation | Universal medical system |
US9579039B2 (en) | 2011-01-10 | 2017-02-28 | Masimo Corporation | Non-invasive intravascular volume index monitor |
US9622692B2 (en) | 2011-05-16 | 2017-04-18 | Masimo Corporation | Personal health device |
US9636055B2 (en) | 1999-01-07 | 2017-05-02 | Masimo Corporation | Pulse and confidence indicator displayed proximate plethysmograph |
US9649054B2 (en) | 2010-08-26 | 2017-05-16 | Cercacor Laboratories, Inc. | Blood pressure measurement method |
USD788312S1 (en) | 2012-02-09 | 2017-05-30 | Masimo Corporation | Wireless patient monitoring device |
US9675286B2 (en) | 1998-12-30 | 2017-06-13 | Masimo Corporation | Plethysmograph pulse recognition processor |
US9697928B2 (en) | 2012-08-01 | 2017-07-04 | Masimo Corporation | Automated assembly sensor cable |
US9717458B2 (en) | 2012-10-20 | 2017-08-01 | Masimo Corporation | Magnetic-flap optical sensor |
US9724024B2 (en) | 2010-03-01 | 2017-08-08 | Masimo Corporation | Adaptive alarm system |
US9724025B1 (en) | 2013-01-16 | 2017-08-08 | Masimo Corporation | Active-pulse blood analysis system |
US9724016B1 (en) | 2009-10-16 | 2017-08-08 | Masimo Corp. | Respiration processor |
US9749232B2 (en) | 2012-09-20 | 2017-08-29 | Masimo Corporation | Intelligent medical network edge router |
US9750461B1 (en) | 2013-01-02 | 2017-09-05 | Masimo Corporation | Acoustic respiratory monitoring sensor with probe-off detection |
US9750442B2 (en) | 2013-03-09 | 2017-09-05 | Masimo Corporation | Physiological status monitor |
US9775545B2 (en) | 2010-09-28 | 2017-10-03 | Masimo Corporation | Magnetic electrical connector for patient monitors |
US9778079B1 (en) | 2011-10-27 | 2017-10-03 | Masimo Corporation | Physiological monitor gauge panel |
US9782077B2 (en) | 2011-08-17 | 2017-10-10 | Masimo Corporation | Modulated physiological sensor |
US9787568B2 (en) | 2012-11-05 | 2017-10-10 | Cercacor Laboratories, Inc. | Physiological test credit method |
US9808188B1 (en) | 2011-10-13 | 2017-11-07 | Masimo Corporation | Robust fractional saturation determination |
US9839379B2 (en) | 2013-10-07 | 2017-12-12 | Masimo Corporation | Regional oximetry pod |
US9839381B1 (en) | 2009-11-24 | 2017-12-12 | Cercacor Laboratories, Inc. | Physiological measurement system with automatic wavelength adjustment |
US9861305B1 (en) | 2006-10-12 | 2018-01-09 | Masimo Corporation | Method and apparatus for calibration to reduce coupling between signals in a measurement system |
US9891079B2 (en) | 2013-07-17 | 2018-02-13 | Masimo Corporation | Pulser with double-bearing position encoder for non-invasive physiological monitoring |
US9924897B1 (en) | 2014-06-12 | 2018-03-27 | Masimo Corporation | Heated reprocessing of physiological sensors |
US9936917B2 (en) | 2013-03-14 | 2018-04-10 | Masimo Laboratories, Inc. | Patient monitor placement indicator |
US9943269B2 (en) | 2011-10-13 | 2018-04-17 | Masimo Corporation | System for displaying medical monitoring data |
US9955937B2 (en) | 2012-09-20 | 2018-05-01 | Masimo Corporation | Acoustic patient sensor coupler |
US9986919B2 (en) | 2011-06-21 | 2018-06-05 | Masimo Corporation | Patient monitoring system |
US9986952B2 (en) | 2013-03-14 | 2018-06-05 | Masimo Corporation | Heart sound simulator |
US10007758B2 (en) | 2009-03-04 | 2018-06-26 | Masimo Corporation | Medical monitoring system |
US10032002B2 (en) | 2009-03-04 | 2018-07-24 | Masimo Corporation | Medical monitoring system |
US10086138B1 (en) | 2014-01-28 | 2018-10-02 | Masimo Corporation | Autonomous drug delivery system |
USD835283S1 (en) | 2017-04-28 | 2018-12-04 | Masimo Corporation | Medical monitoring device |
USD835284S1 (en) | 2017-04-28 | 2018-12-04 | Masimo Corporation | Medical monitoring device |
USD835285S1 (en) | 2017-04-28 | 2018-12-04 | Masimo Corporation | Medical monitoring device |
USD835282S1 (en) | 2017-04-28 | 2018-12-04 | Masimo Corporation | Medical monitoring device |
US10154815B2 (en) | 2014-10-07 | 2018-12-18 | Masimo Corporation | Modular physiological sensors |
US10159412B2 (en) | 2010-12-01 | 2018-12-25 | Cercacor Laboratories, Inc. | Handheld processing device including medical applications for minimally and non invasive glucose measurements |
US10188348B2 (en) | 2006-06-05 | 2019-01-29 | Masimo Corporation | Parameter upgrade system |
US10205272B2 (en) | 2009-03-11 | 2019-02-12 | Masimo Corporation | Magnetic connector |
US10205291B2 (en) | 2015-02-06 | 2019-02-12 | Masimo Corporation | Pogo pin connector |
US10226187B2 (en) | 2015-08-31 | 2019-03-12 | Masimo Corporation | Patient-worn wireless physiological sensor |
US10231657B2 (en) | 2014-09-04 | 2019-03-19 | Masimo Corporation | Total hemoglobin screening sensor |
US10231670B2 (en) | 2014-06-19 | 2019-03-19 | Masimo Corporation | Proximity sensor in pulse oximeter |
US10279247B2 (en) | 2013-12-13 | 2019-05-07 | Masimo Corporation | Avatar-incentive healthcare therapy |
US10292664B2 (en) | 2008-05-02 | 2019-05-21 | Masimo Corporation | Monitor configuration system |
US10307111B2 (en) | 2012-02-09 | 2019-06-04 | Masimo Corporation | Patient position detection system |
US10327337B2 (en) | 2015-02-06 | 2019-06-18 | Masimo Corporation | Fold flex circuit for LNOP |
US10327713B2 (en) | 2017-02-24 | 2019-06-25 | Masimo Corporation | Modular multi-parameter patient monitoring device |
US10332630B2 (en) | 2011-02-13 | 2019-06-25 | Masimo Corporation | Medical characterization system |
US10357209B2 (en) | 2009-10-15 | 2019-07-23 | Masimo Corporation | Bidirectional physiological information display |
US10388120B2 (en) | 2017-02-24 | 2019-08-20 | Masimo Corporation | Localized projection of audible noises in medical settings |
US10383520B2 (en) | 2014-09-18 | 2019-08-20 | Masimo Semiconductor, Inc. | Enhanced visible near-infrared photodiode and non-invasive physiological sensor |
US10438356B2 (en) | 2014-07-24 | 2019-10-08 | University Health Network | Collection and analysis of data for diagnostic purposes |
US10441181B1 (en) | 2013-03-13 | 2019-10-15 | Masimo Corporation | Acoustic pulse and respiration monitoring system |
US10441196B2 (en) | 2015-01-23 | 2019-10-15 | Masimo Corporation | Nasal/oral cannula system and manufacturing |
US10448871B2 (en) | 2015-07-02 | 2019-10-22 | Masimo Corporation | Advanced pulse oximetry sensor |
US10456038B2 (en) | 2013-03-15 | 2019-10-29 | Cercacor Laboratories, Inc. | Cloud-based physiological monitoring system |
US10505311B2 (en) | 2017-08-15 | 2019-12-10 | Masimo Corporation | Water resistant connector for noninvasive patient monitor |
US10524738B2 (en) | 2015-05-04 | 2020-01-07 | Cercacor Laboratories, Inc. | Noninvasive sensor system with visual infographic display |
US10532174B2 (en) | 2014-02-21 | 2020-01-14 | Masimo Corporation | Assistive capnography device |
US10537285B2 (en) | 2016-03-04 | 2020-01-21 | Masimo Corporation | Nose sensor |
US10542903B2 (en) | 2012-06-07 | 2020-01-28 | Masimo Corporation | Depth of consciousness monitor |
US10555678B2 (en) | 2013-08-05 | 2020-02-11 | Masimo Corporation | Blood pressure monitor with valve-chamber assembly |
US10568553B2 (en) | 2015-02-06 | 2020-02-25 | Masimo Corporation | Soft boot pulse oximetry sensor |
US10617302B2 (en) | 2016-07-07 | 2020-04-14 | Masimo Corporation | Wearable pulse oximeter and respiration monitor |
US10672260B2 (en) | 2013-03-13 | 2020-06-02 | Masimo Corporation | Systems and methods for monitoring a patient health network |
US10667764B2 (en) | 2018-04-19 | 2020-06-02 | Masimo Corporation | Mobile patient alarm display |
USD890708S1 (en) | 2017-08-15 | 2020-07-21 | Masimo Corporation | Connector |
US10721785B2 (en) | 2017-01-18 | 2020-07-21 | Masimo Corporation | Patient-worn wireless physiological sensor with pairing functionality |
US10743749B2 (en) | 2018-09-14 | 2020-08-18 | Canon U.S.A., Inc. | System and method for detecting optical probe connection |
US10750984B2 (en) | 2016-12-22 | 2020-08-25 | Cercacor Laboratories, Inc. | Methods and devices for detecting intensity of light with translucent detector |
US10779098B2 (en) | 2018-07-10 | 2020-09-15 | Masimo Corporation | Patient monitor alarm speaker analyzer |
USD897098S1 (en) | 2018-10-12 | 2020-09-29 | Masimo Corporation | Card holder set |
US10825568B2 (en) | 2013-10-11 | 2020-11-03 | Masimo Corporation | Alarm notification system |
US10827961B1 (en) | 2012-08-29 | 2020-11-10 | Masimo Corporation | Physiological measurement calibration |
US10828007B1 (en) | 2013-10-11 | 2020-11-10 | Masimo Corporation | Acoustic sensor with attachment portion |
US10849554B2 (en) | 2017-04-18 | 2020-12-01 | Masimo Corporation | Nose sensor |
US10856750B2 (en) | 2017-04-28 | 2020-12-08 | Masimo Corporation | Spot check measurement system |
US10874797B2 (en) | 2006-01-17 | 2020-12-29 | Masimo Corporation | Drug administration controller |
USD906970S1 (en) | 2017-08-15 | 2021-01-05 | Masimo Corporation | Connector |
US10918281B2 (en) | 2017-04-26 | 2021-02-16 | Masimo Corporation | Medical monitoring device having multiple configurations |
US10932729B2 (en) | 2018-06-06 | 2021-03-02 | Masimo Corporation | Opioid overdose monitoring |
US10932705B2 (en) | 2017-05-08 | 2021-03-02 | Masimo Corporation | System for displaying and controlling medical monitoring data |
US10952641B2 (en) | 2008-09-15 | 2021-03-23 | Masimo Corporation | Gas sampling line |
US10952616B2 (en) | 2018-03-30 | 2021-03-23 | Canon U.S.A., Inc. | Fluorescence imaging apparatus |
US10956950B2 (en) | 2017-02-24 | 2021-03-23 | Masimo Corporation | Managing dynamic licenses for physiological parameters in a patient monitoring environment |
USD916135S1 (en) | 2018-10-11 | 2021-04-13 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
USD917550S1 (en) | 2018-10-11 | 2021-04-27 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
US10991135B2 (en) | 2015-08-11 | 2021-04-27 | Masimo Corporation | Medical monitoring analysis and replay including indicia responsive to light attenuated by body tissue |
US10987066B2 (en) | 2017-10-31 | 2021-04-27 | Masimo Corporation | System for displaying oxygen state indications |
USD917704S1 (en) | 2019-08-16 | 2021-04-27 | Masimo Corporation | Patient monitor |
USD917564S1 (en) | 2018-10-11 | 2021-04-27 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
US10993662B2 (en) | 2016-03-04 | 2021-05-04 | Masimo Corporation | Nose sensor |
USD919100S1 (en) | 2019-08-16 | 2021-05-11 | Masimo Corporation | Holder for a patient monitor |
USD919094S1 (en) | 2019-08-16 | 2021-05-11 | Masimo Corporation | Blood pressure device |
USD921202S1 (en) | 2019-08-16 | 2021-06-01 | Masimo Corporation | Holder for a blood pressure device |
US11024064B2 (en) | 2017-02-24 | 2021-06-01 | Masimo Corporation | Augmented reality system for displaying patient data |
US11026604B2 (en) | 2017-07-13 | 2021-06-08 | Cercacor Laboratories, Inc. | Medical monitoring device for harmonizing physiological measurements |
USD925597S1 (en) | 2017-10-31 | 2021-07-20 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
US11076777B2 (en) | 2016-10-13 | 2021-08-03 | Masimo Corporation | Systems and methods for monitoring orientation to reduce pressure ulcer formation |
US11086609B2 (en) | 2017-02-24 | 2021-08-10 | Masimo Corporation | Medical monitoring hub |
USD927699S1 (en) | 2019-10-18 | 2021-08-10 | Masimo Corporation | Electrode pad |
US11114188B2 (en) | 2009-10-06 | 2021-09-07 | Cercacor Laboratories, Inc. | System for monitoring a physiological parameter of a user |
USD933232S1 (en) | 2020-05-11 | 2021-10-12 | Masimo Corporation | Blood pressure monitor |
US11147518B1 (en) | 2013-10-07 | 2021-10-19 | Masimo Corporation | Regional oximetry signal processor |
US11153089B2 (en) | 2016-07-06 | 2021-10-19 | Masimo Corporation | Secure and zero knowledge data sharing for cloud applications |
US11172890B2 (en) | 2012-01-04 | 2021-11-16 | Masimo Corporation | Automated condition screening and detection |
US11185262B2 (en) | 2017-03-10 | 2021-11-30 | Masimo Corporation | Pneumonia screener |
US11191484B2 (en) | 2016-04-29 | 2021-12-07 | Masimo Corporation | Optical sensor tape |
US11259745B2 (en) | 2014-01-28 | 2022-03-01 | Masimo Corporation | Autonomous drug delivery system |
US11272839B2 (en) | 2018-10-12 | 2022-03-15 | Ma Simo Corporation | System for transmission of sensor data using dual communication protocol |
US11289199B2 (en) | 2010-01-19 | 2022-03-29 | Masimo Corporation | Wellness analysis system |
US11298021B2 (en) | 2017-10-19 | 2022-04-12 | Masimo Corporation | Medical monitoring system |
US11389093B2 (en) | 2018-10-11 | 2022-07-19 | Masimo Corporation | Low noise oximetry cable |
US11406286B2 (en) | 2018-10-11 | 2022-08-09 | Masimo Corporation | Patient monitoring device with improved user interface |
US11417426B2 (en) | 2017-02-24 | 2022-08-16 | Masimo Corporation | System for displaying medical monitoring data |
US11439329B2 (en) | 2011-07-13 | 2022-09-13 | Masimo Corporation | Multiple measurement mode in a physiological sensor |
US11445948B2 (en) | 2018-10-11 | 2022-09-20 | Masimo Corporation | Patient connector assembly with vertical detents |
US11464410B2 (en) | 2018-10-12 | 2022-10-11 | Masimo Corporation | Medical systems and methods |
US11504066B1 (en) | 2015-09-04 | 2022-11-22 | Cercacor Laboratories, Inc. | Low-noise sensor system |
US11504058B1 (en) | 2016-12-02 | 2022-11-22 | Masimo Corporation | Multi-site noninvasive measurement of a physiological parameter |
US11504002B2 (en) | 2012-09-20 | 2022-11-22 | Masimo Corporation | Physiological monitoring system |
USD973072S1 (en) | 2020-09-30 | 2022-12-20 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
USD973686S1 (en) | 2020-09-30 | 2022-12-27 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
USD973685S1 (en) | 2020-09-30 | 2022-12-27 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
USD974193S1 (en) | 2020-07-27 | 2023-01-03 | Masimo Corporation | Wearable temperature measurement device |
US11581091B2 (en) | 2014-08-26 | 2023-02-14 | Vccb Holdings, Inc. | Real-time monitoring systems and methods in a healthcare environment |
USD979516S1 (en) | 2020-05-11 | 2023-02-28 | Masimo Corporation | Connector |
US11596363B2 (en) | 2013-09-12 | 2023-03-07 | Cercacor Laboratories, Inc. | Medical device management system |
USD980091S1 (en) | 2020-07-27 | 2023-03-07 | Masimo Corporation | Wearable temperature measurement device |
US11637437B2 (en) | 2019-04-17 | 2023-04-25 | Masimo Corporation | Charging station for physiological monitoring device |
USD985498S1 (en) | 2019-08-16 | 2023-05-09 | Masimo Corporation | Connector |
US11653862B2 (en) | 2015-05-22 | 2023-05-23 | Cercacor Laboratories, Inc. | Non-invasive optical physiological differential pathlength sensor |
US11679579B2 (en) | 2015-12-17 | 2023-06-20 | Masimo Corporation | Varnish-coated release liner |
US11684296B2 (en) | 2018-12-21 | 2023-06-27 | Cercacor Laboratories, Inc. | Noninvasive physiological sensor |
US11696712B2 (en) | 2014-06-13 | 2023-07-11 | Vccb Holdings, Inc. | Alarm fatigue management systems and methods |
US11721105B2 (en) | 2020-02-13 | 2023-08-08 | Masimo Corporation | System and method for monitoring clinical activities |
US11730379B2 (en) | 2020-03-20 | 2023-08-22 | Masimo Corporation | Remote patient management and monitoring systems and methods |
USD997365S1 (en) | 2021-06-24 | 2023-08-29 | Masimo Corporation | Physiological nose sensor |
USD998630S1 (en) | 2018-10-11 | 2023-09-12 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
USD998631S1 (en) | 2018-10-11 | 2023-09-12 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
USD999246S1 (en) | 2018-10-11 | 2023-09-19 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
US11766198B2 (en) | 2018-02-02 | 2023-09-26 | Cercacor Laboratories, Inc. | Limb-worn patient monitoring device |
USD1000975S1 (en) | 2021-09-22 | 2023-10-10 | Masimo Corporation | Wearable temperature measurement device |
US11803623B2 (en) | 2019-10-18 | 2023-10-31 | Masimo Corporation | Display layout and interactive objects for patient monitoring |
US11832940B2 (en) | 2019-08-27 | 2023-12-05 | Cercacor Laboratories, Inc. | Non-invasive medical monitoring device for blood analyte measurements |
US11872156B2 (en) | 2018-08-22 | 2024-01-16 | Masimo Corporation | Core body temperature measurement |
US11879960B2 (en) | 2020-02-13 | 2024-01-23 | Masimo Corporation | System and method for monitoring clinical activities |
US11883129B2 (en) | 2018-04-24 | 2024-01-30 | Cercacor Laboratories, Inc. | Easy insert finger sensor for transmission based spectroscopy sensor |
US11951186B2 (en) | 2019-10-25 | 2024-04-09 | Willow Laboratories, Inc. | Indicator compounds, devices comprising indicator compounds, and methods of making and using the same |
US11963736B2 (en) | 2009-07-20 | 2024-04-23 | Masimo Corporation | Wireless patient monitoring system |
Families Citing this family (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6826422B1 (en) | 1997-01-13 | 2004-11-30 | Medispectra, Inc. | Spectral volume microprobe arrays |
US6124597A (en) | 1997-07-07 | 2000-09-26 | Cedars-Sinai Medical Center | Method and devices for laser induced fluorescence attenuation spectroscopy |
JP3667947B2 (en) * | 1997-08-29 | 2005-07-06 | 富士写真フイルム株式会社 | Fluorescence image reader |
WO2000042910A1 (en) * | 1999-01-26 | 2000-07-27 | Newton Laboratories, Inc. | Autofluorescence imaging system for endoscopy |
CA2318180A1 (en) * | 1998-01-26 | 1999-07-29 | Massachusetts Institute Of Technology | Fluorescence imaging endoscope |
US7899518B2 (en) | 1998-04-06 | 2011-03-01 | Masimo Laboratories, Inc. | Non-invasive tissue glucose level monitoring |
US20020091324A1 (en) * | 1998-04-06 | 2002-07-11 | Nikiforos Kollias | Non-invasive tissue glucose level monitoring |
US6728560B2 (en) | 1998-04-06 | 2004-04-27 | The General Hospital Corporation | Non-invasive tissue glucose level monitoring |
US6678541B1 (en) * | 1998-10-28 | 2004-01-13 | The Governmemt Of The United States Of America | Optical fiber probe and methods for measuring optical properties |
EP1161178A2 (en) | 1998-12-23 | 2001-12-12 | Medispectra Inc. | Systems and methods for optical examination of samples |
US6587702B1 (en) * | 1999-01-22 | 2003-07-01 | Instrumentation Metrics, Inc | Classification and characterization of tissue through features related to adipose tissue |
US6770028B1 (en) * | 1999-01-25 | 2004-08-03 | Masimo Corporation | Dual-mode pulse oximeter |
DE19922812C2 (en) * | 1999-05-19 | 2001-10-25 | Merck Patent Gmbh | Measurement of turbidity using reflectometry |
US8229549B2 (en) | 2004-07-09 | 2012-07-24 | Tyco Healthcare Group Lp | Surgical imaging device |
US20020007122A1 (en) * | 1999-12-15 | 2002-01-17 | Howard Kaufman | Methods of diagnosing disease |
AU2001238400A1 (en) * | 2000-02-18 | 2001-08-27 | Argose, Inc. | Multivariate analysis of green to ultraviolet spectra of cell and tissue samples |
US6597932B2 (en) | 2000-02-18 | 2003-07-22 | Argose, Inc. | Generation of spatially-averaged excitation-emission map in heterogeneous tissue |
CN1262235C (en) * | 2000-03-31 | 2006-07-05 | 皇家菲利浦电子有限公司 | Method and device for localizing deviant region in turbid medium |
US6377841B1 (en) | 2000-03-31 | 2002-04-23 | Vanderbilt University | Tumor demarcation using optical spectroscopy |
WO2001091626A2 (en) * | 2000-06-01 | 2001-12-06 | Science Applications International Corporation | Systems and methods for monitoring health and delivering drugs transdermally |
AU2001288088A1 (en) * | 2000-09-22 | 2002-04-02 | Organo Corporation | Concentration measurer |
IL138683A0 (en) | 2000-09-25 | 2001-10-31 | Vital Medical Ltd | Apparatus and method for monitoring tissue vitality parameters |
US6839661B2 (en) * | 2000-12-15 | 2005-01-04 | Medispectra, Inc. | System for normalizing spectra |
US6704109B2 (en) * | 2001-01-23 | 2004-03-09 | Schlumberger Technology Corporation | Downhole fluorescence detection apparatus |
US7142306B2 (en) * | 2001-01-23 | 2006-11-28 | Schlumberger Technology Corporation | Optical probes and probe systems for monitoring fluid flow in a well |
US7139598B2 (en) * | 2002-04-04 | 2006-11-21 | Veralight, Inc. | Determination of a measure of a glycation end-product or disease state using tissue fluorescence |
US20070276199A1 (en) * | 2002-04-04 | 2007-11-29 | Ediger Marwood N | Determination of a Measure of a Glycation End-Product or Disease State Using Tissue Fluorescence |
ES2307745T3 (en) * | 2001-04-20 | 2008-12-01 | Power Medical Interventions, Inc. | IMAGE FORMATION DEVICE. |
ES2381407T3 (en) | 2001-04-20 | 2012-05-28 | Tyco Healthcare Group Lp | Bipolar or ultrasonic surgical device |
US6796710B2 (en) * | 2001-06-08 | 2004-09-28 | Ethicon Endo-Surgery, Inc. | System and method of measuring and controlling temperature of optical fiber tip in a laser system |
WO2003032808A2 (en) | 2001-10-15 | 2003-04-24 | University Of Massachusetts | Tissue oxygen measurement system |
US6750006B2 (en) | 2002-01-22 | 2004-06-15 | Microbiosystems, Limited Partnership | Method for detecting the presence of microbes and determining their physiological status |
US7211377B1 (en) | 2002-01-22 | 2007-05-01 | Microbiosystems, Limited Partnership | Method for detecting the presence of dormant cryptobiotic microorganisms |
US7186990B2 (en) * | 2002-01-22 | 2007-03-06 | Microbiosystems, Limited Partnership | Method and apparatus for detecting and imaging the presence of biological materials |
WO2003063694A1 (en) | 2002-01-30 | 2003-08-07 | Power Medical Interventions, Inc. | Surgical imaging device |
IL148795A0 (en) | 2002-03-20 | 2002-09-12 | Vital Medical Ltd | Apparatus and method for monitoring tissue vitality parameters for the diagnosis of body metabolic emergency state |
US8140147B2 (en) * | 2002-04-04 | 2012-03-20 | Veralight, Inc. | Determination of a measure of a glycation end-product or disease state using a flexible probe to determine tissue fluorescence of various sites |
US8131332B2 (en) * | 2002-04-04 | 2012-03-06 | Veralight, Inc. | Determination of a measure of a glycation end-product or disease state using tissue fluorescence of various sites |
US20080009689A1 (en) * | 2002-04-09 | 2008-01-10 | Benaron David A | Difference-weighted somatic spectroscopy |
US20070096039A1 (en) * | 2002-05-03 | 2007-05-03 | Rakesh Kapoor | Evaluation Of Multicomponent Mixtures Using Modulated Light Beams |
WO2005075963A1 (en) * | 2002-05-03 | 2005-08-18 | Rakesh Kapoor | Evaluation of multicomponent mixtures using modulated light beams |
CA2491703A1 (en) * | 2002-07-09 | 2004-01-15 | Medispectra, Inc. | Methods and apparatus for characterization of tissue samples |
US6818903B2 (en) * | 2002-07-09 | 2004-11-16 | Medispectra, Inc. | Method and apparatus for identifying spectral artifacts |
US7103401B2 (en) * | 2002-07-10 | 2006-09-05 | Medispectra, Inc. | Colonic polyp discrimination by tissue fluorescence and fiberoptic probe |
US6768918B2 (en) | 2002-07-10 | 2004-07-27 | Medispectra, Inc. | Fluorescent fiberoptic probe for tissue health discrimination and method of use thereof |
EP2277434B1 (en) | 2002-09-30 | 2013-06-19 | Covidien LP | Self-contained sterilizable surgical system |
CN1493250A (en) * | 2002-10-31 | 2004-05-05 | ƽ | Device using endoscope to diagnose precancer affection |
JP2006522938A (en) * | 2003-03-31 | 2006-10-05 | ゾロ テクノロジーズ,インコーポレイティド | Method and apparatus for combustion monitoring and control |
DE10315541A1 (en) * | 2003-04-04 | 2004-10-28 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method of determining the degree of freshness of food products is based on the wavelength and radiation intensity of emitted florescent radiation |
US7181219B2 (en) * | 2003-05-22 | 2007-02-20 | Lucent Technologies Inc. | Wireless handover using anchor termination |
JP2007500529A (en) * | 2003-07-31 | 2007-01-18 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Method and apparatus with variable numerical aperture for determining the properties of fluid flowing through a biological tube structure |
CN1882278A (en) * | 2003-10-28 | 2006-12-20 | 薇拉莱特公司 | Determination of a measure of a glycation end-product or disease state using tissue fluorescence |
US7587236B2 (en) * | 2004-01-08 | 2009-09-08 | Lawrence Livermore National Security, Llc | Optical spectroscopy for the detection of ischemic tissue injury |
JP3721408B2 (en) | 2004-04-06 | 2005-11-30 | 国立大学法人 岡山大学 | Brain ischemia monitoring monitor |
DE102004024494B4 (en) * | 2004-05-16 | 2019-10-17 | Dürr Dental SE | Medical camera |
US7640046B2 (en) * | 2004-06-18 | 2009-12-29 | Cardiac Pacemakers, Inc. | Methods and apparatuses for localizing myocardial infarction during catheterization |
CA2591237A1 (en) * | 2004-12-09 | 2006-06-15 | Flexible Medical Systems, Llc | Apparatus and method for continuous real-time trace biomolecular sampling, analysis and delivery |
EP1893975A4 (en) * | 2005-06-13 | 2010-08-04 | Stratagene California | System and method for fluorescence excitation and detection having distinct optical paths |
DE102005045906B4 (en) * | 2005-09-26 | 2007-11-29 | Siemens Ag | Device for receiving a tissue containing a fluorescent dye |
US7530942B1 (en) | 2005-10-18 | 2009-05-12 | Masimo Corporation | Remote sensing infant warmer |
US20070180140A1 (en) * | 2005-12-03 | 2007-08-02 | Welch James P | Physiological alarm notification system |
US7847941B2 (en) * | 2005-12-07 | 2010-12-07 | Los Alamos National Security, Llc | Fiber optical assembly for fluorescence spectrometry |
US8333874B2 (en) * | 2005-12-09 | 2012-12-18 | Flexible Medical Systems, Llc | Flexible apparatus and method for monitoring and delivery |
WO2007087560A2 (en) * | 2006-01-26 | 2007-08-02 | The Board Of Trustees Of The University Of Illinois | Stroke inducing and monitoring system and method for using the same |
GB0604231D0 (en) * | 2006-03-02 | 2006-04-12 | Ucl Biomedica Plc | Cancer detection system |
US20070244377A1 (en) * | 2006-03-14 | 2007-10-18 | Cozad Jenny L | Pulse oximeter sleeve |
US7846390B2 (en) * | 2006-03-30 | 2010-12-07 | King Fahd University Of Petroleum And Minerals | Apparatus and method for measuring concentrations of fuel mixtures using depth-resolved laser-induced fluorescence |
US20080064965A1 (en) * | 2006-09-08 | 2008-03-13 | Jay Gregory D | Devices and methods for measuring pulsus paradoxus |
DE102006048317A1 (en) * | 2006-10-12 | 2008-04-17 | Robert Bosch Gmbh | Optical fiber sensor for optical measuring device i.e. interferometric measuring device, has optical fiber modularly provided with mechanically stabilizing coating in area of fiber end piece and/or in area of mechanical receiver |
EP2118642B1 (en) * | 2007-02-12 | 2015-09-02 | Koninklijke Philips N.V. | Wiregrid monitor device |
US8101426B2 (en) * | 2007-03-02 | 2012-01-24 | Icyt Mission Technology, Inc. | System and method for the measurement of multiple fluorescence emissions in a flow cytometry system |
JP5607525B2 (en) * | 2007-07-13 | 2014-10-15 | ユニバーシティ オブ マサチューセッツ | Physical ability monitoring and monitoring |
US20100270479A1 (en) * | 2007-11-12 | 2010-10-28 | Cornell University | Non-imaging, weakly focused fluorescence emission apparatus and method |
EP2209412B1 (en) * | 2007-11-12 | 2018-08-29 | Cornell University | Multi-path, multi-magnification, non-confocal fluorescence emission endoscopy apparatus and methods |
US9717896B2 (en) | 2007-12-18 | 2017-08-01 | Gearbox, Llc | Treatment indications informed by a priori implant information |
US9672471B2 (en) | 2007-12-18 | 2017-06-06 | Gearbox Llc | Systems, devices, and methods for detecting occlusions in a biological subject including spectral learning |
US8636670B2 (en) | 2008-05-13 | 2014-01-28 | The Invention Science Fund I, Llc | Circulatory monitoring systems and methods |
US20090287120A1 (en) | 2007-12-18 | 2009-11-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Circulatory monitoring systems and methods |
US8280484B2 (en) | 2007-12-18 | 2012-10-02 | The Invention Science Fund I, Llc | System, devices, and methods for detecting occlusions in a biological subject |
DE202008009859U1 (en) * | 2007-12-21 | 2009-03-05 | Berthold Technologies Gmbh & Co. Kg | Device for the optional measurement of in particular luminescence and / or fluorescence radiation |
US8512975B2 (en) * | 2008-07-24 | 2013-08-20 | Biomerieux, Inc. | Method for detection and characterization of a microorganism in a sample using time dependent spectroscopic measurements |
WO2010062350A1 (en) * | 2008-10-31 | 2010-06-03 | Biomerieux, Inc. | Methods for detection, characterization and/or identification of microorganisms in a sealed container |
CA2748793C (en) | 2009-01-09 | 2016-06-07 | Michael John Estes | Method and apparatus for monitoring combustion properties in an interior of a boiler |
US20100234718A1 (en) * | 2009-03-12 | 2010-09-16 | Anand Sampath | Open architecture medical communication system |
CA2756225A1 (en) | 2009-03-25 | 2010-09-30 | Los Alamos National Security, Llc | Fiber optical assembly for fluorescence spectrometry |
JP2012522222A (en) * | 2009-03-25 | 2012-09-20 | ロス アラモス ナショナル セキュリティー,エルエルシー | Rapid prenatal detection of infectious agents |
US20110040197A1 (en) * | 2009-07-20 | 2011-02-17 | Masimo Corporation | Wireless patient monitoring system |
US20110028806A1 (en) * | 2009-07-29 | 2011-02-03 | Sean Merritt | Reflectance calibration of fluorescence-based glucose measurements |
US20110028809A1 (en) * | 2009-07-29 | 2011-02-03 | Masimo Corporation | Patient monitor ambient display device |
US20110087081A1 (en) * | 2009-08-03 | 2011-04-14 | Kiani Massi Joe E | Personalized physiological monitor |
JP2011053135A (en) * | 2009-09-03 | 2011-03-17 | Japan Aerospace Exploration Agency | Device and method for multi-wavelength fluorescence imaging for evaluation of biological metabolic function |
US8401608B2 (en) * | 2009-09-30 | 2013-03-19 | Covidien Lp | Method of analyzing photon density waves in a medical monitor |
JP2013511341A (en) * | 2009-11-17 | 2013-04-04 | ヴェラライト,インコーポレイテッド | Method and apparatus for detecting coronary artery calcification or coronary artery disease |
JP2011185842A (en) | 2010-03-10 | 2011-09-22 | Fujifilm Corp | Method and device for analyzing low oxygen region of biosample by time resolving measurement of light induced self-fluorescence |
EP2620093A1 (en) * | 2010-10-29 | 2013-07-31 | Olympus Corporation | Optical measurement device and probe |
US9451913B2 (en) | 2010-12-10 | 2016-09-27 | Touchtek Labs, Llc | Transdermal sampling and analysis device |
US9877673B2 (en) | 2010-12-10 | 2018-01-30 | Clinitech, Llc | Transdermal sampling and analysis device |
JP5926806B2 (en) | 2011-09-22 | 2016-05-25 | ザ・ジョージ・ワシントン・ユニバーシティThe George Washingtonuniversity | System and method for visualizing ablated tissue |
EP2757933B1 (en) | 2011-09-22 | 2019-02-06 | The George Washington University | Systems for visualizing ablated tissue |
JP5970785B2 (en) * | 2011-11-16 | 2016-08-17 | ソニー株式会社 | Biological measuring device, biological measuring method, program, and recording medium |
US9968284B2 (en) | 2011-12-02 | 2018-05-15 | Clinitech, Llc | Anti-interferent barrier layers for non-invasive transdermal sampling and analysis device |
US9366621B2 (en) | 2012-04-19 | 2016-06-14 | Zolo Technologies, Inc. | In-furnace retro-reflectors with steerable tunable diode laser absorption spectrometer |
RU2511262C2 (en) * | 2012-05-29 | 2014-04-10 | Общество с ограниченной ответственностью "Научно-производственный центр медицинских и промышленных биотехнологий Спектролюкс" | Method for monitoring of treatment of disease involving fluorescence diagnostics of disease, and device for implementing it |
US20160112684A1 (en) * | 2013-05-23 | 2016-04-21 | Medibotics Llc | Spectroscopic Finger Ring for Compositional Analysis of Food or Other Environmental Objects |
US10004434B1 (en) | 2013-03-15 | 2018-06-26 | Georgetown University | Microfluidic systems for electrochemical transdermal analyte sensing using a capillary-located electrode |
WO2014168734A1 (en) | 2013-03-15 | 2014-10-16 | Cedars-Sinai Medical Center | Time-resolved laser-induced fluorescence spectroscopy systems and uses thereof |
RU2539817C1 (en) * | 2013-07-16 | 2015-01-27 | Федеральное государственное бюджетное учреждение "Федеральный Центр сердца, крови и Эндокринологии имени В.А. Алмазова" Министерства здравоохранения Российской Федерации | Apparatus for fluorescent spectroscopy of biological tissue |
WO2015073871A2 (en) * | 2013-11-14 | 2015-05-21 | The George Washington University | Systems and methods for determining lesion depth using fluorescence imaging |
EP3071095A4 (en) | 2013-11-20 | 2017-07-26 | The George Washington University | Systems and methods for hyperspectral analysis of cardiac tissue |
RU2551634C1 (en) * | 2014-04-28 | 2015-05-27 | Закрытое акционерное общество "Полупроводниковые приборы" | Device for fluorescent diagnostics of malignant neoplasms |
WO2016073492A1 (en) | 2014-11-03 | 2016-05-12 | Luxcath, Llc. | Systems and methods for assessment of contact quality |
AU2015343258B2 (en) | 2014-11-03 | 2020-07-16 | 460Medical, Inc. | Systems and methods for lesion assessment |
CN104483299A (en) * | 2014-12-10 | 2015-04-01 | 安徽理工大学 | Method for identifying water hazard water source of mining area |
EP3282928B1 (en) * | 2015-04-17 | 2019-08-07 | Koninklijke Philips N.V. | Detection of anisotropic biological tissue |
US10779904B2 (en) | 2015-07-19 | 2020-09-22 | 460Medical, Inc. | Systems and methods for lesion formation and assessment |
CN108351300A (en) * | 2015-08-03 | 2018-07-31 | Ysi公司 | More excitations-multi-emitting fluorimeter for multi-parameter water quality monitoring |
US11219390B2 (en) | 2015-08-03 | 2022-01-11 | Georgetown University | Apparatus and method for delivery of antimicrobial during a transdermal sampling and delivery process |
US11656180B2 (en) | 2015-08-03 | 2023-05-23 | Ysi, Inc. | Multi excitation-multi emission fluorometer for multiparameter water quality monitoring |
US10799129B2 (en) * | 2016-01-07 | 2020-10-13 | Panasonic Intellectual Property Management Co., Ltd. | Biological information measuring device including light source, light detector, and control circuit |
JP7266519B2 (en) | 2016-04-01 | 2023-04-28 | ブラック ライト サージカル, インコーポレイテッド | Systems, devices and methods for time-resolved fluorescence spectroscopy |
JP2019078715A (en) * | 2017-10-27 | 2019-05-23 | セイコーエプソン株式会社 | Spectrometry device and method for spectrometry |
CN109270044A (en) * | 2018-11-28 | 2019-01-25 | 安徽理工大学 | A kind of laser induced fluorescence vegetable oil doping strong tea water identification method |
US11633129B2 (en) | 2019-04-05 | 2023-04-25 | Cambridge Medical Technologies LLC | Non-invasive transdermal sampling and analysis device incorporating redox cofactors |
US11375931B2 (en) | 2019-08-08 | 2022-07-05 | Cambridge Medical Technologies LLC | Non-invasive transdermal sampling and analysis device incorporating an electrochemical bioassay |
US10952655B1 (en) * | 2020-09-21 | 2021-03-23 | The Florida International University Board Of Trustees | Retinal blood vessel oximetry using retinal auofluorescence |
Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4641650A (en) | 1985-03-11 | 1987-02-10 | Mcm Laboratories, Inc. | Probe-and-fire lasers |
US4675529A (en) | 1984-03-31 | 1987-06-23 | Olympus Optical Co., Ltd. | Fluorescent spectral analysis apparatus |
US4707131A (en) | 1984-11-01 | 1987-11-17 | Oswald Schiek | Optical arrangement for photometrical analysis measuring devices |
US4753530A (en) | 1980-08-21 | 1988-06-28 | Oriel Scientific Ltd. | Analytical optical instruments |
US4786813A (en) | 1984-10-22 | 1988-11-22 | Hightech Network Sci Ab | Fluorescence imaging system |
WO1989012223A1 (en) | 1988-06-08 | 1989-12-14 | Barbour Randall L | A method of imaging a random medium |
US4945245A (en) | 1986-01-14 | 1990-07-31 | Levin Herman W | Evanescent wave background fluorescence/absorbance detection |
US4957114A (en) | 1985-04-01 | 1990-09-18 | Kun Zeng | Diagnostic apparatus for intrinsic fluorescence of malignant tumor |
US5122974A (en) | 1989-02-06 | 1992-06-16 | Nim, Inc. | Phase modulated spectrophotometry |
US5341805A (en) | 1993-04-06 | 1994-08-30 | Cedars-Sinai Medical Center | Glucose fluorescence monitor and method |
US5452723A (en) | 1992-07-24 | 1995-09-26 | Massachusetts Institute Of Technology | Calibrated spectrographic imaging |
US5456252A (en) | 1993-09-30 | 1995-10-10 | Cedars-Sinai Medical Center | Induced fluorescence spectroscopy blood perfusion and pH monitor and method |
US5495850A (en) | 1994-04-21 | 1996-03-05 | Zuckerman; Ralph | Method for the measurement of oxygen concentration levels by the steady-state determination of fluorescence lifetime |
EP0703445A2 (en) | 1994-09-22 | 1996-03-27 | Hamamatsu Photonics K.K. | Method and apparatus for measuring concentration of absorptive constituent in scattering medium |
US5507287A (en) | 1991-05-08 | 1996-04-16 | Xillix Technologies Corporation | Endoscopic imaging system for diseased tissue |
WO1997008538A1 (en) | 1995-08-24 | 1997-03-06 | Purdue Research Foundation | Fluorescence lifetime-based imaging and spectroscopy in tissues and other random media |
US5635402A (en) | 1992-03-05 | 1997-06-03 | Alfano; Robert R. | Technique for determining whether a cell is malignant as opposed to non-malignant using extrinsic fluorescence spectroscopy |
US5760406A (en) | 1996-06-03 | 1998-06-02 | Powers; Linda | Method and apparatus for sensing the presence of microbes |
WO1999002956A2 (en) | 1997-07-07 | 1999-01-21 | Cedars-Sinai Medical Center | Method and devices for laser induced fluorescence attenuation spectroscopy (lifas) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4569354A (en) * | 1982-03-22 | 1986-02-11 | Boston University | Method and apparatus for measuring natural retinal fluorescence |
US4996421A (en) * | 1988-10-31 | 1991-02-26 | Amoco Corporation | Method an system of geophysical exploration |
US5187672A (en) * | 1989-02-06 | 1993-02-16 | Nim Incorporated | Phase modulation spectroscopic system |
EP0449883B1 (en) * | 1988-12-21 | 1996-01-31 | Massachusetts Institute Of Technology | A method for laser induced fluorescence of tissue |
US5349954A (en) * | 1993-07-23 | 1994-09-27 | General Electric Company | Tumor tissue characterization apparatus and method |
US6219575B1 (en) * | 1998-10-23 | 2001-04-17 | Babak Nemati | Method and apparatus to enhance optical transparency of biological tissues |
-
1997
- 1997-07-07 US US08/889,017 patent/US6124597A/en not_active Expired - Lifetime
-
1998
- 1998-06-09 AU AU78306/98A patent/AU752061B2/en not_active Ceased
- 1998-06-09 EP EP98926475A patent/EP0995095B1/en not_active Expired - Lifetime
- 1998-06-09 DE DE69829664T patent/DE69829664D1/en not_active Expired - Lifetime
- 1998-06-09 EP EP05007322A patent/EP1562038A3/en not_active Withdrawn
- 1998-06-09 JP JP2000502389A patent/JP2001509589A/en active Pending
- 1998-06-09 WO PCT/US1998/011937 patent/WO1999002956A2/en active IP Right Grant
-
2000
- 2000-06-28 US US09/605,176 patent/US6697657B1/en not_active Expired - Fee Related
-
2002
- 2002-01-23 US US10/056,335 patent/USRE39672E1/en not_active Expired - Lifetime
Patent Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4753530A (en) | 1980-08-21 | 1988-06-28 | Oriel Scientific Ltd. | Analytical optical instruments |
US4675529A (en) | 1984-03-31 | 1987-06-23 | Olympus Optical Co., Ltd. | Fluorescent spectral analysis apparatus |
US4786813A (en) | 1984-10-22 | 1988-11-22 | Hightech Network Sci Ab | Fluorescence imaging system |
US4707131A (en) | 1984-11-01 | 1987-11-17 | Oswald Schiek | Optical arrangement for photometrical analysis measuring devices |
US4641650A (en) | 1985-03-11 | 1987-02-10 | Mcm Laboratories, Inc. | Probe-and-fire lasers |
US4957114A (en) | 1985-04-01 | 1990-09-18 | Kun Zeng | Diagnostic apparatus for intrinsic fluorescence of malignant tumor |
US4945245A (en) | 1986-01-14 | 1990-07-31 | Levin Herman W | Evanescent wave background fluorescence/absorbance detection |
WO1989012223A1 (en) | 1988-06-08 | 1989-12-14 | Barbour Randall L | A method of imaging a random medium |
US5122974A (en) | 1989-02-06 | 1992-06-16 | Nim, Inc. | Phase modulated spectrophotometry |
US5507287A (en) | 1991-05-08 | 1996-04-16 | Xillix Technologies Corporation | Endoscopic imaging system for diseased tissue |
US5635402A (en) | 1992-03-05 | 1997-06-03 | Alfano; Robert R. | Technique for determining whether a cell is malignant as opposed to non-malignant using extrinsic fluorescence spectroscopy |
US5452723A (en) | 1992-07-24 | 1995-09-26 | Massachusetts Institute Of Technology | Calibrated spectrographic imaging |
US5341805A (en) | 1993-04-06 | 1994-08-30 | Cedars-Sinai Medical Center | Glucose fluorescence monitor and method |
US5456252A (en) | 1993-09-30 | 1995-10-10 | Cedars-Sinai Medical Center | Induced fluorescence spectroscopy blood perfusion and pH monitor and method |
US5495850A (en) | 1994-04-21 | 1996-03-05 | Zuckerman; Ralph | Method for the measurement of oxygen concentration levels by the steady-state determination of fluorescence lifetime |
EP0703445A2 (en) | 1994-09-22 | 1996-03-27 | Hamamatsu Photonics K.K. | Method and apparatus for measuring concentration of absorptive constituent in scattering medium |
WO1997008538A1 (en) | 1995-08-24 | 1997-03-06 | Purdue Research Foundation | Fluorescence lifetime-based imaging and spectroscopy in tissues and other random media |
US5760406A (en) | 1996-06-03 | 1998-06-02 | Powers; Linda | Method and apparatus for sensing the presence of microbes |
WO1999002956A2 (en) | 1997-07-07 | 1999-01-21 | Cedars-Sinai Medical Center | Method and devices for laser induced fluorescence attenuation spectroscopy (lifas) |
Cited By (785)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8046042B2 (en) | 1991-03-07 | 2011-10-25 | Masimo Corporation | Signal processing apparatus |
US8364226B2 (en) | 1991-03-07 | 2013-01-29 | Masimo Corporation | Signal processing apparatus |
US20070249918A1 (en) * | 1991-03-07 | 2007-10-25 | Diab Mohamed K | Signal processing apparatus |
US8128572B2 (en) | 1991-03-07 | 2012-03-06 | Masimo Corporation | Signal processing apparatus |
US8046041B2 (en) | 1991-03-07 | 2011-10-25 | Masimo Corporation | Signal processing apparatus |
US8036728B2 (en) | 1991-03-07 | 2011-10-11 | Masimo Corporation | Signal processing apparatus |
US8942777B2 (en) | 1991-03-07 | 2015-01-27 | Masimo Corporation | Signal processing apparatus |
US8948834B2 (en) | 1991-03-07 | 2015-02-03 | Masimo Corporation | Signal processing apparatus |
US7962190B1 (en) | 1991-03-07 | 2011-06-14 | Masimo Corporation | Signal processing apparatus |
US7937130B2 (en) | 1991-03-07 | 2011-05-03 | Masimo Corporation | Signal processing apparatus |
US8229533B2 (en) | 1991-03-21 | 2012-07-24 | Masimo Corporation | Low-noise optical probes for reducing ambient noise |
US8670814B2 (en) | 1991-03-21 | 2014-03-11 | Masimo Corporation | Low-noise optical probes for reducing ambient noise |
US8560034B1 (en) | 1993-10-06 | 2013-10-15 | Masimo Corporation | Signal processing apparatus |
US8126528B2 (en) | 1994-10-07 | 2012-02-28 | Masimo Corporation | Signal processing apparatus |
US8359080B2 (en) | 1994-10-07 | 2013-01-22 | Masimo Corporation | Signal processing apparatus |
US8019400B2 (en) | 1994-10-07 | 2011-09-13 | Masimo Corporation | Signal processing apparatus |
US8755856B2 (en) | 1994-10-07 | 2014-06-17 | Masimo Corporation | Signal processing apparatus |
US8463349B2 (en) | 1994-10-07 | 2013-06-11 | Masimo Corporation | Signal processing apparatus |
US8781543B2 (en) | 1995-06-07 | 2014-07-15 | Jpmorgan Chase Bank, National Association | Manual and automatic probe calibration |
US8190227B2 (en) | 1997-04-14 | 2012-05-29 | Masimo Corporation | Signal processing apparatus and method |
US20080036752A1 (en) * | 1997-04-14 | 2008-02-14 | Diab Mohamed K | Signal processing apparatus and method |
US9289167B2 (en) | 1997-04-14 | 2016-03-22 | Masimo Corporation | Signal processing apparatus and method |
US8888708B2 (en) | 1997-04-14 | 2014-11-18 | Masimo Corporation | Signal processing apparatus and method |
US9351673B2 (en) | 1997-04-14 | 2016-05-31 | Masimo Corporation | Method and apparatus for demodulating signals in a pulse oximetry system |
US8180420B2 (en) | 1997-04-14 | 2012-05-15 | Masimo Corporation | Signal processing apparatus and method |
US8718737B2 (en) | 1997-04-14 | 2014-05-06 | Masimo Corporation | Method and apparatus for demodulating signals in a pulse oximetry system |
US8721541B2 (en) | 1998-06-03 | 2014-05-13 | Masimo Corporation | Physiological monitor |
US10335072B2 (en) | 1998-06-03 | 2019-07-02 | Masimo Corporation | Physiological monitor |
US9492110B2 (en) | 1998-06-03 | 2016-11-15 | Masimo Corporation | Physiological monitor |
USRE43169E1 (en) | 1998-10-15 | 2012-02-07 | Masimo Corporation | Universal modular pulse oximeter probe for use with reusable and disposable patient attachment devices |
USRE41317E1 (en) | 1998-10-15 | 2010-05-04 | Masimo Corporation | Universal modular pulse oximeter probe for use with reusable and disposable patient attachment devices |
USRE44823E1 (en) | 1998-10-15 | 2014-04-01 | Masimo Corporation | Universal modular pulse oximeter probe for use with reusable and disposable patient attachment devices |
USRE43860E1 (en) | 1998-10-15 | 2012-12-11 | Masimo Corporation | Reusable pulse oximeter probe and disposable bandage apparatus |
USRE41912E1 (en) | 1998-10-15 | 2010-11-02 | Masimo Corporation | Reusable pulse oximeter probe and disposable bandage apparatus |
US8706179B2 (en) | 1998-10-15 | 2014-04-22 | Masimo Corporation | Reusable pulse oximeter probe and disposable bandage apparatii |
US9675286B2 (en) | 1998-12-30 | 2017-06-13 | Masimo Corporation | Plethysmograph pulse recognition processor |
US9636055B2 (en) | 1999-01-07 | 2017-05-02 | Masimo Corporation | Pulse and confidence indicator displayed proximate plethysmograph |
US10130289B2 (en) | 1999-01-07 | 2018-11-20 | Masimo Corporation | Pulse and confidence indicator displayed proximate plethysmograph |
US20060258926A1 (en) * | 1999-01-25 | 2006-11-16 | Ali Ammar A | Systems and methods for acquiring calibration data usable in a pulse oximeter |
US7991446B2 (en) | 1999-01-25 | 2011-08-02 | Masimo Corporation | Systems and methods for acquiring calibration data usable in a pulse oximeter |
US8405608B2 (en) | 1999-01-25 | 2013-03-26 | Masimo Corporation | System and method for altering a display mode |
US8532727B2 (en) | 1999-01-25 | 2013-09-10 | Masimo Corporation | Dual-mode pulse oximeter |
US9375185B2 (en) | 1999-01-25 | 2016-06-28 | Masimo Corporation | Systems and methods for acquiring calibration data usable in a pulse oximeter |
US10231676B2 (en) | 1999-01-25 | 2019-03-19 | Masimo Corporation | Dual-mode patient monitor |
US8532728B2 (en) | 1999-03-25 | 2013-09-10 | Masimo Corporation | Pulse oximeter probe-off detector |
US9730640B2 (en) | 1999-03-25 | 2017-08-15 | Masimo Corporation | Pulse oximeter probe-off detector |
US8175672B2 (en) | 1999-04-12 | 2012-05-08 | Masimo Corporation | Reusable pulse oximeter probe and disposable bandage apparatii |
US8399822B2 (en) | 1999-08-26 | 2013-03-19 | Masimo Corporation | Systems and methods for indicating an amount of use of a sensor |
US9386953B2 (en) | 1999-12-09 | 2016-07-12 | Masimo Corporation | Method of sterilizing a reusable portion of a noninvasive optical probe |
US8000761B2 (en) | 1999-12-09 | 2011-08-16 | Masimo Corporation | Resposable pulse oximetry sensor |
US7734320B2 (en) | 1999-12-09 | 2010-06-08 | Masimo Corporation | Sensor isolation |
US7873497B2 (en) | 2000-06-05 | 2011-01-18 | Masimo Corporation | Variable indication estimator |
US8260577B2 (en) | 2000-06-05 | 2012-09-04 | Masimo Corporation | Variable indication estimator |
US8489364B2 (en) | 2000-06-05 | 2013-07-16 | Masimo Corporation | Variable indication estimator |
US10357206B2 (en) | 2000-06-05 | 2019-07-23 | Masimo Corporation | Variable indication estimator |
US9138192B2 (en) | 2000-06-05 | 2015-09-22 | Masimo Corporation | Variable indication estimator |
US7904132B2 (en) | 2001-06-29 | 2011-03-08 | Masimo Corporation | Sine saturation transform |
US8892180B2 (en) | 2001-06-29 | 2014-11-18 | Masimo Corporation | Sine saturation transform |
US8498684B2 (en) | 2001-06-29 | 2013-07-30 | Masimo Corporation | Sine saturation transform |
US20060270921A1 (en) * | 2001-06-29 | 2006-11-30 | Weber Walter M | Sine saturation transform |
US9814418B2 (en) | 2001-06-29 | 2017-11-14 | Masimo Corporation | Sine saturation transform |
US10959652B2 (en) | 2001-07-02 | 2021-03-30 | Masimo Corporation | Low power pulse oximeter |
US8457703B2 (en) | 2001-07-02 | 2013-06-04 | Masimo Corporation | Low power pulse oximeter |
US10433776B2 (en) | 2001-07-02 | 2019-10-08 | Masimo Corporation | Low power pulse oximeter |
US10980455B2 (en) | 2001-07-02 | 2021-04-20 | Masimo Corporation | Low power pulse oximeter |
US20080064936A1 (en) * | 2001-07-02 | 2008-03-13 | Ammar Al-Ali | Low power pulse oximeter |
US11219391B2 (en) | 2001-07-02 | 2022-01-11 | Masimo Corporation | Low power pulse oximeter |
US9848806B2 (en) | 2001-07-02 | 2017-12-26 | Masimo Corporation | Low power pulse oximeter |
US8228181B2 (en) | 2002-01-24 | 2012-07-24 | Masimo Corporation | Physiological trend monitor |
US9636056B2 (en) | 2002-01-24 | 2017-05-02 | Masimo Corporation | Physiological trend monitor |
US9131883B2 (en) | 2002-01-24 | 2015-09-15 | Masimo Corporation | Physiological trend monitor |
US8570167B2 (en) | 2002-01-24 | 2013-10-29 | Masimo Corporation | Physiological trend monitor |
US7880606B2 (en) | 2002-01-24 | 2011-02-01 | Masimo Corporation | Physiological trend monitor |
USRE49034E1 (en) | 2002-01-24 | 2022-04-19 | Masimo Corporation | Physiological trend monitor |
US9795300B2 (en) | 2002-03-25 | 2017-10-24 | Masimo Corporation | Wearable portable patient monitor |
US9113832B2 (en) | 2002-03-25 | 2015-08-25 | Masimo Corporation | Wrist-mounted physiological measurement device |
US11484205B2 (en) | 2002-03-25 | 2022-11-01 | Masimo Corporation | Physiological measurement device |
US9113831B2 (en) | 2002-03-25 | 2015-08-25 | Masimo Corporation | Physiological measurement communications adapter |
US9788735B2 (en) | 2002-03-25 | 2017-10-17 | Masimo Corporation | Body worn mobile medical patient monitor |
US10869602B2 (en) | 2002-03-25 | 2020-12-22 | Masimo Corporation | Physiological measurement communications adapter |
US9872623B2 (en) | 2002-03-25 | 2018-01-23 | Masimo Corporation | Arm mountable portable patient monitor |
US8548548B2 (en) | 2002-03-25 | 2013-10-01 | Masimo Corporation | Physiological measurement communications adapter |
US10219706B2 (en) | 2002-03-25 | 2019-03-05 | Masimo Corporation | Physiological measurement device |
US10213108B2 (en) | 2002-03-25 | 2019-02-26 | Masimo Corporation | Arm mountable portable patient monitor |
US10335033B2 (en) | 2002-03-25 | 2019-07-02 | Masimo Corporation | Physiological measurement device |
US8948835B2 (en) | 2002-12-04 | 2015-02-03 | Cercacor Laboratories, Inc. | Systems and methods for determining blood oxygen saturation values using complex number encoding |
US8447374B2 (en) | 2002-12-04 | 2013-05-21 | Ceracor Laboratories, Inc. | Systems and methods for determining blood oxygen saturation values using complex number encoding |
US9622693B2 (en) | 2002-12-04 | 2017-04-18 | Masimo Corporation | Systems and methods for determining blood oxygen saturation values using complex number encoding |
US8921699B2 (en) | 2002-12-19 | 2014-12-30 | Masimo Corporation | Low noise oximetry cable including conductive cords |
US10201298B2 (en) | 2003-01-24 | 2019-02-12 | Masimo Corporation | Noninvasive oximetry optical sensor including disposable and reusable elements |
US9693719B2 (en) | 2003-01-24 | 2017-07-04 | Masimo Corporation | Noninvasive oximetry optical sensor including disposable and reusable elements |
US10973447B2 (en) | 2003-01-24 | 2021-04-13 | Masimo Corporation | Noninvasive oximetry optical sensor including disposable and reusable elements |
US8781549B2 (en) | 2003-01-24 | 2014-07-15 | Cercacor Laboratories, Inc. | Noninvasive oximetry optical sensor including disposable and reusable elements |
US8676286B2 (en) | 2003-07-08 | 2014-03-18 | Cercacor Laboratories, Inc. | Method and apparatus for reducing coupling between signals in a measurement system |
US9084569B2 (en) | 2003-07-08 | 2015-07-21 | Cercacor Laboratories, Inc. | Method and apparatus for reducing coupling between signals in a measurement system |
US9801588B2 (en) | 2003-07-08 | 2017-10-31 | Cercacor Laboratories, Inc. | Method and apparatus for reducing coupling between signals in a measurement system |
US11020029B2 (en) | 2003-07-25 | 2021-06-01 | Masimo Corporation | Multipurpose sensor port |
US8920317B2 (en) | 2003-07-25 | 2014-12-30 | Masimo Corporation | Multipurpose sensor port |
US10058275B2 (en) | 2003-07-25 | 2018-08-28 | Masimo Corporation | Multipurpose sensor port |
US20080027294A1 (en) * | 2003-08-28 | 2008-01-31 | Ammar Al-Ali | Physiological parameter tracking system |
US8385995B2 (en) | 2003-08-28 | 2013-02-26 | Masimo Corporation | Physiological parameter tracking system |
US9788768B2 (en) | 2003-08-28 | 2017-10-17 | Masimo Corporation | Physiological parameter tracking system |
US9072474B2 (en) | 2003-11-05 | 2015-07-07 | Masimo Corporation | Pulse oximeter access apparatus and method |
US10531835B2 (en) | 2003-11-05 | 2020-01-14 | Masimo Corporation | Pulse oximeter access apparatus and method |
US9743887B2 (en) | 2003-11-05 | 2017-08-29 | Masimo Corporation | Pulse oximeter access apparatus and method |
US11690574B2 (en) | 2003-11-05 | 2023-07-04 | Masimo Corporation | Pulse oximeter access apparatus and method |
US9161713B2 (en) | 2004-03-04 | 2015-10-20 | Masimo Corporation | Multi-mode patient monitor configured to self-configure for a selected or determined mode of operation |
US8337403B2 (en) | 2004-03-04 | 2012-12-25 | Masimo Corporation | Patient monitor having context-based sensitivity adjustments |
US11937949B2 (en) | 2004-03-08 | 2024-03-26 | Masimo Corporation | Physiological parameter system |
US10098591B2 (en) | 2004-03-08 | 2018-10-16 | Masimo Corporation | Physiological parameter system |
US11109814B2 (en) | 2004-03-08 | 2021-09-07 | Masimo Corporation | Physiological parameter system |
US8721542B2 (en) | 2004-03-08 | 2014-05-13 | Masimo Corporation | Physiological parameter system |
US8641631B2 (en) | 2004-04-08 | 2014-02-04 | Masimo Corporation | Non-invasive monitoring of respiratory rate, heart rate and apnea |
US9341565B2 (en) | 2004-07-07 | 2016-05-17 | Masimo Corporation | Multiple-wavelength physiological monitor |
US8423106B2 (en) | 2004-07-07 | 2013-04-16 | Cercacor Laboratories, Inc. | Multi-wavelength physiological monitor |
US9339220B2 (en) | 2004-07-07 | 2016-05-17 | Masimo Corporation | Multi-wavelength physiological monitor |
US8682407B2 (en) | 2004-07-09 | 2014-03-25 | Masimo Corporation | Cyanotic infant sensor |
US9480422B2 (en) | 2004-07-09 | 2016-11-01 | Masimo Corporation | Cyanotic infant sensor |
US8306596B2 (en) | 2004-08-11 | 2012-11-06 | Glt Acquisition Corp. | Method for data reduction and calibration of an OCT-based physiological monitor |
US9078560B2 (en) | 2004-08-11 | 2015-07-14 | Glt Acquisition Corp. | Method for data reduction and calibration of an OCT-based physiological monitor |
US10130291B2 (en) | 2004-08-11 | 2018-11-20 | Masimo Corporation | Method for data reduction and calibration of an OCT-based physiological monitor |
US9554737B2 (en) | 2004-08-11 | 2017-01-31 | Masimo Corporation | Noninvasively measuring analyte levels in a subject |
US7822452B2 (en) | 2004-08-11 | 2010-10-26 | Glt Acquisition Corp. | Method for data reduction and calibration of an OCT-based blood glucose monitor |
US8204566B2 (en) | 2004-08-11 | 2012-06-19 | Glt Acquisition Corp. | Method and apparatus for monitoring blood constituent levels in biological tissue |
US9668679B2 (en) | 2004-08-11 | 2017-06-06 | Masimo Corporation | Method for data reduction and calibration of an OCT-based physiological monitor |
US8548549B2 (en) | 2004-08-11 | 2013-10-01 | Glt Acquisition Corp. | Methods for noninvasively measuring analyte levels in a subject |
US11426104B2 (en) | 2004-08-11 | 2022-08-30 | Masimo Corporation | Method for data reduction and calibration of an OCT-based physiological monitor |
US10791971B2 (en) | 2004-08-11 | 2020-10-06 | Masimo Corporation | Method for data reduction and calibration of an OCT-based physiological monitor |
US8788003B2 (en) | 2004-08-11 | 2014-07-22 | Glt Acquisition Corp. | Monitoring blood constituent levels in biological tissue |
US8036727B2 (en) | 2004-08-11 | 2011-10-11 | Glt Acquisition Corp. | Methods for noninvasively measuring analyte levels in a subject |
US20060188869A1 (en) * | 2005-01-13 | 2006-08-24 | Whitehead Institute For Biomedical Research | Method and apparatus for UV imaging |
US7491943B2 (en) * | 2005-01-13 | 2009-02-17 | Whitehead Institute For Biomedical Research | Method and apparatus for UV imaging |
US8353842B2 (en) | 2005-02-18 | 2013-01-15 | Masimo Corporation | Portable patient monitor |
US8050728B2 (en) | 2005-03-01 | 2011-11-01 | Masimo Laboratories, Inc. | Multiple wavelength sensor drivers |
US8385996B2 (en) | 2005-03-01 | 2013-02-26 | Cercacor Laboratories, Inc. | Multiple wavelength sensor emitters |
US9549696B2 (en) | 2005-03-01 | 2017-01-24 | Cercacor Laboratories, Inc. | Physiological parameter confidence measure |
US8581732B2 (en) | 2005-03-01 | 2013-11-12 | Carcacor Laboratories, Inc. | Noninvasive multi-parameter patient monitor |
US8849365B2 (en) | 2005-03-01 | 2014-09-30 | Cercacor Laboratories, Inc. | Multiple wavelength sensor emitters |
US10251585B2 (en) | 2005-03-01 | 2019-04-09 | Cercacor Laboratories, Inc. | Noninvasive multi-parameter patient monitor |
US8718735B2 (en) | 2005-03-01 | 2014-05-06 | Cercacor Laboratories, Inc. | Physiological parameter confidence measure |
US10856788B2 (en) | 2005-03-01 | 2020-12-08 | Cercacor Laboratories, Inc. | Noninvasive multi-parameter patient monitor |
US8634889B2 (en) | 2005-03-01 | 2014-01-21 | Cercacor Laboratories, Inc. | Configurable physiological measurement system |
US9750443B2 (en) | 2005-03-01 | 2017-09-05 | Cercacor Laboratories, Inc. | Multiple wavelength sensor emitters |
US8626255B2 (en) | 2005-03-01 | 2014-01-07 | Cercacor Laboratories, Inc. | Noninvasive multi-parameter patient monitor |
US8224411B2 (en) | 2005-03-01 | 2012-07-17 | Masimo Laboratories, Inc. | Noninvasive multi-parameter patient monitor |
US9241662B2 (en) | 2005-03-01 | 2016-01-26 | Cercacor Laboratories, Inc. | Configurable physiological measurement system |
US8912909B2 (en) | 2005-03-01 | 2014-12-16 | Cercacor Laboratories, Inc. | Noninvasive multi-parameter patient monitor |
US9167995B2 (en) | 2005-03-01 | 2015-10-27 | Cercacor Laboratories, Inc. | Physiological parameter confidence measure |
US10984911B2 (en) | 2005-03-01 | 2021-04-20 | Cercacor Laboratories, Inc. | Multiple wavelength sensor emitters |
US9131882B2 (en) | 2005-03-01 | 2015-09-15 | Cercacor Laboratories, Inc. | Noninvasive multi-parameter patient monitor |
US11430572B2 (en) | 2005-03-01 | 2022-08-30 | Cercacor Laboratories, Inc. | Multiple wavelength sensor emitters |
US9351675B2 (en) | 2005-03-01 | 2016-05-31 | Cercacor Laboratories, Inc. | Noninvasive multi-parameter patient monitor |
US8190223B2 (en) | 2005-03-01 | 2012-05-29 | Masimo Laboratories, Inc. | Noninvasive multi-parameter patient monitor |
US11545263B2 (en) | 2005-03-01 | 2023-01-03 | Cercacor Laboratories, Inc. | Multiple wavelength sensor emitters |
US8255027B2 (en) | 2005-03-01 | 2012-08-28 | Cercacor Laboratories, Inc. | Multiple wavelength sensor substrate |
US10327683B2 (en) | 2005-03-01 | 2019-06-25 | Cercacor Laboratories, Inc. | Multiple wavelength sensor emitters |
US8130105B2 (en) | 2005-03-01 | 2012-03-06 | Masimo Laboratories, Inc. | Noninvasive multi-parameter patient monitor |
US10123726B2 (en) | 2005-03-01 | 2018-11-13 | Cercacor Laboratories, Inc. | Configurable physiological measurement system |
US8929964B2 (en) | 2005-03-01 | 2015-01-06 | Cercacor Laboratories, Inc. | Multiple wavelength sensor drivers |
US8560032B2 (en) | 2005-03-01 | 2013-10-15 | Cercacor Laboratories, Inc. | Noninvasive multi-parameter patient monitor |
US8301217B2 (en) | 2005-03-01 | 2012-10-30 | Cercacor Laboratories, Inc. | Multiple wavelength sensor emitters |
US8483787B2 (en) | 2005-03-01 | 2013-07-09 | Cercacor Laboratories, Inc. | Multiple wavelength sensor drivers |
US8996085B2 (en) | 2005-10-14 | 2015-03-31 | Masimo Corporation | Robust alarm system |
US10092249B2 (en) | 2005-10-14 | 2018-10-09 | Masimo Corporation | Robust alarm system |
US11839498B2 (en) | 2005-10-14 | 2023-12-12 | Masimo Corporation | Robust alarm system |
US10939877B2 (en) | 2005-10-14 | 2021-03-09 | Masimo Corporation | Robust alarm system |
US8548550B2 (en) | 2005-11-29 | 2013-10-01 | Cercacor Laboratories, Inc. | Optical sensor including disposable and reusable elements |
US10420493B2 (en) | 2005-11-29 | 2019-09-24 | Masimo Corporation | Optical sensor including disposable and reusable elements |
US8868150B2 (en) | 2005-11-29 | 2014-10-21 | Cercacor Laboratories, Inc. | Optical sensor including disposable and reusable elements |
US7990382B2 (en) | 2006-01-03 | 2011-08-02 | Masimo Corporation | Virtual display |
US11724031B2 (en) | 2006-01-17 | 2023-08-15 | Masimo Corporation | Drug administration controller |
US10874797B2 (en) | 2006-01-17 | 2020-12-29 | Masimo Corporation | Drug administration controller |
US8831700B2 (en) | 2006-03-17 | 2014-09-09 | Glt Acquisition Corp. | Apparatus and method for creating a stable optical interface |
US9924893B2 (en) | 2006-03-17 | 2018-03-27 | Masimo Corporation | Apparatus and method for creating a stable optical interface |
US8219172B2 (en) | 2006-03-17 | 2012-07-10 | Glt Acquisition Corp. | System and method for creating a stable optical interface |
US11944431B2 (en) | 2006-03-17 | 2024-04-02 | Masimo Corportation | Apparatus and method for creating a stable optical interface |
US10278626B2 (en) | 2006-03-17 | 2019-05-07 | Masimo Corporation | Apparatus and method for creating a stable optical interface |
US11207007B2 (en) | 2006-03-17 | 2021-12-28 | Masimo Corporation | Apparatus and method for creating a stable optical interface |
US8663107B2 (en) | 2006-05-15 | 2014-03-04 | Cercacor Laboratories, Inc. | Sepsis monitor |
US10226576B2 (en) | 2006-05-15 | 2019-03-12 | Masimo Corporation | Sepsis monitor |
US9176141B2 (en) | 2006-05-15 | 2015-11-03 | Cercacor Laboratories, Inc. | Physiological monitor calibration system |
US7941199B2 (en) | 2006-05-15 | 2011-05-10 | Masimo Laboratories, Inc. | Sepsis monitor |
US8998809B2 (en) | 2006-05-15 | 2015-04-07 | Cercacor Laboratories, Inc. | Systems and methods for calibrating minimally invasive and non-invasive physiological sensor devices |
US20070265514A1 (en) * | 2006-05-15 | 2007-11-15 | Kiani Massi E | Systems and methods for calibrating minimally invasive and non-invasive physiological sensor devices |
US8667967B2 (en) | 2006-05-31 | 2014-03-11 | Masimo Corporation | Respiratory monitoring |
US9566019B2 (en) | 2006-05-31 | 2017-02-14 | Masimo Corporation | Respiratory monitoring |
US8028701B2 (en) | 2006-05-31 | 2011-10-04 | Masimo Corporation | Respiratory monitoring |
US11191485B2 (en) | 2006-06-05 | 2021-12-07 | Masimo Corporation | Parameter upgrade system |
US10188348B2 (en) | 2006-06-05 | 2019-01-29 | Masimo Corporation | Parameter upgrade system |
US20080039735A1 (en) * | 2006-06-06 | 2008-02-14 | Hickerson Barry L | Respiratory monitor display |
US10588518B2 (en) | 2006-09-20 | 2020-03-17 | Masimo Corporation | Congenital heart disease monitor |
US9687160B2 (en) | 2006-09-20 | 2017-06-27 | Masimo Corporation | Congenital heart disease monitor |
US8457707B2 (en) | 2006-09-20 | 2013-06-04 | Masimo Corporation | Congenital heart disease monitor |
US11607139B2 (en) | 2006-09-20 | 2023-03-21 | Masimo Corporation | Congenital heart disease monitor |
US20080071155A1 (en) * | 2006-09-20 | 2008-03-20 | Kiani Massi E | Congenital heart disease monitor |
US8315683B2 (en) | 2006-09-20 | 2012-11-20 | Masimo Corporation | Duo connector patient cable |
US20080071153A1 (en) * | 2006-09-20 | 2008-03-20 | Ammar Al-Ali | Duo connector patient cable |
US9397448B2 (en) | 2006-09-20 | 2016-07-19 | Masimo Corporation | Shielded connector assembly |
US20080103375A1 (en) * | 2006-09-22 | 2008-05-01 | Kiani Massi E | Patient monitor user interface |
US8840549B2 (en) | 2006-09-22 | 2014-09-23 | Masimo Corporation | Modular patient monitor |
US9161696B2 (en) | 2006-09-22 | 2015-10-20 | Masimo Corporation | Modular patient monitor |
US10912524B2 (en) | 2006-09-22 | 2021-02-09 | Masimo Corporation | Modular patient monitor |
US8983564B2 (en) | 2006-10-12 | 2015-03-17 | Masimo Corporation | Perfusion index smoother |
US11857319B2 (en) | 2006-10-12 | 2024-01-02 | Masimo Corporation | System and method for monitoring the life of a physiological sensor |
US9370326B2 (en) | 2006-10-12 | 2016-06-21 | Masimo Corporation | Oximeter probe off indicator defining probe off space |
US10039482B2 (en) | 2006-10-12 | 2018-08-07 | Masimo Corporation | System and method for monitoring the life of a physiological sensor |
US9107626B2 (en) | 2006-10-12 | 2015-08-18 | Masimo Corporation | System and method for monitoring the life of a physiological sensor |
US8255026B1 (en) | 2006-10-12 | 2012-08-28 | Masimo Corporation, Inc. | Patient monitor capable of monitoring the quality of attached probes and accessories |
US10342470B2 (en) | 2006-10-12 | 2019-07-09 | Masimo Corporation | System and method for monitoring the life of a physiological sensor |
US20080091093A1 (en) * | 2006-10-12 | 2008-04-17 | Ammar Al-Ali | Perfusion index smoother |
US9861305B1 (en) | 2006-10-12 | 2018-01-09 | Masimo Corporation | Method and apparatus for calibration to reduce coupling between signals in a measurement system |
US8265723B1 (en) | 2006-10-12 | 2012-09-11 | Cercacor Laboratories, Inc. | Oximeter probe off indicator defining probe off space |
US11759130B2 (en) | 2006-10-12 | 2023-09-19 | Masimo Corporation | Perfusion index smoother |
US11317837B2 (en) | 2006-10-12 | 2022-05-03 | Masimo Corporation | System and method for monitoring the life of a physiological sensor |
US8280473B2 (en) | 2006-10-12 | 2012-10-02 | Masino Corporation, Inc. | Perfusion index smoother |
US11006867B2 (en) | 2006-10-12 | 2021-05-18 | Masimo Corporation | Perfusion index smoother |
US10993643B2 (en) | 2006-10-12 | 2021-05-04 | Masimo Corporation | Patient monitor capable of monitoring the quality of attached probes and accessories |
US10064562B2 (en) | 2006-10-12 | 2018-09-04 | Masimo Corporation | Variable mode pulse indicator |
US7880626B2 (en) | 2006-10-12 | 2011-02-01 | Masimo Corporation | System and method for monitoring the life of a physiological sensor |
US9949676B2 (en) | 2006-10-12 | 2018-04-24 | Masimo Corporation | Patient monitor capable of monitoring the quality of attached probes and accessories |
US10799163B2 (en) | 2006-10-12 | 2020-10-13 | Masimo Corporation | Perfusion index smoother |
US9192329B2 (en) | 2006-10-12 | 2015-11-24 | Masimo Corporation | Variable mode pulse indicator |
US11672447B2 (en) | 2006-10-12 | 2023-06-13 | Masimo Corporation | Method and apparatus for calibration to reduce coupling between signals in a measurement system |
US11857315B2 (en) | 2006-10-12 | 2024-01-02 | Masimo Corporation | Patient monitor capable of monitoring the quality of attached probes and accessories |
US10194847B2 (en) | 2006-10-12 | 2019-02-05 | Masimo Corporation | Perfusion index smoother |
US10219746B2 (en) | 2006-10-12 | 2019-03-05 | Masimo Corporation | Oximeter probe off indicator defining probe off space |
US11224381B2 (en) | 2006-10-12 | 2022-01-18 | Masimo Corporation | Oximeter probe off indicator defining probe off space |
US10772542B2 (en) | 2006-10-12 | 2020-09-15 | Masimo Corporation | Method and apparatus for calibration to reduce coupling between signals in a measurement system |
US20080094228A1 (en) * | 2006-10-12 | 2008-04-24 | Welch James P | Patient monitor using radio frequency identification tags |
US10863938B2 (en) | 2006-10-12 | 2020-12-15 | Masimo Corporation | System and method for monitoring the life of a physiological sensor |
US9560998B2 (en) | 2006-10-12 | 2017-02-07 | Masimo Corporation | System and method for monitoring the life of a physiological sensor |
US8922382B2 (en) | 2006-10-12 | 2014-12-30 | Masimo Corporation | System and method for monitoring the life of a physiological sensor |
US9861304B2 (en) | 2006-11-29 | 2018-01-09 | Cercacor Laboratories, Inc. | Optical sensor including disposable and reusable elements |
US9138182B2 (en) | 2006-11-29 | 2015-09-22 | Cercacor Laboratories, Inc. | Optical sensor including disposable and reusable elements |
US10463284B2 (en) | 2006-11-29 | 2019-11-05 | Cercacor Laboratories, Inc. | Optical sensor including disposable and reusable elements |
US8600467B2 (en) | 2006-11-29 | 2013-12-03 | Cercacor Laboratories, Inc. | Optical sensor including disposable and reusable elements |
US10092200B2 (en) | 2006-12-09 | 2018-10-09 | Masimo Corporation | Plethysmograph variability processor |
US8414499B2 (en) | 2006-12-09 | 2013-04-09 | Masimo Corporation | Plethysmograph variability processor |
US11229374B2 (en) | 2006-12-09 | 2022-01-25 | Masimo Corporation | Plethysmograph variability processor |
US7791155B2 (en) | 2006-12-22 | 2010-09-07 | Masimo Laboratories, Inc. | Detector shield |
US10918341B2 (en) | 2006-12-22 | 2021-02-16 | Masimo Corporation | Physiological parameter system |
US8852094B2 (en) | 2006-12-22 | 2014-10-07 | Masimo Corporation | Physiological parameter system |
US20080197301A1 (en) * | 2006-12-22 | 2008-08-21 | Diab Mohamed K | Detector shield |
US11229408B2 (en) | 2006-12-22 | 2022-01-25 | Masimo Corporation | Optical patient monitor |
US11234655B2 (en) | 2007-01-20 | 2022-02-01 | Masimo Corporation | Perfusion trend indicator |
US8652060B2 (en) | 2007-01-20 | 2014-02-18 | Masimo Corporation | Perfusion trend indicator |
US8781544B2 (en) | 2007-03-27 | 2014-07-15 | Cercacor Laboratories, Inc. | Multiple wavelength optical sensor |
US7919713B2 (en) | 2007-04-16 | 2011-04-05 | Masimo Corporation | Low noise oximetry cable including conductive cords |
US8374665B2 (en) | 2007-04-21 | 2013-02-12 | Cercacor Laboratories, Inc. | Tissue profile wellness monitor |
US8965471B2 (en) | 2007-04-21 | 2015-02-24 | Cercacor Laboratories, Inc. | Tissue profile wellness monitor |
US10251586B2 (en) | 2007-04-21 | 2019-04-09 | Masimo Corporation | Tissue profile wellness monitor |
US9848807B2 (en) | 2007-04-21 | 2017-12-26 | Masimo Corporation | Tissue profile wellness monitor |
US11647923B2 (en) | 2007-04-21 | 2023-05-16 | Masimo Corporation | Tissue profile wellness monitor |
US10980457B2 (en) | 2007-04-21 | 2021-04-20 | Masimo Corporation | Tissue profile wellness monitor |
US8764671B2 (en) | 2007-06-28 | 2014-07-01 | Masimo Corporation | Disposable active pulse sensor |
US9211072B2 (en) | 2007-06-28 | 2015-12-15 | Masimo Corporation | Disposable active pulse sensor |
US9820691B2 (en) | 2007-09-13 | 2017-11-21 | Masimo Corporation | Fluid titration system |
US8048040B2 (en) | 2007-09-13 | 2011-11-01 | Masimo Corporation | Fluid titration system |
US9142117B2 (en) | 2007-10-12 | 2015-09-22 | Masimo Corporation | Systems and methods for storing, analyzing, retrieving and displaying streaming medical data |
US8888539B2 (en) | 2007-10-12 | 2014-11-18 | Masimo Corporation | Shielded connector assembly |
US8118620B2 (en) | 2007-10-12 | 2012-02-21 | Masimo Corporation | Connector assembly with reduced unshielded area |
US8355766B2 (en) | 2007-10-12 | 2013-01-15 | Masimo Corporation | Ceramic emitter substrate |
USD609193S1 (en) | 2007-10-12 | 2010-02-02 | Masimo Corporation | Connector assembly |
US8529301B2 (en) | 2007-10-12 | 2013-09-10 | Masimo Corporation | Shielded connector assembly |
US8274360B2 (en) | 2007-10-12 | 2012-09-25 | Masimo Corporation | Systems and methods for storing, analyzing, and retrieving medical data |
USD614305S1 (en) | 2008-02-29 | 2010-04-20 | Masimo Corporation | Connector assembly |
US11426105B2 (en) | 2008-03-04 | 2022-08-30 | Masimo Corporation | Flowometry in optical coherence tomography for analyte level estimation |
US8768423B2 (en) | 2008-03-04 | 2014-07-01 | Glt Acquisition Corp. | Multispot monitoring for use in optical coherence tomography |
US11660028B2 (en) | 2008-03-04 | 2023-05-30 | Masimo Corporation | Multispot monitoring for use in optical coherence tomography |
US10368787B2 (en) | 2008-03-04 | 2019-08-06 | Masimo Corporation | Flowometry in optical coherence tomography for analyte level estimation |
US8571617B2 (en) | 2008-03-04 | 2013-10-29 | Glt Acquisition Corp. | Flowometry in optical coherence tomography for analyte level estimation |
US9060721B2 (en) | 2008-03-04 | 2015-06-23 | Glt Acquisition Corp. | Flowometry in optical coherence tomography for analyte level estimation |
US9833180B2 (en) | 2008-03-04 | 2017-12-05 | Masimo Corporation | Multispot monitoring for use in optical coherence tomography |
US11033210B2 (en) | 2008-03-04 | 2021-06-15 | Masimo Corporation | Multispot monitoring for use in optical coherence tomography |
US11622733B2 (en) | 2008-05-02 | 2023-04-11 | Masimo Corporation | Monitor configuration system |
US10292664B2 (en) | 2008-05-02 | 2019-05-21 | Masimo Corporation | Monitor configuration system |
US9107625B2 (en) | 2008-05-05 | 2015-08-18 | Masimo Corporation | Pulse oximetry system with electrical decoupling circuitry |
US10524706B2 (en) | 2008-05-05 | 2020-01-07 | Masimo Corporation | Pulse oximetry system with electrical decoupling circuitry |
US11412964B2 (en) | 2008-05-05 | 2022-08-16 | Masimo Corporation | Pulse oximetry system with electrical decoupling circuitry |
US11375898B2 (en) | 2008-05-20 | 2022-07-05 | University Health Network | Method and system with spectral filtering and thermal mapping for imaging and collection of data for diagnostic purposes from bacteria |
US11284800B2 (en) | 2008-05-20 | 2022-03-29 | University Health Network | Devices, methods, and systems for fluorescence-based endoscopic imaging and collection of data with optical filters with corresponding discrete spectral bandwidth |
US11154198B2 (en) | 2008-05-20 | 2021-10-26 | University Health Network | Method and system for imaging and collection of data for diagnostic purposes |
US9042967B2 (en) | 2008-05-20 | 2015-05-26 | University Health Network | Device and method for wound imaging and monitoring |
US11751773B2 (en) | 2008-07-03 | 2023-09-12 | Masimo Corporation | Emitter arrangement for physiological measurements |
US9591975B2 (en) | 2008-07-03 | 2017-03-14 | Masimo Corporation | Contoured protrusion for improving spectroscopic measurement of blood constituents |
US10624563B2 (en) | 2008-07-03 | 2020-04-21 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
US10912500B2 (en) | 2008-07-03 | 2021-02-09 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
US9717425B2 (en) | 2008-07-03 | 2017-08-01 | Masimo Corporation | Noise shielding for a noninvaise device |
US10292628B1 (en) | 2008-07-03 | 2019-05-21 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
US10709366B1 (en) | 2008-07-03 | 2020-07-14 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
US10335068B2 (en) | 2008-07-03 | 2019-07-02 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
US9277880B2 (en) | 2008-07-03 | 2016-03-08 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
US10624564B1 (en) | 2008-07-03 | 2020-04-21 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
US10617338B2 (en) | 2008-07-03 | 2020-04-14 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
US10610138B2 (en) | 2008-07-03 | 2020-04-07 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
US10702194B1 (en) | 2008-07-03 | 2020-07-07 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
US10376190B1 (en) | 2008-07-03 | 2019-08-13 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
US10912502B2 (en) | 2008-07-03 | 2021-02-09 | Masimo Corporation | User-worn device for noninvasively measuring a physiological parameter of a user |
US10588554B2 (en) | 2008-07-03 | 2020-03-17 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
US10588553B2 (en) | 2008-07-03 | 2020-03-17 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
US11484229B2 (en) | 2008-07-03 | 2022-11-01 | Masimo Corporation | User-worn device for noninvasively measuring a physiological parameter of a user |
US11426103B2 (en) | 2008-07-03 | 2022-08-30 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
US10258265B1 (en) | 2008-07-03 | 2019-04-16 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
US11647914B2 (en) | 2008-07-03 | 2023-05-16 | Masimo Corporation | User-worn device for noninvasively measuring a physiological parameter of a user |
US10912501B2 (en) | 2008-07-03 | 2021-02-09 | Masimo Corporation | User-worn device for noninvasively measuring a physiological parameter of a user |
US10945648B2 (en) | 2008-07-03 | 2021-03-16 | Masimo Corporation | User-worn device for noninvasively measuring a physiological parameter of a user |
US10582886B2 (en) | 2008-07-03 | 2020-03-10 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
US10376191B1 (en) | 2008-07-03 | 2019-08-13 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
US11642037B2 (en) | 2008-07-03 | 2023-05-09 | Masimo Corporation | User-worn device for noninvasively measuring a physiological parameter of a user |
US8437825B2 (en) | 2008-07-03 | 2013-05-07 | Cercacor Laboratories, Inc. | Contoured protrusion for improving spectroscopic measurement of blood constituents |
US10631765B1 (en) | 2008-07-03 | 2020-04-28 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
US8577431B2 (en) | 2008-07-03 | 2013-11-05 | Cercacor Laboratories, Inc. | Noise shielding for a noninvasive device |
US10702195B1 (en) | 2008-07-03 | 2020-07-07 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
US10299708B1 (en) | 2008-07-03 | 2019-05-28 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
US11638532B2 (en) | 2008-07-03 | 2023-05-02 | Masimo Corporation | User-worn device for noninvasively measuring a physiological parameter of a user |
US11484230B2 (en) | 2008-07-03 | 2022-11-01 | Masimo Corporation | User-worn device for noninvasively measuring a physiological parameter of a user |
US10258266B1 (en) | 2008-07-03 | 2019-04-16 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
US11642036B2 (en) | 2008-07-03 | 2023-05-09 | Masimo Corporation | User-worn device for noninvasively measuring a physiological parameter of a user |
US10758166B2 (en) | 2008-07-03 | 2020-09-01 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
US10743803B2 (en) | 2008-07-03 | 2020-08-18 | Masimo Corporation | Multi-stream data collection system for noninvasive measurement of blood constituents |
USRE47249E1 (en) | 2008-07-29 | 2019-02-19 | Masimo Corporation | Alarm suspend system |
USRE47244E1 (en) | 2008-07-29 | 2019-02-19 | Masimo Corporation | Alarm suspend system |
US8847740B2 (en) | 2008-07-29 | 2014-09-30 | Masimo Corporation | Alarm suspend system |
US8547209B2 (en) | 2008-07-29 | 2013-10-01 | Masimo Corporation | Alarm suspend system |
US9153121B2 (en) | 2008-07-29 | 2015-10-06 | Masimo Corporation | Alarm suspend system |
USRE47353E1 (en) | 2008-07-29 | 2019-04-16 | Masimo Corporation | Alarm suspend system |
US8203438B2 (en) | 2008-07-29 | 2012-06-19 | Masimo Corporation | Alarm suspend system |
US8203704B2 (en) | 2008-08-04 | 2012-06-19 | Cercacor Laboratories, Inc. | Multi-stream sensor for noninvasive measurement of blood constituents |
US8630691B2 (en) | 2008-08-04 | 2014-01-14 | Cercacor Laboratories, Inc. | Multi-stream sensor front ends for noninvasive measurement of blood constituents |
US8515509B2 (en) | 2008-08-04 | 2013-08-20 | Cercacor Laboratories, Inc. | Multi-stream emitter for noninvasive measurement of blood constituents |
US8570503B2 (en) | 2008-08-04 | 2013-10-29 | Cercacor Laboratories, Inc. | Heat sink for noninvasive medical sensor |
US8909310B2 (en) | 2008-08-04 | 2014-12-09 | Cercacor Laboratories, Inc. | Multi-stream sensor front ends for noninvasive measurement of blood constituents |
USD621516S1 (en) | 2008-08-25 | 2010-08-10 | Masimo Laboratories, Inc. | Patient monitoring sensor |
US10952641B2 (en) | 2008-09-15 | 2021-03-23 | Masimo Corporation | Gas sampling line |
US11564593B2 (en) | 2008-09-15 | 2023-01-31 | Masimo Corporation | Gas sampling line |
US8911377B2 (en) | 2008-09-15 | 2014-12-16 | Masimo Corporation | Patient monitor including multi-parameter graphical display |
US8310336B2 (en) | 2008-10-10 | 2012-11-13 | Masimo Corporation | Systems and methods for storing, analyzing, retrieving and displaying streaming medical data |
US8761850B2 (en) | 2008-10-13 | 2014-06-24 | Masimo Corporation | Reflection-detector sensor position indicator |
US8346330B2 (en) | 2008-10-13 | 2013-01-01 | Masimo Corporation | Reflection-detector sensor position indicator |
US9119595B2 (en) | 2008-10-13 | 2015-09-01 | Masimo Corporation | Reflection-detector sensor position indicator |
US8401602B2 (en) | 2008-10-13 | 2013-03-19 | Masimo Corporation | Secondary-emitter sensor position indicator |
US8700112B2 (en) | 2008-10-13 | 2014-04-15 | Masimo Corporation | Secondary-emitter sensor position indicator |
US9795358B2 (en) | 2008-12-30 | 2017-10-24 | Masimo Corporation | Acoustic sensor assembly |
US9028429B2 (en) | 2008-12-30 | 2015-05-12 | Masimo Corporation | Acoustic sensor assembly |
US11559275B2 (en) | 2008-12-30 | 2023-01-24 | Masimo Corporation | Acoustic sensor assembly |
US9131917B2 (en) | 2008-12-30 | 2015-09-15 | Masimo Corporation | Acoustic sensor assembly |
US10548561B2 (en) | 2008-12-30 | 2020-02-04 | Masimo Corporation | Acoustic sensor assembly |
US8771204B2 (en) | 2008-12-30 | 2014-07-08 | Masimo Corporation | Acoustic sensor assembly |
US11877867B2 (en) | 2009-02-16 | 2024-01-23 | Masimo Corporation | Physiological measurement device |
US8588880B2 (en) | 2009-02-16 | 2013-11-19 | Masimo Corporation | Ear sensor |
US10292657B2 (en) | 2009-02-16 | 2019-05-21 | Masimo Corporation | Ear sensor |
US11432771B2 (en) | 2009-02-16 | 2022-09-06 | Masimo Corporation | Physiological measurement device |
US9259185B2 (en) | 2009-02-16 | 2016-02-16 | Masimo Corporation | Ear sensor |
US11426125B2 (en) | 2009-02-16 | 2022-08-30 | Masimo Corporation | Physiological measurement device |
US10325681B2 (en) | 2009-03-04 | 2019-06-18 | Masimo Corporation | Physiological alarm threshold determination |
US11087875B2 (en) | 2009-03-04 | 2021-08-10 | Masimo Corporation | Medical monitoring system |
US11133105B2 (en) | 2009-03-04 | 2021-09-28 | Masimo Corporation | Medical monitoring system |
US10255994B2 (en) | 2009-03-04 | 2019-04-09 | Masimo Corporation | Physiological parameter alarm delay |
US10366787B2 (en) | 2009-03-04 | 2019-07-30 | Masimo Corporation | Physiological alarm threshold determination |
US10007758B2 (en) | 2009-03-04 | 2018-06-26 | Masimo Corporation | Medical monitoring system |
US9218454B2 (en) | 2009-03-04 | 2015-12-22 | Masimo Corporation | Medical monitoring system |
US11145408B2 (en) | 2009-03-04 | 2021-10-12 | Masimo Corporation | Medical communication protocol translator |
US10032002B2 (en) | 2009-03-04 | 2018-07-24 | Masimo Corporation | Medical monitoring system |
US11923080B2 (en) | 2009-03-04 | 2024-03-05 | Masimo Corporation | Medical monitoring system |
US11158421B2 (en) | 2009-03-04 | 2021-10-26 | Masimo Corporation | Physiological parameter alarm delay |
US11848515B1 (en) | 2009-03-11 | 2023-12-19 | Masimo Corporation | Magnetic connector |
US11515664B2 (en) | 2009-03-11 | 2022-11-29 | Masimo Corporation | Magnetic connector |
US10855023B2 (en) | 2009-03-11 | 2020-12-01 | Masimo Corporation | Magnetic connector for a data communications cable |
US10205272B2 (en) | 2009-03-11 | 2019-02-12 | Masimo Corporation | Magnetic connector |
US8897847B2 (en) | 2009-03-23 | 2014-11-25 | Masimo Corporation | Digit gauge for noninvasive optical sensor |
US11331042B2 (en) | 2009-05-19 | 2022-05-17 | Masimo Corporation | Disposable components for reusable physiological sensor |
US8989831B2 (en) | 2009-05-19 | 2015-03-24 | Masimo Corporation | Disposable components for reusable physiological sensor |
US10342487B2 (en) | 2009-05-19 | 2019-07-09 | Masimo Corporation | Disposable components for reusable physiological sensor |
US9895107B2 (en) | 2009-05-19 | 2018-02-20 | Masimo Corporation | Disposable components for reusable physiological sensor |
US9037207B2 (en) | 2009-05-20 | 2015-05-19 | Masimo Corporation | Hemoglobin display and patient treatment |
US8571619B2 (en) | 2009-05-20 | 2013-10-29 | Masimo Corporation | Hemoglobin display and patient treatment |
US9370325B2 (en) | 2009-05-20 | 2016-06-21 | Masimo Corporation | Hemoglobin display and patient treatment |
US10953156B2 (en) | 2009-05-20 | 2021-03-23 | Masimo Corporation | Hemoglobin display and patient treatment |
US10413666B2 (en) | 2009-05-20 | 2019-09-17 | Masimo Corporation | Hemoglobin display and patient treatment |
US11752262B2 (en) | 2009-05-20 | 2023-09-12 | Masimo Corporation | Hemoglobin display and patient treatment |
US9795739B2 (en) | 2009-05-20 | 2017-10-24 | Masimo Corporation | Hemoglobin display and patient treatment |
US8720249B2 (en) | 2009-06-12 | 2014-05-13 | Masimo Corporation | Non-invasive sensor calibration device |
US8418524B2 (en) | 2009-06-12 | 2013-04-16 | Masimo Corporation | Non-invasive sensor calibration device |
US8670811B2 (en) | 2009-06-30 | 2014-03-11 | Masimo Corporation | Pulse oximetry system for adjusting medical ventilation |
US11963736B2 (en) | 2009-07-20 | 2024-04-23 | Masimo Corporation | Wireless patient monitoring system |
US8471713B2 (en) | 2009-07-24 | 2013-06-25 | Cercacor Laboratories, Inc. | Interference detector for patient monitor |
US9989560B2 (en) | 2009-07-24 | 2018-06-05 | Masimo Corporation | Interference detector for patient monitor |
US8754776B2 (en) | 2009-07-24 | 2014-06-17 | Cercacor Laboratories, Inc. | Interference detector for patient monitor |
US9295421B2 (en) | 2009-07-29 | 2016-03-29 | Masimo Corporation | Non-invasive physiological sensor cover |
US11779247B2 (en) | 2009-07-29 | 2023-10-10 | Masimo Corporation | Non-invasive physiological sensor cover |
US8473020B2 (en) | 2009-07-29 | 2013-06-25 | Cercacor Laboratories, Inc. | Non-invasive physiological sensor cover |
US8886271B2 (en) | 2009-07-29 | 2014-11-11 | Cercacor Laboratories, Inc. | Non-invasive physiological sensor cover |
US11559227B2 (en) | 2009-07-29 | 2023-01-24 | Masimo Corporation | Non-invasive physiological sensor cover |
US9980667B2 (en) | 2009-07-29 | 2018-05-29 | Masimo Corporation | Non-invasive physiological sensor cover |
US10588556B2 (en) | 2009-07-29 | 2020-03-17 | Masimo Corporation | Non-invasive physiological sensor cover |
US10478107B2 (en) | 2009-07-29 | 2019-11-19 | Masimo Corporation | Non-invasive physiological sensor cover |
US11369293B2 (en) | 2009-07-29 | 2022-06-28 | Masimo Corporation | Non-invasive physiological sensor cover |
US10188331B1 (en) | 2009-07-29 | 2019-01-29 | Masimo Corporation | Non-invasive physiological sensor cover |
US10194848B1 (en) | 2009-07-29 | 2019-02-05 | Masimo Corporation | Non-invasive physiological sensor cover |
US9186102B2 (en) | 2009-09-03 | 2015-11-17 | Cercacor Laboratories, Inc. | Emitter driver for noninvasive patient monitor |
US8688183B2 (en) | 2009-09-03 | 2014-04-01 | Ceracor Laboratories, Inc. | Emitter driver for noninvasive patient monitor |
US9668680B2 (en) | 2009-09-03 | 2017-06-06 | Masimo Corporation | Emitter driver for noninvasive patient monitor |
US8428967B2 (en) | 2009-09-14 | 2013-04-23 | Cercacor Laboratories, Inc. | Spot check monitor credit system |
US10687715B2 (en) | 2009-09-15 | 2020-06-23 | Masimo Corporation | Non-invasive intravascular volume index monitor |
US9833152B2 (en) | 2009-09-17 | 2017-12-05 | Masimo Corporation | Optical-based physiological monitoring system |
US9517024B2 (en) | 2009-09-17 | 2016-12-13 | Masimo Corporation | Optical-based physiological monitoring system |
US11744471B2 (en) | 2009-09-17 | 2023-09-05 | Masimo Corporation | Optical-based physiological monitoring system |
US10398320B2 (en) | 2009-09-17 | 2019-09-03 | Masimo Corporation | Optical-based physiological monitoring system |
US11103143B2 (en) | 2009-09-17 | 2021-08-31 | Masimo Corporation | Optical-based physiological monitoring system |
US9510779B2 (en) | 2009-09-17 | 2016-12-06 | Masimo Corporation | Analyte monitoring using one or more accelerometers |
US8571618B1 (en) | 2009-09-28 | 2013-10-29 | Cercacor Laboratories, Inc. | Adaptive calibration system for spectrophotometric measurements |
US11342072B2 (en) | 2009-10-06 | 2022-05-24 | Cercacor Laboratories, Inc. | Optical sensing systems and methods for detecting a physiological condition of a patient |
US11114188B2 (en) | 2009-10-06 | 2021-09-07 | Cercacor Laboratories, Inc. | System for monitoring a physiological parameter of a user |
US8690799B2 (en) | 2009-10-15 | 2014-04-08 | Masimo Corporation | Acoustic respiratory monitoring sensor having multiple sensing elements |
US9867578B2 (en) | 2009-10-15 | 2018-01-16 | Masimo Corporation | Physiological acoustic monitoring system |
US9538980B2 (en) | 2009-10-15 | 2017-01-10 | Masimo Corporation | Acoustic respiratory monitoring sensor having multiple sensing elements |
US10357209B2 (en) | 2009-10-15 | 2019-07-23 | Masimo Corporation | Bidirectional physiological information display |
US10342497B2 (en) | 2009-10-15 | 2019-07-09 | Masimo Corporation | Physiological acoustic monitoring system |
US8430817B1 (en) | 2009-10-15 | 2013-04-30 | Masimo Corporation | System for determining confidence in respiratory rate measurements |
US10349895B2 (en) | 2009-10-15 | 2019-07-16 | Masimo Corporation | Acoustic respiratory monitoring sensor having multiple sensing elements |
US9386961B2 (en) | 2009-10-15 | 2016-07-12 | Masimo Corporation | Physiological acoustic monitoring system |
US9370335B2 (en) | 2009-10-15 | 2016-06-21 | Masimo Corporation | Physiological acoustic monitoring system |
US10813598B2 (en) | 2009-10-15 | 2020-10-27 | Masimo Corporation | System and method for monitoring respiratory rate measurements |
US9106038B2 (en) | 2009-10-15 | 2015-08-11 | Masimo Corporation | Pulse oximetry system with low noise cable hub |
US10980507B2 (en) | 2009-10-15 | 2021-04-20 | Masimo Corporation | Physiological acoustic monitoring system |
US9877686B2 (en) | 2009-10-15 | 2018-01-30 | Masimo Corporation | System for determining confidence in respiratory rate measurements |
US9066680B1 (en) | 2009-10-15 | 2015-06-30 | Masimo Corporation | System for determining confidence in respiratory rate measurements |
US8870792B2 (en) | 2009-10-15 | 2014-10-28 | Masimo Corporation | Physiological acoustic monitoring system |
US10925544B2 (en) | 2009-10-15 | 2021-02-23 | Masimo Corporation | Acoustic respiratory monitoring sensor having multiple sensing elements |
US8821415B2 (en) | 2009-10-15 | 2014-09-02 | Masimo Corporation | Physiological acoustic monitoring system |
US8702627B2 (en) | 2009-10-15 | 2014-04-22 | Masimo Corporation | Acoustic respiratory monitoring sensor having multiple sensing elements |
US10098610B2 (en) | 2009-10-15 | 2018-10-16 | Masimo Corporation | Physiological acoustic monitoring system |
US8755535B2 (en) | 2009-10-15 | 2014-06-17 | Masimo Corporation | Acoustic respiratory monitoring sensor having multiple sensing elements |
US10463340B2 (en) | 2009-10-15 | 2019-11-05 | Masimo Corporation | Acoustic respiratory monitoring systems and methods |
US8715206B2 (en) | 2009-10-15 | 2014-05-06 | Masimo Corporation | Acoustic patient sensor |
US9724016B1 (en) | 2009-10-16 | 2017-08-08 | Masimo Corp. | Respiration processor |
US11974841B2 (en) | 2009-10-16 | 2024-05-07 | Masimo Corporation | Respiration processor |
US9848800B1 (en) | 2009-10-16 | 2017-12-26 | Masimo Corporation | Respiratory pause detector |
US10595747B2 (en) | 2009-10-16 | 2020-03-24 | Masimo Corporation | Respiration processor |
US11534087B2 (en) | 2009-11-24 | 2022-12-27 | Cercacor Laboratories, Inc. | Physiological measurement system with automatic wavelength adjustment |
US9839381B1 (en) | 2009-11-24 | 2017-12-12 | Cercacor Laboratories, Inc. | Physiological measurement system with automatic wavelength adjustment |
US10750983B2 (en) | 2009-11-24 | 2020-08-25 | Cercacor Laboratories, Inc. | Physiological measurement system with automatic wavelength adjustment |
US10729402B2 (en) | 2009-12-04 | 2020-08-04 | Masimo Corporation | Calibration for multi-stage physiological monitors |
US11571152B2 (en) | 2009-12-04 | 2023-02-07 | Masimo Corporation | Calibration for multi-stage physiological monitors |
US8801613B2 (en) | 2009-12-04 | 2014-08-12 | Masimo Corporation | Calibration for multi-stage physiological monitors |
US10943450B2 (en) | 2009-12-21 | 2021-03-09 | Masimo Corporation | Modular patient monitor |
US11900775B2 (en) | 2009-12-21 | 2024-02-13 | Masimo Corporation | Modular patient monitor |
US9153112B1 (en) | 2009-12-21 | 2015-10-06 | Masimo Corporation | Modular patient monitor |
US10354504B2 (en) | 2009-12-21 | 2019-07-16 | Masimo Corporation | Modular patient monitor |
US9847002B2 (en) | 2009-12-21 | 2017-12-19 | Masimo Corporation | Modular patient monitor |
US11289199B2 (en) | 2010-01-19 | 2022-03-29 | Masimo Corporation | Wellness analysis system |
USRE49007E1 (en) | 2010-03-01 | 2022-04-05 | Masimo Corporation | Adaptive alarm system |
US9775570B2 (en) | 2010-03-01 | 2017-10-03 | Masimo Corporation | Adaptive alarm system |
USRE47882E1 (en) | 2010-03-01 | 2020-03-03 | Masimo Corporation | Adaptive alarm system |
USRE47218E1 (en) | 2010-03-01 | 2019-02-05 | Masimo Corporation | Adaptive alarm system |
US9724024B2 (en) | 2010-03-01 | 2017-08-08 | Masimo Corporation | Adaptive alarm system |
US8584345B2 (en) | 2010-03-08 | 2013-11-19 | Masimo Corporation | Reprocessing of a physiological sensor |
US11484231B2 (en) | 2010-03-08 | 2022-11-01 | Masimo Corporation | Reprocessing of a physiological sensor |
US9662052B2 (en) | 2010-03-08 | 2017-05-30 | Masimo Corporation | Reprocessing of a physiological sensor |
US10729362B2 (en) | 2010-03-08 | 2020-08-04 | Masimo Corporation | Reprocessing of a physiological sensor |
US10098550B2 (en) | 2010-03-30 | 2018-10-16 | Masimo Corporation | Plethysmographic respiration rate detection |
US11399722B2 (en) | 2010-03-30 | 2022-08-02 | Masimo Corporation | Plethysmographic respiration rate detection |
US9307928B1 (en) | 2010-03-30 | 2016-04-12 | Masimo Corporation | Plethysmographic respiration processor |
US8655807B2 (en) | 2010-04-05 | 2014-02-18 | Applied Research Associates, Inc. | Methods for forming recognition algorithms for laser-induced breakdown spectroscopy |
US8712494B1 (en) | 2010-05-03 | 2014-04-29 | Masimo Corporation | Reflective non-invasive sensor |
US9876320B2 (en) | 2010-05-03 | 2018-01-23 | Masimo Corporation | Sensor adapter cable |
US9138180B1 (en) | 2010-05-03 | 2015-09-22 | Masimo Corporation | Sensor adapter cable |
US8666468B1 (en) | 2010-05-06 | 2014-03-04 | Masimo Corporation | Patient monitor for determining microcirculation state |
US10271748B2 (en) | 2010-05-06 | 2019-04-30 | Masimo Corporation | Patient monitor for determining microcirculation state |
US9192312B2 (en) | 2010-05-06 | 2015-11-24 | Masimo Corporation | Patient monitor for determining microcirculation state |
US11330996B2 (en) | 2010-05-06 | 2022-05-17 | Masimo Corporation | Patient monitor for determining microcirculation state |
US9795310B2 (en) | 2010-05-06 | 2017-10-24 | Masimo Corporation | Patient monitor for determining microcirculation state |
US9782110B2 (en) | 2010-06-02 | 2017-10-10 | Masimo Corporation | Opticoustic sensor |
US9326712B1 (en) | 2010-06-02 | 2016-05-03 | Masimo Corporation | Opticoustic sensor |
US8740792B1 (en) | 2010-07-12 | 2014-06-03 | Masimo Corporation | Patient monitor capable of accounting for environmental conditions |
US11234602B2 (en) | 2010-07-22 | 2022-02-01 | Masimo Corporation | Non-invasive blood pressure measurement system |
US10052037B2 (en) | 2010-07-22 | 2018-08-21 | Masimo Corporation | Non-invasive blood pressure measurement system |
US9408542B1 (en) | 2010-07-22 | 2016-08-09 | Masimo Corporation | Non-invasive blood pressure measurement system |
US9649054B2 (en) | 2010-08-26 | 2017-05-16 | Cercacor Laboratories, Inc. | Blood pressure measurement method |
US10531811B2 (en) | 2010-09-28 | 2020-01-14 | Masimo Corporation | Depth of consciousness monitor including oximeter |
US9995681B2 (en) * | 2010-09-28 | 2018-06-12 | Authentix, Inc. | Determining the quantity of a taggant in a liquid sample |
US8821397B2 (en) | 2010-09-28 | 2014-09-02 | Masimo Corporation | Depth of consciousness monitor including oximeter |
US9775545B2 (en) | 2010-09-28 | 2017-10-03 | Masimo Corporation | Magnetic electrical connector for patient monitors |
US11717210B2 (en) | 2010-09-28 | 2023-08-08 | Masimo Corporation | Depth of consciousness monitor including oximeter |
US20150355091A1 (en) * | 2010-09-28 | 2015-12-10 | Authentix, Inc. | Determining the Quantity of a Taggant in a Liquid Sample |
US9538949B2 (en) | 2010-09-28 | 2017-01-10 | Masimo Corporation | Depth of consciousness monitor including oximeter |
US9693737B2 (en) | 2010-10-13 | 2017-07-04 | Masimo Corporation | Physiological measurement logic engine |
US10405804B2 (en) | 2010-10-13 | 2019-09-10 | Masimo Corporation | Physiological measurement logic engine |
US9211095B1 (en) | 2010-10-13 | 2015-12-15 | Masimo Corporation | Physiological measurement logic engine |
US11399774B2 (en) | 2010-10-13 | 2022-08-02 | Masimo Corporation | Physiological measurement logic engine |
US8723677B1 (en) | 2010-10-20 | 2014-05-13 | Masimo Corporation | Patient safety system with automatically adjusting bed |
US9226696B2 (en) | 2010-10-20 | 2016-01-05 | Masimo Corporation | Patient safety system with automatically adjusting bed |
US10159412B2 (en) | 2010-12-01 | 2018-12-25 | Cercacor Laboratories, Inc. | Handheld processing device including medical applications for minimally and non invasive glucose measurements |
US10729335B2 (en) | 2010-12-01 | 2020-08-04 | Cercacor Laboratories, Inc. | Handheld processing device including medical applications for minimally and non invasive glucose measurements |
US9579039B2 (en) | 2011-01-10 | 2017-02-28 | Masimo Corporation | Non-invasive intravascular volume index monitor |
US11488715B2 (en) | 2011-02-13 | 2022-11-01 | Masimo Corporation | Medical characterization system |
US10332630B2 (en) | 2011-02-13 | 2019-06-25 | Masimo Corporation | Medical characterization system |
US11363960B2 (en) | 2011-02-25 | 2022-06-21 | Masimo Corporation | Patient monitor for monitoring microcirculation |
US9066666B2 (en) | 2011-02-25 | 2015-06-30 | Cercacor Laboratories, Inc. | Patient monitor for monitoring microcirculation |
US10271749B2 (en) | 2011-02-25 | 2019-04-30 | Masimo Corporation | Patient monitor for monitoring microcirculation |
US9801556B2 (en) | 2011-02-25 | 2017-10-31 | Masimo Corporation | Patient monitor for monitoring microcirculation |
US8830449B1 (en) | 2011-04-18 | 2014-09-09 | Cercacor Laboratories, Inc. | Blood analysis system |
US9095316B2 (en) | 2011-04-20 | 2015-08-04 | Masimo Corporation | System for generating alarms based on alarm patterns |
US9622692B2 (en) | 2011-05-16 | 2017-04-18 | Masimo Corporation | Personal health device |
US9986919B2 (en) | 2011-06-21 | 2018-06-05 | Masimo Corporation | Patient monitoring system |
US11925445B2 (en) | 2011-06-21 | 2024-03-12 | Masimo Corporation | Patient monitoring system |
US11272852B2 (en) | 2011-06-21 | 2022-03-15 | Masimo Corporation | Patient monitoring system |
US9532722B2 (en) | 2011-06-21 | 2017-01-03 | Masimo Corporation | Patient monitoring system |
US11109770B2 (en) | 2011-06-21 | 2021-09-07 | Masimo Corporation | Patient monitoring system |
US9245668B1 (en) | 2011-06-29 | 2016-01-26 | Cercacor Laboratories, Inc. | Low noise cable providing communication between electronic sensor components and patient monitor |
US11439329B2 (en) | 2011-07-13 | 2022-09-13 | Masimo Corporation | Multiple measurement mode in a physiological sensor |
US9192351B1 (en) | 2011-07-22 | 2015-11-24 | Masimo Corporation | Acoustic respiratory monitoring sensor with probe-off detection |
US8755872B1 (en) | 2011-07-28 | 2014-06-17 | Masimo Corporation | Patient monitoring system for indicating an abnormal condition |
US11877824B2 (en) | 2011-08-17 | 2024-01-23 | Masimo Corporation | Modulated physiological sensor |
US10952614B2 (en) | 2011-08-17 | 2021-03-23 | Masimo Corporation | Modulated physiological sensor |
US9782077B2 (en) | 2011-08-17 | 2017-10-10 | Masimo Corporation | Modulated physiological sensor |
US11816973B2 (en) | 2011-08-19 | 2023-11-14 | Masimo Corporation | Health care sanitation monitoring system |
US9323894B2 (en) | 2011-08-19 | 2016-04-26 | Masimo Corporation | Health care sanitation monitoring system |
US11176801B2 (en) | 2011-08-19 | 2021-11-16 | Masimo Corporation | Health care sanitation monitoring system |
US11179114B2 (en) | 2011-10-13 | 2021-11-23 | Masimo Corporation | Medical monitoring hub |
US10925550B2 (en) | 2011-10-13 | 2021-02-23 | Masimo Corporation | Medical monitoring hub |
US10299709B2 (en) | 2011-10-13 | 2019-05-28 | Masimo Corporation | Robust fractional saturation determination |
US9943269B2 (en) | 2011-10-13 | 2018-04-17 | Masimo Corporation | System for displaying medical monitoring data |
US9993207B2 (en) | 2011-10-13 | 2018-06-12 | Masimo Corporation | Medical monitoring hub |
US9913617B2 (en) | 2011-10-13 | 2018-03-13 | Masimo Corporation | Medical monitoring hub |
US11089982B2 (en) | 2011-10-13 | 2021-08-17 | Masimo Corporation | Robust fractional saturation determination |
US9808188B1 (en) | 2011-10-13 | 2017-11-07 | Masimo Corporation | Robust fractional saturation determination |
US9436645B2 (en) | 2011-10-13 | 2016-09-06 | Masimo Corporation | Medical monitoring hub |
US10512436B2 (en) | 2011-10-13 | 2019-12-24 | Masimo Corporation | System for displaying medical monitoring data |
US11786183B2 (en) | 2011-10-13 | 2023-10-17 | Masimo Corporation | Medical monitoring hub |
US11241199B2 (en) | 2011-10-13 | 2022-02-08 | Masimo Corporation | System for displaying medical monitoring data |
US10955270B2 (en) | 2011-10-27 | 2021-03-23 | Masimo Corporation | Physiological monitor gauge panel |
US11747178B2 (en) | 2011-10-27 | 2023-09-05 | Masimo Corporation | Physiological monitor gauge panel |
US9778079B1 (en) | 2011-10-27 | 2017-10-03 | Masimo Corporation | Physiological monitor gauge panel |
US9445759B1 (en) | 2011-12-22 | 2016-09-20 | Cercacor Laboratories, Inc. | Blood glucose calibration system |
US10278648B2 (en) | 2012-01-04 | 2019-05-07 | Masimo Corporation | Automated CCHD screening and detection |
US10729384B2 (en) | 2012-01-04 | 2020-08-04 | Masimo Corporation | Automated condition screening and detection |
US11172890B2 (en) | 2012-01-04 | 2021-11-16 | Masimo Corporation | Automated condition screening and detection |
US11179111B2 (en) | 2012-01-04 | 2021-11-23 | Masimo Corporation | Automated CCHD screening and detection |
US9392945B2 (en) | 2012-01-04 | 2016-07-19 | Masimo Corporation | Automated CCHD screening and detection |
US10349898B2 (en) | 2012-01-04 | 2019-07-16 | Masimo Corporation | Automated CCHD screening and detection |
US10149616B2 (en) | 2012-02-09 | 2018-12-11 | Masimo Corporation | Wireless patient monitoring device |
US11918353B2 (en) | 2012-02-09 | 2024-03-05 | Masimo Corporation | Wireless patient monitoring device |
US9480435B2 (en) | 2012-02-09 | 2016-11-01 | Masimo Corporation | Configurable patient monitoring system |
US11083397B2 (en) | 2012-02-09 | 2021-08-10 | Masimo Corporation | Wireless patient monitoring device |
USD788312S1 (en) | 2012-02-09 | 2017-05-30 | Masimo Corporation | Wireless patient monitoring device |
US10307111B2 (en) | 2012-02-09 | 2019-06-04 | Masimo Corporation | Patient position detection system |
US10188296B2 (en) | 2012-02-09 | 2019-01-29 | Masimo Corporation | Wireless patient monitoring device |
US10503379B2 (en) | 2012-03-25 | 2019-12-10 | Masimo Corporation | Physiological monitor touchscreen interface |
US9195385B2 (en) | 2012-03-25 | 2015-11-24 | Masimo Corporation | Physiological monitor touchscreen interface |
US11132117B2 (en) | 2012-03-25 | 2021-09-28 | Masimo Corporation | Physiological monitor touchscreen interface |
US9131881B2 (en) | 2012-04-17 | 2015-09-15 | Masimo Corporation | Hypersaturation index |
US10674948B2 (en) | 2012-04-17 | 2020-06-09 | Mastmo Corporation | Hypersaturation index |
US9775546B2 (en) | 2012-04-17 | 2017-10-03 | Masimo Corporation | Hypersaturation index |
US10531819B2 (en) | 2012-04-17 | 2020-01-14 | Masimo Corporation | Hypersaturation index |
US11071480B2 (en) | 2012-04-17 | 2021-07-27 | Masimo Corporation | Hypersaturation index |
US10542903B2 (en) | 2012-06-07 | 2020-01-28 | Masimo Corporation | Depth of consciousness monitor |
US11557407B2 (en) | 2012-08-01 | 2023-01-17 | Masimo Corporation | Automated assembly sensor cable |
US11069461B2 (en) | 2012-08-01 | 2021-07-20 | Masimo Corporation | Automated assembly sensor cable |
US9697928B2 (en) | 2012-08-01 | 2017-07-04 | Masimo Corporation | Automated assembly sensor cable |
US10827961B1 (en) | 2012-08-29 | 2020-11-10 | Masimo Corporation | Physiological measurement calibration |
USD989112S1 (en) | 2012-09-20 | 2023-06-13 | Masimo Corporation | Display screen or portion thereof with a graphical user interface for physiological monitoring |
US9955937B2 (en) | 2012-09-20 | 2018-05-01 | Masimo Corporation | Acoustic patient sensor coupler |
US11020084B2 (en) | 2012-09-20 | 2021-06-01 | Masimo Corporation | Acoustic patient sensor coupler |
US10833983B2 (en) | 2012-09-20 | 2020-11-10 | Masimo Corporation | Intelligent medical escalation process |
US11887728B2 (en) | 2012-09-20 | 2024-01-30 | Masimo Corporation | Intelligent medical escalation process |
US9749232B2 (en) | 2012-09-20 | 2017-08-29 | Masimo Corporation | Intelligent medical network edge router |
US11504002B2 (en) | 2012-09-20 | 2022-11-22 | Masimo Corporation | Physiological monitoring system |
US9717458B2 (en) | 2012-10-20 | 2017-08-01 | Masimo Corporation | Magnetic-flap optical sensor |
US9560996B2 (en) | 2012-10-30 | 2017-02-07 | Masimo Corporation | Universal medical system |
US11452449B2 (en) | 2012-10-30 | 2022-09-27 | Masimo Corporation | Universal medical system |
US10305775B2 (en) | 2012-11-05 | 2019-05-28 | Cercacor Laboratories, Inc. | Physiological test credit method |
US9787568B2 (en) | 2012-11-05 | 2017-10-10 | Cercacor Laboratories, Inc. | Physiological test credit method |
US11367529B2 (en) | 2012-11-05 | 2022-06-21 | Cercacor Laboratories, Inc. | Physiological test credit method |
US9750461B1 (en) | 2013-01-02 | 2017-09-05 | Masimo Corporation | Acoustic respiratory monitoring sensor with probe-off detection |
US9724025B1 (en) | 2013-01-16 | 2017-08-08 | Masimo Corporation | Active-pulse blood analysis system |
US10610139B2 (en) | 2013-01-16 | 2020-04-07 | Masimo Corporation | Active-pulse blood analysis system |
US11224363B2 (en) | 2013-01-16 | 2022-01-18 | Masimo Corporation | Active-pulse blood analysis system |
US11839470B2 (en) | 2013-01-16 | 2023-12-12 | Masimo Corporation | Active-pulse blood analysis system |
US9750442B2 (en) | 2013-03-09 | 2017-09-05 | Masimo Corporation | Physiological status monitor |
US11645905B2 (en) | 2013-03-13 | 2023-05-09 | Masimo Corporation | Systems and methods for monitoring a patient health network |
US10441181B1 (en) | 2013-03-13 | 2019-10-15 | Masimo Corporation | Acoustic pulse and respiration monitoring system |
US10672260B2 (en) | 2013-03-13 | 2020-06-02 | Masimo Corporation | Systems and methods for monitoring a patient health network |
US11963749B2 (en) | 2013-03-13 | 2024-04-23 | Masimo Corporation | Acoustic physiological monitoring system |
US9936917B2 (en) | 2013-03-14 | 2018-04-10 | Masimo Laboratories, Inc. | Patient monitor placement indicator |
US9474474B2 (en) | 2013-03-14 | 2016-10-25 | Masimo Corporation | Patient monitor as a minimally invasive glucometer |
US10575779B2 (en) | 2013-03-14 | 2020-03-03 | Masimo Corporation | Patient monitor placement indicator |
US9986952B2 (en) | 2013-03-14 | 2018-06-05 | Masimo Corporation | Heart sound simulator |
US11504062B2 (en) | 2013-03-14 | 2022-11-22 | Masimo Corporation | Patient monitor placement indicator |
US10456038B2 (en) | 2013-03-15 | 2019-10-29 | Cercacor Laboratories, Inc. | Cloud-based physiological monitoring system |
US9891079B2 (en) | 2013-07-17 | 2018-02-13 | Masimo Corporation | Pulser with double-bearing position encoder for non-invasive physiological monitoring |
US11022466B2 (en) | 2013-07-17 | 2021-06-01 | Masimo Corporation | Pulser with double-bearing position encoder for non-invasive physiological monitoring |
US11944415B2 (en) | 2013-08-05 | 2024-04-02 | Masimo Corporation | Systems and methods for measuring blood pressure |
US10555678B2 (en) | 2013-08-05 | 2020-02-11 | Masimo Corporation | Blood pressure monitor with valve-chamber assembly |
US10980432B2 (en) | 2013-08-05 | 2021-04-20 | Masimo Corporation | Systems and methods for measuring blood pressure |
US11596363B2 (en) | 2013-09-12 | 2023-03-07 | Cercacor Laboratories, Inc. | Medical device management system |
US11076782B2 (en) | 2013-10-07 | 2021-08-03 | Masimo Corporation | Regional oximetry user interface |
US11147518B1 (en) | 2013-10-07 | 2021-10-19 | Masimo Corporation | Regional oximetry signal processor |
US11751780B2 (en) | 2013-10-07 | 2023-09-12 | Masimo Corporation | Regional oximetry sensor |
US10617335B2 (en) | 2013-10-07 | 2020-04-14 | Masimo Corporation | Regional oximetry sensor |
US10010276B2 (en) | 2013-10-07 | 2018-07-03 | Masimo Corporation | Regional oximetry user interface |
US9839379B2 (en) | 2013-10-07 | 2017-12-12 | Masimo Corporation | Regional oximetry pod |
US11717194B2 (en) | 2013-10-07 | 2023-08-08 | Masimo Corporation | Regional oximetry pod |
US10799160B2 (en) | 2013-10-07 | 2020-10-13 | Masimo Corporation | Regional oximetry pod |
US10825568B2 (en) | 2013-10-11 | 2020-11-03 | Masimo Corporation | Alarm notification system |
US11488711B2 (en) | 2013-10-11 | 2022-11-01 | Masimo Corporation | Alarm notification system |
US11699526B2 (en) | 2013-10-11 | 2023-07-11 | Masimo Corporation | Alarm notification system |
US10828007B1 (en) | 2013-10-11 | 2020-11-10 | Masimo Corporation | Acoustic sensor with attachment portion |
US10832818B2 (en) | 2013-10-11 | 2020-11-10 | Masimo Corporation | Alarm notification system |
US10279247B2 (en) | 2013-12-13 | 2019-05-07 | Masimo Corporation | Avatar-incentive healthcare therapy |
US11969645B2 (en) | 2013-12-13 | 2024-04-30 | Masimo Corporation | Avatar-incentive healthcare therapy |
US10881951B2 (en) | 2013-12-13 | 2021-01-05 | Masimo Corporation | Avatar-incentive healthcare therapy |
US11673041B2 (en) | 2013-12-13 | 2023-06-13 | Masimo Corporation | Avatar-incentive healthcare therapy |
US10086138B1 (en) | 2014-01-28 | 2018-10-02 | Masimo Corporation | Autonomous drug delivery system |
US11883190B2 (en) | 2014-01-28 | 2024-01-30 | Masimo Corporation | Autonomous drug delivery system |
US11259745B2 (en) | 2014-01-28 | 2022-03-01 | Masimo Corporation | Autonomous drug delivery system |
US10532174B2 (en) | 2014-02-21 | 2020-01-14 | Masimo Corporation | Assistive capnography device |
US9924897B1 (en) | 2014-06-12 | 2018-03-27 | Masimo Corporation | Heated reprocessing of physiological sensors |
US11696712B2 (en) | 2014-06-13 | 2023-07-11 | Vccb Holdings, Inc. | Alarm fatigue management systems and methods |
US11000232B2 (en) | 2014-06-19 | 2021-05-11 | Masimo Corporation | Proximity sensor in pulse oximeter |
US10231670B2 (en) | 2014-06-19 | 2019-03-19 | Masimo Corporation | Proximity sensor in pulse oximeter |
US10438356B2 (en) | 2014-07-24 | 2019-10-08 | University Health Network | Collection and analysis of data for diagnostic purposes |
US11961236B2 (en) | 2014-07-24 | 2024-04-16 | University Health Network | Collection and analysis of data for diagnostic purposes |
US11954861B2 (en) | 2014-07-24 | 2024-04-09 | University Health Network | Systems, devices, and methods for visualization of tissue and collection and analysis of data regarding same |
US11676276B2 (en) | 2014-07-24 | 2023-06-13 | University Health Network | Collection and analysis of data for diagnostic purposes |
US11961616B2 (en) | 2014-08-26 | 2024-04-16 | Vccb Holdings, Inc. | Real-time monitoring systems and methods in a healthcare environment |
US11581091B2 (en) | 2014-08-26 | 2023-02-14 | Vccb Holdings, Inc. | Real-time monitoring systems and methods in a healthcare environment |
US10231657B2 (en) | 2014-09-04 | 2019-03-19 | Masimo Corporation | Total hemoglobin screening sensor |
US11331013B2 (en) | 2014-09-04 | 2022-05-17 | Masimo Corporation | Total hemoglobin screening sensor |
US10568514B2 (en) | 2014-09-18 | 2020-02-25 | Masimo Semiconductor, Inc. | Enhanced visible near-infrared photodiode and non-invasive physiological sensor |
US10383520B2 (en) | 2014-09-18 | 2019-08-20 | Masimo Semiconductor, Inc. | Enhanced visible near-infrared photodiode and non-invasive physiological sensor |
US11850024B2 (en) | 2014-09-18 | 2023-12-26 | Masimo Semiconductor, Inc. | Enhanced visible near-infrared photodiode and non-invasive physiological sensor |
US11103134B2 (en) | 2014-09-18 | 2021-08-31 | Masimo Semiconductor, Inc. | Enhanced visible near-infrared photodiode and non-invasive physiological sensor |
US10765367B2 (en) | 2014-10-07 | 2020-09-08 | Masimo Corporation | Modular physiological sensors |
US11717218B2 (en) | 2014-10-07 | 2023-08-08 | Masimo Corporation | Modular physiological sensor |
US10154815B2 (en) | 2014-10-07 | 2018-12-18 | Masimo Corporation | Modular physiological sensors |
US10441196B2 (en) | 2015-01-23 | 2019-10-15 | Masimo Corporation | Nasal/oral cannula system and manufacturing |
US11903140B2 (en) | 2015-02-06 | 2024-02-13 | Masimo Corporation | Fold flex circuit for LNOP |
US11602289B2 (en) | 2015-02-06 | 2023-03-14 | Masimo Corporation | Soft boot pulse oximetry sensor |
US10568553B2 (en) | 2015-02-06 | 2020-02-25 | Masimo Corporation | Soft boot pulse oximetry sensor |
US10327337B2 (en) | 2015-02-06 | 2019-06-18 | Masimo Corporation | Fold flex circuit for LNOP |
US10205291B2 (en) | 2015-02-06 | 2019-02-12 | Masimo Corporation | Pogo pin connector |
US11178776B2 (en) | 2015-02-06 | 2021-11-16 | Masimo Corporation | Fold flex circuit for LNOP |
US11894640B2 (en) | 2015-02-06 | 2024-02-06 | Masimo Corporation | Pogo pin connector |
US11437768B2 (en) | 2015-02-06 | 2022-09-06 | Masimo Corporation | Pogo pin connector |
US10784634B2 (en) | 2015-02-06 | 2020-09-22 | Masimo Corporation | Pogo pin connector |
USD755392S1 (en) | 2015-02-06 | 2016-05-03 | Masimo Corporation | Pulse oximetry sensor |
US11291415B2 (en) | 2015-05-04 | 2022-04-05 | Cercacor Laboratories, Inc. | Noninvasive sensor system with visual infographic display |
US10524738B2 (en) | 2015-05-04 | 2020-01-07 | Cercacor Laboratories, Inc. | Noninvasive sensor system with visual infographic display |
US11653862B2 (en) | 2015-05-22 | 2023-05-23 | Cercacor Laboratories, Inc. | Non-invasive optical physiological differential pathlength sensor |
US10470695B2 (en) | 2015-07-02 | 2019-11-12 | Masimo Corporation | Advanced pulse oximetry sensor |
US10687743B1 (en) | 2015-07-02 | 2020-06-23 | Masimo Corporation | Physiological measurement devices, systems, and methods |
US10687745B1 (en) | 2015-07-02 | 2020-06-23 | Masimo Corporation | Physiological monitoring devices, systems, and methods |
US10687744B1 (en) | 2015-07-02 | 2020-06-23 | Masimo Corporation | Physiological measurement devices, systems, and methods |
US10646146B2 (en) | 2015-07-02 | 2020-05-12 | Masimo Corporation | Physiological monitoring devices, systems, and methods |
US10448871B2 (en) | 2015-07-02 | 2019-10-22 | Masimo Corporation | Advanced pulse oximetry sensor |
US10638961B2 (en) | 2015-07-02 | 2020-05-05 | Masimo Corporation | Physiological measurement devices, systems, and methods |
US10722159B2 (en) | 2015-07-02 | 2020-07-28 | Masimo Corporation | Physiological monitoring devices, systems, and methods |
US10991135B2 (en) | 2015-08-11 | 2021-04-27 | Masimo Corporation | Medical monitoring analysis and replay including indicia responsive to light attenuated by body tissue |
US11605188B2 (en) | 2015-08-11 | 2023-03-14 | Masimo Corporation | Medical monitoring analysis and replay including indicia responsive to light attenuated by body tissue |
US11967009B2 (en) | 2015-08-11 | 2024-04-23 | Masimo Corporation | Medical monitoring analysis and replay including indicia responsive to light attenuated by body tissue |
US10448844B2 (en) | 2015-08-31 | 2019-10-22 | Masimo Corporation | Systems and methods for patient fall detection |
US10383527B2 (en) | 2015-08-31 | 2019-08-20 | Masimo Corporation | Wireless patient monitoring systems and methods |
US11576582B2 (en) | 2015-08-31 | 2023-02-14 | Masimo Corporation | Patient-worn wireless physiological sensor |
US10736518B2 (en) | 2015-08-31 | 2020-08-11 | Masimo Corporation | Systems and methods to monitor repositioning of a patient |
US10226187B2 (en) | 2015-08-31 | 2019-03-12 | Masimo Corporation | Patient-worn wireless physiological sensor |
US11089963B2 (en) | 2015-08-31 | 2021-08-17 | Masimo Corporation | Systems and methods for patient fall detection |
US11504066B1 (en) | 2015-09-04 | 2022-11-22 | Cercacor Laboratories, Inc. | Low-noise sensor system |
US11864922B2 (en) | 2015-09-04 | 2024-01-09 | Cercacor Laboratories, Inc. | Low-noise sensor system |
US11679579B2 (en) | 2015-12-17 | 2023-06-20 | Masimo Corporation | Varnish-coated release liner |
US10993662B2 (en) | 2016-03-04 | 2021-05-04 | Masimo Corporation | Nose sensor |
US10537285B2 (en) | 2016-03-04 | 2020-01-21 | Masimo Corporation | Nose sensor |
US11931176B2 (en) | 2016-03-04 | 2024-03-19 | Masimo Corporation | Nose sensor |
US11272883B2 (en) | 2016-03-04 | 2022-03-15 | Masimo Corporation | Physiological sensor |
US11191484B2 (en) | 2016-04-29 | 2021-12-07 | Masimo Corporation | Optical sensor tape |
US11706029B2 (en) | 2016-07-06 | 2023-07-18 | Masimo Corporation | Secure and zero knowledge data sharing for cloud applications |
US11153089B2 (en) | 2016-07-06 | 2021-10-19 | Masimo Corporation | Secure and zero knowledge data sharing for cloud applications |
US11202571B2 (en) | 2016-07-07 | 2021-12-21 | Masimo Corporation | Wearable pulse oximeter and respiration monitor |
US10617302B2 (en) | 2016-07-07 | 2020-04-14 | Masimo Corporation | Wearable pulse oximeter and respiration monitor |
US11076777B2 (en) | 2016-10-13 | 2021-08-03 | Masimo Corporation | Systems and methods for monitoring orientation to reduce pressure ulcer formation |
US11504058B1 (en) | 2016-12-02 | 2022-11-22 | Masimo Corporation | Multi-site noninvasive measurement of a physiological parameter |
US10750984B2 (en) | 2016-12-22 | 2020-08-25 | Cercacor Laboratories, Inc. | Methods and devices for detecting intensity of light with translucent detector |
US11864890B2 (en) | 2016-12-22 | 2024-01-09 | Cercacor Laboratories, Inc. | Methods and devices for detecting intensity of light with translucent detector |
US11291061B2 (en) | 2017-01-18 | 2022-03-29 | Masimo Corporation | Patient-worn wireless physiological sensor with pairing functionality |
US10721785B2 (en) | 2017-01-18 | 2020-07-21 | Masimo Corporation | Patient-worn wireless physiological sensor with pairing functionality |
US11825536B2 (en) | 2017-01-18 | 2023-11-21 | Masimo Corporation | Patient-worn wireless physiological sensor with pairing functionality |
US10327713B2 (en) | 2017-02-24 | 2019-06-25 | Masimo Corporation | Modular multi-parameter patient monitoring device |
US11830349B2 (en) | 2017-02-24 | 2023-11-28 | Masimo Corporation | Localized projection of audible noises in medical settings |
US10388120B2 (en) | 2017-02-24 | 2019-08-20 | Masimo Corporation | Localized projection of audible noises in medical settings |
US10956950B2 (en) | 2017-02-24 | 2021-03-23 | Masimo Corporation | Managing dynamic licenses for physiological parameters in a patient monitoring environment |
US11596365B2 (en) | 2017-02-24 | 2023-03-07 | Masimo Corporation | Modular multi-parameter patient monitoring device |
US11886858B2 (en) | 2017-02-24 | 2024-01-30 | Masimo Corporation | Medical monitoring hub |
US11096631B2 (en) | 2017-02-24 | 2021-08-24 | Masimo Corporation | Modular multi-parameter patient monitoring device |
US11410507B2 (en) | 2017-02-24 | 2022-08-09 | Masimo Corporation | Localized projection of audible noises in medical settings |
US11901070B2 (en) | 2017-02-24 | 2024-02-13 | Masimo Corporation | System for displaying medical monitoring data |
US11969269B2 (en) | 2017-02-24 | 2024-04-30 | Masimo Corporation | Modular multi-parameter patient monitoring device |
US11024064B2 (en) | 2017-02-24 | 2021-06-01 | Masimo Corporation | Augmented reality system for displaying patient data |
US11816771B2 (en) | 2017-02-24 | 2023-11-14 | Masimo Corporation | Augmented reality system for displaying patient data |
US11417426B2 (en) | 2017-02-24 | 2022-08-16 | Masimo Corporation | System for displaying medical monitoring data |
US10667762B2 (en) | 2017-02-24 | 2020-06-02 | Masimo Corporation | Modular multi-parameter patient monitoring device |
US11086609B2 (en) | 2017-02-24 | 2021-08-10 | Masimo Corporation | Medical monitoring hub |
US11185262B2 (en) | 2017-03-10 | 2021-11-30 | Masimo Corporation | Pneumonia screener |
US10849554B2 (en) | 2017-04-18 | 2020-12-01 | Masimo Corporation | Nose sensor |
US11534110B2 (en) | 2017-04-18 | 2022-12-27 | Masimo Corporation | Nose sensor |
US11813036B2 (en) | 2017-04-26 | 2023-11-14 | Masimo Corporation | Medical monitoring device having multiple configurations |
US10918281B2 (en) | 2017-04-26 | 2021-02-16 | Masimo Corporation | Medical monitoring device having multiple configurations |
US10856750B2 (en) | 2017-04-28 | 2020-12-08 | Masimo Corporation | Spot check measurement system |
USD835284S1 (en) | 2017-04-28 | 2018-12-04 | Masimo Corporation | Medical monitoring device |
USD835285S1 (en) | 2017-04-28 | 2018-12-04 | Masimo Corporation | Medical monitoring device |
USD835283S1 (en) | 2017-04-28 | 2018-12-04 | Masimo Corporation | Medical monitoring device |
USD835282S1 (en) | 2017-04-28 | 2018-12-04 | Masimo Corporation | Medical monitoring device |
US10932705B2 (en) | 2017-05-08 | 2021-03-02 | Masimo Corporation | System for displaying and controlling medical monitoring data |
US11026604B2 (en) | 2017-07-13 | 2021-06-08 | Cercacor Laboratories, Inc. | Medical monitoring device for harmonizing physiological measurements |
US11095068B2 (en) | 2017-08-15 | 2021-08-17 | Masimo Corporation | Water resistant connector for noninvasive patient monitor |
US11705666B2 (en) | 2017-08-15 | 2023-07-18 | Masimo Corporation | Water resistant connector for noninvasive patient monitor |
US10505311B2 (en) | 2017-08-15 | 2019-12-10 | Masimo Corporation | Water resistant connector for noninvasive patient monitor |
USD890708S1 (en) | 2017-08-15 | 2020-07-21 | Masimo Corporation | Connector |
USD906970S1 (en) | 2017-08-15 | 2021-01-05 | Masimo Corporation | Connector |
US10637181B2 (en) | 2017-08-15 | 2020-04-28 | Masimo Corporation | Water resistant connector for noninvasive patient monitor |
US11298021B2 (en) | 2017-10-19 | 2022-04-12 | Masimo Corporation | Medical monitoring system |
US10987066B2 (en) | 2017-10-31 | 2021-04-27 | Masimo Corporation | System for displaying oxygen state indications |
USD925597S1 (en) | 2017-10-31 | 2021-07-20 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
US11766198B2 (en) | 2018-02-02 | 2023-09-26 | Cercacor Laboratories, Inc. | Limb-worn patient monitoring device |
US10952616B2 (en) | 2018-03-30 | 2021-03-23 | Canon U.S.A., Inc. | Fluorescence imaging apparatus |
US11109818B2 (en) | 2018-04-19 | 2021-09-07 | Masimo Corporation | Mobile patient alarm display |
US11844634B2 (en) | 2018-04-19 | 2023-12-19 | Masimo Corporation | Mobile patient alarm display |
US10667764B2 (en) | 2018-04-19 | 2020-06-02 | Masimo Corporation | Mobile patient alarm display |
US11883129B2 (en) | 2018-04-24 | 2024-01-30 | Cercacor Laboratories, Inc. | Easy insert finger sensor for transmission based spectroscopy sensor |
US10932729B2 (en) | 2018-06-06 | 2021-03-02 | Masimo Corporation | Opioid overdose monitoring |
US11627919B2 (en) | 2018-06-06 | 2023-04-18 | Masimo Corporation | Opioid overdose monitoring |
US10939878B2 (en) | 2018-06-06 | 2021-03-09 | Masimo Corporation | Opioid overdose monitoring |
US11564642B2 (en) | 2018-06-06 | 2023-01-31 | Masimo Corporation | Opioid overdose monitoring |
US11812229B2 (en) | 2018-07-10 | 2023-11-07 | Masimo Corporation | Patient monitor alarm speaker analyzer |
US11082786B2 (en) | 2018-07-10 | 2021-08-03 | Masimo Corporation | Patient monitor alarm speaker analyzer |
US10779098B2 (en) | 2018-07-10 | 2020-09-15 | Masimo Corporation | Patient monitor alarm speaker analyzer |
US11872156B2 (en) | 2018-08-22 | 2024-01-16 | Masimo Corporation | Core body temperature measurement |
US10743749B2 (en) | 2018-09-14 | 2020-08-18 | Canon U.S.A., Inc. | System and method for detecting optical probe connection |
USD916135S1 (en) | 2018-10-11 | 2021-04-13 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
US11445948B2 (en) | 2018-10-11 | 2022-09-20 | Masimo Corporation | Patient connector assembly with vertical detents |
USD999245S1 (en) | 2018-10-11 | 2023-09-19 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
USD999246S1 (en) | 2018-10-11 | 2023-09-19 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
USD917564S1 (en) | 2018-10-11 | 2021-04-27 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
USD998625S1 (en) | 2018-10-11 | 2023-09-12 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
USD998630S1 (en) | 2018-10-11 | 2023-09-12 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
USD998631S1 (en) | 2018-10-11 | 2023-09-12 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
USD917550S1 (en) | 2018-10-11 | 2021-04-27 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
US11406286B2 (en) | 2018-10-11 | 2022-08-09 | Masimo Corporation | Patient monitoring device with improved user interface |
US11389093B2 (en) | 2018-10-11 | 2022-07-19 | Masimo Corporation | Low noise oximetry cable |
USD999244S1 (en) | 2018-10-11 | 2023-09-19 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
USD897098S1 (en) | 2018-10-12 | 2020-09-29 | Masimo Corporation | Card holder set |
USD989327S1 (en) | 2018-10-12 | 2023-06-13 | Masimo Corporation | Holder |
US11464410B2 (en) | 2018-10-12 | 2022-10-11 | Masimo Corporation | Medical systems and methods |
US11272839B2 (en) | 2018-10-12 | 2022-03-15 | Ma Simo Corporation | System for transmission of sensor data using dual communication protocol |
US11684296B2 (en) | 2018-12-21 | 2023-06-27 | Cercacor Laboratories, Inc. | Noninvasive physiological sensor |
US11701043B2 (en) | 2019-04-17 | 2023-07-18 | Masimo Corporation | Blood pressure monitor attachment assembly |
US11678829B2 (en) | 2019-04-17 | 2023-06-20 | Masimo Corporation | Physiological monitoring device attachment assembly |
US11637437B2 (en) | 2019-04-17 | 2023-04-25 | Masimo Corporation | Charging station for physiological monitoring device |
USD917704S1 (en) | 2019-08-16 | 2021-04-27 | Masimo Corporation | Patient monitor |
USD919100S1 (en) | 2019-08-16 | 2021-05-11 | Masimo Corporation | Holder for a patient monitor |
USD985498S1 (en) | 2019-08-16 | 2023-05-09 | Masimo Corporation | Connector |
USD967433S1 (en) | 2019-08-16 | 2022-10-18 | Masimo Corporation | Patient monitor |
USD921202S1 (en) | 2019-08-16 | 2021-06-01 | Masimo Corporation | Holder for a blood pressure device |
USD933233S1 (en) | 2019-08-16 | 2021-10-12 | Masimo Corporation | Blood pressure device |
USD919094S1 (en) | 2019-08-16 | 2021-05-11 | Masimo Corporation | Blood pressure device |
USD933234S1 (en) | 2019-08-16 | 2021-10-12 | Masimo Corporation | Patient monitor |
US11832940B2 (en) | 2019-08-27 | 2023-12-05 | Cercacor Laboratories, Inc. | Non-invasive medical monitoring device for blood analyte measurements |
US11803623B2 (en) | 2019-10-18 | 2023-10-31 | Masimo Corporation | Display layout and interactive objects for patient monitoring |
USD950738S1 (en) | 2019-10-18 | 2022-05-03 | Masimo Corporation | Electrode pad |
USD927699S1 (en) | 2019-10-18 | 2021-08-10 | Masimo Corporation | Electrode pad |
US11951186B2 (en) | 2019-10-25 | 2024-04-09 | Willow Laboratories, Inc. | Indicator compounds, devices comprising indicator compounds, and methods of making and using the same |
US11721105B2 (en) | 2020-02-13 | 2023-08-08 | Masimo Corporation | System and method for monitoring clinical activities |
US11879960B2 (en) | 2020-02-13 | 2024-01-23 | Masimo Corporation | System and method for monitoring clinical activities |
US11730379B2 (en) | 2020-03-20 | 2023-08-22 | Masimo Corporation | Remote patient management and monitoring systems and methods |
US11974833B2 (en) | 2020-03-20 | 2024-05-07 | Masimo Corporation | Wearable device for noninvasive body temperature measurement |
USD933232S1 (en) | 2020-05-11 | 2021-10-12 | Masimo Corporation | Blood pressure monitor |
USD979516S1 (en) | 2020-05-11 | 2023-02-28 | Masimo Corporation | Connector |
USD965789S1 (en) | 2020-05-11 | 2022-10-04 | Masimo Corporation | Blood pressure monitor |
USD1022729S1 (en) | 2020-07-27 | 2024-04-16 | Masimo Corporation | Wearable temperature measurement device |
USD980091S1 (en) | 2020-07-27 | 2023-03-07 | Masimo Corporation | Wearable temperature measurement device |
USD974193S1 (en) | 2020-07-27 | 2023-01-03 | Masimo Corporation | Wearable temperature measurement device |
USD973686S1 (en) | 2020-09-30 | 2022-12-27 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
USD973685S1 (en) | 2020-09-30 | 2022-12-27 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
USD973072S1 (en) | 2020-09-30 | 2022-12-20 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
USD997365S1 (en) | 2021-06-24 | 2023-08-29 | Masimo Corporation | Physiological nose sensor |
USD1000975S1 (en) | 2021-09-22 | 2023-10-10 | Masimo Corporation | Wearable temperature measurement device |
Also Published As
Publication number | Publication date |
---|---|
EP1562038A2 (en) | 2005-08-10 |
US6124597A (en) | 2000-09-26 |
AU7830698A (en) | 1999-02-08 |
DE69829664D1 (en) | 2005-05-12 |
EP0995095B1 (en) | 2005-04-06 |
EP0995095A2 (en) | 2000-04-26 |
US6697657B1 (en) | 2004-02-24 |
JP2001509589A (en) | 2001-07-24 |
EP1562038A3 (en) | 2005-11-23 |
WO1999002956A3 (en) | 1999-04-29 |
AU752061B2 (en) | 2002-09-05 |
WO1999002956A2 (en) | 1999-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE39672E1 (en) | Method and devices for laser induced fluorescence attenuation spectroscopy | |
JP4936203B2 (en) | Glucose concentration determination device | |
Ge et al. | Identification of colonic dysplasia and neoplasia by diffuse reflectance spectroscopy and pattern recognition techniques | |
US7330746B2 (en) | Non-invasive biochemical analysis | |
US6668181B2 (en) | Method for quantification of stratum corneum hydration using diffuse reflectance spectroscopy | |
US8532726B2 (en) | Invasive chemometry | |
US6675029B2 (en) | Apparatus and method for quantification of tissue hydration using diffuse reflectance spectroscopy | |
US11147482B2 (en) | Method and system for non-invasive blood glucose measurement using signal change of the non-glucose components induced by the presence of glucose | |
US7809418B2 (en) | Optical device components | |
US5876121A (en) | Substrate temperature measurement by infrared spectroscopy | |
US6088087A (en) | Transcutaneous measurement of substance in body tissues or fluid | |
JPS60236631A (en) | Method and apparatus for light measuring detection of glucose | |
US7961304B2 (en) | Optical device components | |
JP4472794B2 (en) | Glucose concentration determination device | |
KR20020005697A (en) | Method for improving calibration of a blood monitoring instrument | |
US20230148312A1 (en) | Device for non-invasive blood glucose concentration measurement | |
KR100300960B1 (en) | Method and device for noninvasive determination of the concentrations of blood components | |
KR20070055614A (en) | Instrument for noninvasively measuring blood sugar level | |
Benaron et al. | Automated quantitation of tissue components using real-time spectroscopy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CEDARS-SINAI MEDICAL CENTER, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHEHADA, RAMEZ E. N.;MARMARELIS, VASILIS Z.;GRUNDFEST, WARREN S.;REEL/FRAME:013634/0191;SIGNING DATES FROM 19980211 TO 19980220 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |